chloroquine has been researched along with Parasitemia in 309 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P." | 9.30 | Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM, 2019) |
| " Artesunate cleared parasitemia significantly faster than chloroquine." | 9.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| " Asiatic acid suppressed parasitaemia while oral chloroquine (30 mg/kg) did not influence malaria induction." | 9.22 | Pre-infection administration of asiatic acid retards parasitaemia induction in Plasmodium berghei murine malaria infected Sprague-Dawley rats. ( Mabandla, MV; Mavondo, GA; Mkhwananzi, BN, 2016) |
| "This was an open-label, non-comparative study (NCT01103713) in 5 countries in East and sub-Saharan Africa (Benin, Kenya, Malawi, Tanzania, and Uganda) to assess parasitological response and drug concentrations of a single, 3-day course of four tablets of a fixed-dose combination of azithromycin-chloroquine (AZCQ) 250/155 mg given during the second or third trimester to women with asymptomatic Plasmodium falciparum parasitemia in their first or second pregnancy." | 9.22 | Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa. ( Ayoub, A; Duparc, S; Kimani, J; Mtove, GA; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P; Zhao, Q, 2016) |
| "Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia." | 9.15 | Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. ( Bacha, K; Getahun, K; Ketema, T, 2011) |
| "To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital." | 9.14 | Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009) |
| "To assess the safety of chloroquine (CQ) as prophylaxis against Plasmodium vivax infection during pregnancy." | 9.12 | Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. ( Arunjerdja, R; Greenwood, B; Htway, M; McGready, R; Nosten, F; Paw, MK; Pimanpanarak, M; Viladpai-Nguen, SJ; Villegas, L; White, NJ, 2007) |
| " The aims were (i) to update our knowledge of the burden of Plasmodium malariae infection and (ii) to assess the therapeutic efficacy of chloroquine for uncomplicated quartan malaria." | 9.12 | Short report: prevalence and chloroquine sensitivity of Plasmodium malariae in Madagascar. ( Barnadas, C; Ménard, D; Picot, S; Rabekotonorina, V; Ralaizandry, D; Ranaivosoa, H; Ratsimbasoa, A; Raveloariseheno, D, 2007) |
| "The efficacy of a single dose of 45 mg primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe Plasmodium falciparum malaria." | 9.11 | A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. ( Aigal, U; Chogle, AR; Dalvi, SS; Gogtay, NJ; Kamtekar, KD; Karnad, DR; Kshirsagar, NA, 2004) |
| "In November-December 2002, 98 patients presented at the Elhara Eloula health centre, in the New Halfa area of eastern Sudan, with Plasmodium falciparum malaria that had failed to respond to chloroquine treatment." | 9.11 | Low-dose quinine is effective in the treatment of chloroquine-resistant Plasmodium falciparum malaria in eastern Sudan. ( Adam, I; Aelbasit, IA; Elbashir, MI; Ibrahim, MH; Kheir, MM; Naser, A, 2004) |
| "Naltrexone exerted an antipruritic action, at least to a similar extent to promethazine in patients with chloroquine-induced itching in malaria fever." | 9.11 | Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching. ( Ajayi, AA; Kolawole, BA; Udoh, SJ, 2004) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 9.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| "A randomized, double-blind, placebo-controlled trial, which compared the effects of three interventions (weekly chloroquine prophylaxis, daily iron and weekly folic-acid supplementation, and case management of malaria) on congenital malaria, maternal haemoglobin (Hb) and foetal outcome, was conducted among primigravidae resident in Hoima district, Uganda." | 9.09 | Chloroquine prophylaxis, iron/folic-acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and infant haemoglobin concentrations. ( Magnussen, P; Ndyomugyenyi, R, 2000) |
| "The quest for the development of a novel antimalarial drug informed the decision to subject phytol to in vivo trials following a demonstration of therapeutic potential against chloroquine sensitive strain of Plasmodium falciparum under in vitro condition." | 8.02 | Phytol suppresses parasitemia and ameliorates anaemia and oxidative brain damage in mice infected with Plasmodium berghei. ( Abubakar, MS; Adamu, A; Ibrahim, MA; Salman, AA; Usman, FI; Usman, MA, 2021) |
| "Treatment Failure with chloroquine is one of the challenges that faced the dedicated efforts to eradicate malaria This study aims at investigating the impact of treatment failure with chloroquine on the progression of the disease-induced histo-pathogenic and immunogenic outcomes." | 7.96 | Progression of malaria induced pathogenicity during chloroquine therapy. ( Abd Majid, R; Abd Rachman-Isnadi, MF; Basir, R; Bello, RO; Chin, VK; Noor, SM; Sidek, HM; Zaid, OI, 2020) |
| "Antimalarial interventions mostly rely upon drugs, as chloroquine." | 7.88 | In vivo and in vitro antimalarial effect and toxicological evaluation of the chloroquine analogue PQUI08001/06. ( Areas, ALL; Bozza, PT; Costa, NF; da Silva Frutuoso, V; de Castro-Faria-Neto, HC; de Lima Ferreira, M; de Souza, MVN; Douradinha, B; Kaiser, CR; Pais, KC; Pereira, MF; Reis, PA; Zalis, MG, 2018) |
| "Oral Asiatic acid administration influenced %parasitaemia suppression, ameliorated malarial anaemia and increased biophysical properties on infected animals." | 7.83 | Asiatic acid influences parasitaemia reduction and ameliorates malaria anaemia in P. berghei infected Sprague-Dawley male rats. ( Mabandla, MV; Mavondo, GA; Mkhwananzi, BN; Musabayane, CT, 2016) |
| "The present study investigated the effects of transdermally delivered oleanolic acid (OA) monotherapy and in combination with chloroquine (CHQ) on malaria parasites and glucose homeostasis of P." | 7.83 | The Effects of Transdermally Delivered Oleanolic Acid on Malaria Parasites and Blood Glucose Homeostasis in P. berghei-Infected Male Sprague-Dawley Rats. ( Mabandla, MV; Musabayane, CT; Sibiya, HP, 2016) |
| " In our study, chitosan-tripolyphosphate (CS-TPP) particles was conjugated with an undervalued antimalarial drug, chloroquine to find out the proficiency against ROS mediated caspase activation and apoptosis in liver during Plasmodium berghei NK65 infection." | 7.81 | Chitosan conjugated chloroquine: proficient to protect the induction of liver apoptosis during malaria. ( Chattopadhyay, S; Chowdhuri, AR; Das, S; Dash, SK; Majumdar, S; Roy, S; Sahu, SK; Tripathy, S, 2015) |
| "The antimalarial activity and lipid profiles of Methyl Jasmonate (MJ) were investigated against established malaria infection in vivo using BALB/c mice." | 7.81 | Potential antimalarial activity of Methyl Jasmonate and its effect on lipid profiles in Plasmodium Berghei infected mice. ( Ademowo, OG; Emikpe, B; Falade, CO; Kosoko, AM; Oyinloye, OE, 2015) |
| "To investigate the antimalarial potential of kolaviron (KV), a biflavonoid fraction from Garcinia kola seeds, against Plasmodium berghei (P." | 7.80 | Antimalarial potential of kolaviron, a biflavonoid from Garcinia kola seeds, against Plasmodium berghei infection in Swiss albino mice. ( Aderemi, K; Ayokulehin, K; Catherine, F; Olusegun, A; Oluwatosin, A; Patricia, O; Tolulope, A, 2014) |
| "Results indicate prominent anti-malarial action of tigecycline in vitro and in vivo in combination with CQ and support further evaluation of tigecycline as a potential combination candidate for treatment of drug-resistant cases of malaria." | 7.80 | In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. ( Sahu, R; Tekwani, BL; Walker, LA, 2014) |
| "Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria." | 7.78 | Lead optimization of antimalarial propafenone analogues. ( Clark, JA; Connelly, MC; Derisi, JL; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, LV; Kyle, DE; Lemoff, A; Lowes, D; Mirsalis, J; Parman, T; Pradhan, A; Sigal, M; Tang, L; Wilson, E; Zhu, F, 2012) |
| "An ethnopharmacological investigation was undertaken on Western Ghats plants traditionally used to treat malaria; 50 plants were very carefully selected from total of 372 plants, and 216 extracts were prepared and tested for in vivo antiplasmodial activity alone and in combination with chloroquine (CQ) against CQ-tolerant Plasmodium berghei (strain NK65)." | 7.77 | Antimalarial activity of traditionally used Western Ghats plants from India and their interactions with chloroquine against chloroquine-tolerant Plasmodium berghei. ( Kadarkari, M; Samy, K, 2011) |
| "Chloroquine (CQ) is an important antimalarial drug for the treatment of special patient groups and as a comparator for preclinical testing of new drugs." | 7.77 | Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ( Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M; Stoney, JR, 2011) |
| "Methanolic extracts from 15 medicinal plants representing 11 families, used traditionally for malaria treatment in Kenya were screened for their in vivo antimalarial activity in mice against a chloroquine (CQ)-tolerant Plasmodium berghei NK65, either alone or in combination with CQ." | 7.74 | Antimalarial activity of methanolic extracts from plants used in Kenyan ethnomedicine and their interactions with chloroquine (CQ) against a CQ-tolerant rodent parasite, in mice. ( Amano, T; Ishih, A; Kino, H; Miyase, T; Mkoji, GM; Muregi, FW; Suzuki, T; Terada, M, 2007) |
| "In West Africa, administration of chloroquine chemoprophylaxis during pregnancy is common, but little is known about its impact on Plasmodium falciparum infection during pregnancy." | 7.72 | Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso. ( Diarra, A; Konate, A; Moran, AC; Newman, RD; Parise, ME; Sawadogo, R; Sirima, SB; Yameogo, M, 2003) |
| "To study the antimalarial effect of agmatine (Agm) on chloroquine-susceptible Plasmodium berghei K173 strain (S strain) and the P berghei K173 resistant strain (R strain)." | 7.72 | Antimalarial effect of agmatine on Plasmodium berghei K173 strain. ( Li, J; Liu, Y; Su, RB; Wei, XL, 2003) |
| "Several compounds in current clinical use as antihistaminic agents, among them cyproheptadine (CYP), have been shown, in experimental models, to reverse resistance of the asexual, intra-erythrocytic stages of rodent or human malarial parasites to chloroquine (CQ)." | 7.70 | The chemotherapy of rodent malaria. LIX. Drug combinations to impede the selection of drug resistance, Part 3: Observations on cyproheptadine, an antihistaminic agent, with chloroquine. ( Butcher, GA; Peters, W; Robinson, BL; Stewart, LB, 2000) |
| " In a cohort of pregnant women enrolled at first antenatal clinic visit in rural Malawi, we evaluated reported fever, determined parasitemia, and placed the women on antimalarial regimens containing chloroquine (CQ) or mefloquine (MQ)." | 7.69 | Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. ( Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, L; Steketee, RW; Wirima, JJ, 1996) |
| "The objective of the study was to determine the efficacy of chloroquine in pregnant women with Plasmodium falciparum parasitemia at therapeutic doses of 25 mg/kg body weight divided over 3 days." | 7.69 | Resistance to chloroquine therapy in pregnant women with malaria parasitemia. ( Ojwang, SB; Oyieke, JB; Rukaria-Kaumbutho, RM, 1996) |
| "Fenozan B07, a 1,2,4-trioxane endoperoxide with potent blood schizontocidal activity against drug-sensitive and drug-resistant rodent malaria parasites, exerted a modest potentiating action when administered with chloroquine (CQ) to mice infected with parasites of the CQ-resistant P." | 7.69 | The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites. ( Fleck, SL; Peters, W; Robinson, BL, 1997) |
| "Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P." | 6.90 | Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A, 2019) |
| "Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy." | 6.80 | Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. ( Abera, A; Aseffa, A; Auburn, S; Gadisa, E; Getachew, S; Petros, B; Price, RN; Thriemer, K, 2015) |
| " Serious adverse events (AEs; all causality) were observed more frequently with MQ compared with AZCQ (four vs one, respectively), though discontinuations for AEs were similar (four vs three, respectively)." | 6.79 | Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. ( Chandra, R; Dieng, Y; Djimdé, AA; Dunne, MW; Kain, KC; Mugyenyi, P; Mulenga, M; Oduro, AR; Ogutu, B; Robbins, J; Sagara, I; Sarkar, S; Sie, A; Tiono, AB; Wasunna, M, 2014) |
| " We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P." | 6.72 | Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. ( Alvarez, G; Blair, S; Carmona-Fonseca, J; Maestre, A; Piñeros, JG; Ríos, A; Tobón, A, 2006) |
| "falciparum malaria were treated with either CQ monotherapy (n=120) or the combination of CQ plus three doses of AS (CQ/AS; n=352)." | 6.71 | Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. ( Coleman, R; Drakeley, CJ; Jawara, M; Obisike, U; Pinder, M; Sutherland, CJ; Targett, GA; Walraven, G, 2004) |
| "falciparum malaria was compared with that of CQ, each drug being given at 10 mg/kg per day for 3 days (days 0, 1 and 2)." | 6.70 | Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Adedeji, AA; Ayede, AI; Falade, AG; Falade, CO; Happi, TC; Ndikum, VN; Oduola, AM; Sowunmi, A; Sowunmi, CO, 2001) |
| "falciparum for at least 14 days." | 6.68 | Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. ( Alin, MH; Ashton, M; Bjorkman, A; Bwijo, BA; Kihamia, CM; Mtey, GJ; Premji, Z, 1995) |
| "Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 6.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| "Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P." | 5.42 | Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015) |
| "The chloroquine was treated by the actual drug content of effective nanochloroquine and the nanodrug was charged with its effective dose for fifteen days, after successive infection development in Swiss mice." | 5.39 | A novel chitosan based antimalarial drug delivery against Plasmodium berghei infection. ( Chattopadhyay, S; Das, S; Dash, SK; Mahapatra, SK; Majumder, S; Pramanik, P; Roy, S; Tripathy, S, 2013) |
| "Parasitemia was 4% on day 8 when compared to that on day 0, whereas it was 9% on day 9." | 5.38 | Comparative study of chloroquine and quinine on malaria rodents and their effects on the mouse testis. ( Abolghasemi, E; Davoudi, M; Moosa-Kazemi, SH; Reisi, A; Satvat, MT, 2012) |
| "In addition, on the day of recurrence of parasitaemia the levels of chloroquine-desethylchloroquine (CQ-DCQ) were above the minimum effective concentration (>or=100 etag/ml) in all the three cases, showing that treatment failure could not be attributed to low level of drug in the patients blood." | 5.35 | Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. ( Bacha, K; Birhanu, T; Ketema, T; Petros, B, 2009) |
| " The study findings showed that antimalarial property of goniothalamin was enhanced by combination with chloroquine at lower dose of each drug." | 5.33 | Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice. ( Khozirah, S; Mohd Ridzuan, MA; Noor Rain, A; Ruenruetai, U; Zakiah, I, 2006) |
| "Chloroquine-treated and artemether-treated parasites displayed a pigment-clumping morphology and lowered the parasitaemia faster than dioncophylline B." | 5.31 | A comparison of the stage-specific efficacy of chloroquine, artemether and dioncophylline B against the rodent malaria parasite Plasmodium chabaudi chabaudi in vivo. ( Bringmann, G; Chimanuka, B; François, G; Heyden, YV; Holenz, J; Plaizier-Vercammen, J; Timperman, G, 2001) |
| "Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P." | 5.30 | Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. ( Angus, B; Aruachan, S; Bancone, G; Breton, JJ; Brito, MAM; Casapía, M; Chu, CS; Chuquiyauri, R; Clover, DD; Costa, MRF; Craig, G; Duparc, S; Green, JA; Hardaker, E; Hien, TT; Jones, SW; Kendall, L; Koh, GCKW; Lacerda, MVG; Llanos-Cuentas, A; Mohamed, K; Monteiro, WM; Namaik-Larp, C; Nguyen, CH; Nosten, FH; Papwijitsil, R; Rousell, VM; Val, F; Vélez, ID; Villegas, MF; Wilches, VM, 2019) |
| " Artesunate cleared parasitemia significantly faster than chloroquine." | 5.27 | Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018) |
| " Asiatic acid suppressed parasitaemia while oral chloroquine (30 mg/kg) did not influence malaria induction." | 5.22 | Pre-infection administration of asiatic acid retards parasitaemia induction in Plasmodium berghei murine malaria infected Sprague-Dawley rats. ( Mabandla, MV; Mavondo, GA; Mkhwananzi, BN, 2016) |
| "This was an open-label, non-comparative study (NCT01103713) in 5 countries in East and sub-Saharan Africa (Benin, Kenya, Malawi, Tanzania, and Uganda) to assess parasitological response and drug concentrations of a single, 3-day course of four tablets of a fixed-dose combination of azithromycin-chloroquine (AZCQ) 250/155 mg given during the second or third trimester to women with asymptomatic Plasmodium falciparum parasitemia in their first or second pregnancy." | 5.22 | Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa. ( Ayoub, A; Duparc, S; Kimani, J; Mtove, GA; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P; Zhao, Q, 2016) |
| "Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia." | 5.15 | Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. ( Bacha, K; Getahun, K; Ketema, T, 2011) |
| "To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital." | 5.14 | Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009) |
| "Chloroquine plus primaqine is an inexpensive and highly effective treatment for uncomplicated knowlesi malaria infections in humans and there is no evidence of drug resistance." | 5.14 | Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. ( Cox-Singh, J; Daneshvar, C; Davis, TM; Divis, PC; Rafa'ee, MZ; Singh, B; Zakaria, SK, 2010) |
| "To assess the safety of chloroquine (CQ) as prophylaxis against Plasmodium vivax infection during pregnancy." | 5.12 | Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial. ( Arunjerdja, R; Greenwood, B; Htway, M; McGready, R; Nosten, F; Paw, MK; Pimanpanarak, M; Viladpai-Nguen, SJ; Villegas, L; White, NJ, 2007) |
| "Few studies have documented the effectiveness in west Africa of intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine (SP) in pregnancy." | 5.12 | A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. ( Madaki, JK; Sagay, AS; Thacher, TD; Tukur, IU, 2007) |
| " The aims were (i) to update our knowledge of the burden of Plasmodium malariae infection and (ii) to assess the therapeutic efficacy of chloroquine for uncomplicated quartan malaria." | 5.12 | Short report: prevalence and chloroquine sensitivity of Plasmodium malariae in Madagascar. ( Barnadas, C; Ménard, D; Picot, S; Rabekotonorina, V; Ralaizandry, D; Ranaivosoa, H; Ratsimbasoa, A; Raveloariseheno, D, 2007) |
| "The efficacy of a single dose of 45 mg primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe Plasmodium falciparum malaria." | 5.11 | A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. ( Aigal, U; Chogle, AR; Dalvi, SS; Gogtay, NJ; Kamtekar, KD; Karnad, DR; Kshirsagar, NA, 2004) |
| "In November-December 2002, 98 patients presented at the Elhara Eloula health centre, in the New Halfa area of eastern Sudan, with Plasmodium falciparum malaria that had failed to respond to chloroquine treatment." | 5.11 | Low-dose quinine is effective in the treatment of chloroquine-resistant Plasmodium falciparum malaria in eastern Sudan. ( Adam, I; Aelbasit, IA; Elbashir, MI; Ibrahim, MH; Kheir, MM; Naser, A, 2004) |
| "Naltrexone exerted an antipruritic action, at least to a similar extent to promethazine in patients with chloroquine-induced itching in malaria fever." | 5.11 | Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching. ( Ajayi, AA; Kolawole, BA; Udoh, SJ, 2004) |
| "In Mali, IPT with SP appears more efficacious than weekly chloroquine chemoprophylaxis in preventing malaria during pregnancy." | 5.11 | Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. ( Coulibaly, D; Doumbo, O; Doumtabe, D; Kayentao, K; Keita, AS; Kodio, M; Maiga, B; Maiga, H; Mungai, M; Newman, RD; Ongoiba, A; Parise, ME, 2005) |
| "The study examined the efficacy of chloroquine (CQ), amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria in Ghana." | 5.11 | A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. ( Amankwa, J; Ansah, NA; Ansah, P; Anto, F; Anyorigiya, T; Atuguba, F; Hodgson, A; Mumuni, G; Oduro, AR, 2005) |
| " The authors recommend that the treatment to be used in Abie must be firstly amodiaquine followed by sulfadoxine-pyrimethamine in cases where there is persistent asymptomatic parasitemia." | 5.11 | [Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire]. ( Adjetey, TA; Affoumou, GB; Barro-Kiki, P; Kone, M; Loukou, DD; Menan, EI; Nebavi, NG; Yavo, W, 2005) |
| " Children with fever and >or=2000 asexual forms of Plasmodium falciparum/ micro L in a thick blood smear received chloroquine and were randomly assigned to receive zinc (20 mg/d for infants, 40 mg/d for older children) or placebo for 4 d." | 5.10 | Effect of zinc on the treatment of Plasmodium falciparum malaria in children: a randomized controlled trial. ( , 2002) |
| "We evaluated gametocyte carriage and intensities of gametocytaemia in 710 children presenting with acute, symptomatic, uncomplicated Plasmodium falciparum malaria who were treated with various antimalarial drug regimens: chloroquine (CQ); chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist that reverses CQ resistance in P." | 5.10 | Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. ( Fateye, BA; Sowunmi, A, 2003) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 5.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| "A randomized, double-blind, placebo-controlled trial, which compared the effects of three interventions (weekly chloroquine prophylaxis, daily iron and weekly folic-acid supplementation, and case management of malaria) on congenital malaria, maternal haemoglobin (Hb) and foetal outcome, was conducted among primigravidae resident in Hoima district, Uganda." | 5.09 | Chloroquine prophylaxis, iron/folic-acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and infant haemoglobin concentrations. ( Magnussen, P; Ndyomugyenyi, R, 2000) |
| "In a randomized trial, a high dosage chloroquine monotherapy (45 mg/kg over 3 days) was compared with combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin for treating Gabonese school children with Plasmodium falciparum malaria." | 5.08 | Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. ( Bienzle, U; Graninger, W; Kremsner, PG; Metzger, W; Mordmüller, B, 1995) |
| "To define an effective and deliverable antimalarial regimen for use during pregnancy, pregnant women at highest risk of malaria (those in their first or second pregnancy) in an area of Malawi with high transmission of chloroquine (CQ)-resistant Plasmodium falciparum were placed on CQ and/or sulfadoxine-pyrimethamine (SP)." | 5.07 | The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. ( Chitsulo, L; Kazembe, P; Macheso, A; Schultz, LJ; Steketee, RW; Wirima, JJ, 1994) |
| "Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030." | 4.31 | Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response. ( Abadura, GS; Bayissa, GA; Behaksra, SW; Bulto, MG; Gadisa, E; Mekonnen, DA; Tadesse, FG; Taffese, HS; Tessema, TS, 2023) |
| " The mice were infected with standard inoculum of the strain NK65 Plasmodium berghei (chloroquine sensitive) and the percentage parasitemia suppression were evaluated." | 4.12 | Effect of black seeds (Nigella sativa) on inflammatory and immunomodulatory markers in Plasmodium berghei-infected mice. ( Ademosun, AO; Oboh, G; Ojueromi, OO, 2022) |
| "The quest for the development of a novel antimalarial drug informed the decision to subject phytol to in vivo trials following a demonstration of therapeutic potential against chloroquine sensitive strain of Plasmodium falciparum under in vitro condition." | 4.02 | Phytol suppresses parasitemia and ameliorates anaemia and oxidative brain damage in mice infected with Plasmodium berghei. ( Abubakar, MS; Adamu, A; Ibrahim, MA; Salman, AA; Usman, FI; Usman, MA, 2021) |
| " The antimalarial activity was evaluated using chloroquine-sensitive Plasmodium berghei on swiss albino mice, in a chemosuppressive test, at 150, 350, and 700 mg/kg, p." | 4.02 | Developmental stages influence in vivo antimalarial activity of aerial part extracts of Schkuhria pinnata. ( Adriko, J; Ajayi, CO; Kagoro, GR; Nuwagira, C; Ogwang, PE; Olet, EA; Peter, EL; Tolo, CU, 2021) |
| "Probiotic in combination with chloroquine showed complete suppression in parasitemia rate." | 4.02 | Evaluation of the effect of probiotic as add-on therapy with conventional therapy and alone in malaria induced mice. ( Bhatia, A; Mahajan, E; Medhi, B; Sehgal, R; Sinha, S, 2021) |
| "Hence, this study was therefore aimed at evaluating the antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in mice infected with chloroquine sensitive Plasmodium berghei ANKA." | 4.02 | In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA. ( Achidi, EA; Bila, RB; Feugaing Sofeu, DD; Ivo, EP; Taiwe, GS; Tatsinkou Fossi, B; Toukam, LL, 2021) |
| " Two of the molecules which were designed based on the results of this QSAR study, had shown good percentage of parasitemia against both chloroquine sensitive (3D7) and chloroquine resistant (Dd2) strains of Plasmodium falciparum respectively." | 3.96 | Discovery of potential 1,3,5-Triazine compounds against strains of Plasmodium falciparum using supervised machine learning models. ( Ghosh, SK; Ginjupalli, MC; K, KR; Kalita, JM; Sahu, S, 2020) |
| "Treatment Failure with chloroquine is one of the challenges that faced the dedicated efforts to eradicate malaria This study aims at investigating the impact of treatment failure with chloroquine on the progression of the disease-induced histo-pathogenic and immunogenic outcomes." | 3.96 | Progression of malaria induced pathogenicity during chloroquine therapy. ( Abd Majid, R; Abd Rachman-Isnadi, MF; Basir, R; Bello, RO; Chin, VK; Noor, SM; Sidek, HM; Zaid, OI, 2020) |
| "Antimalarial interventions mostly rely upon drugs, as chloroquine." | 3.88 | In vivo and in vitro antimalarial effect and toxicological evaluation of the chloroquine analogue PQUI08001/06. ( Areas, ALL; Bozza, PT; Costa, NF; da Silva Frutuoso, V; de Castro-Faria-Neto, HC; de Lima Ferreira, M; de Souza, MVN; Douradinha, B; Kaiser, CR; Pais, KC; Pereira, MF; Reis, PA; Zalis, MG, 2018) |
| "Oral Asiatic acid administration influenced %parasitaemia suppression, ameliorated malarial anaemia and increased biophysical properties on infected animals." | 3.83 | Asiatic acid influences parasitaemia reduction and ameliorates malaria anaemia in P. berghei infected Sprague-Dawley male rats. ( Mabandla, MV; Mavondo, GA; Mkhwananzi, BN; Musabayane, CT, 2016) |
| "The present study investigated the effects of transdermally delivered oleanolic acid (OA) monotherapy and in combination with chloroquine (CHQ) on malaria parasites and glucose homeostasis of P." | 3.83 | The Effects of Transdermally Delivered Oleanolic Acid on Malaria Parasites and Blood Glucose Homeostasis in P. berghei-Infected Male Sprague-Dawley Rats. ( Mabandla, MV; Musabayane, CT; Sibiya, HP, 2016) |
| " In our study, chitosan-tripolyphosphate (CS-TPP) particles was conjugated with an undervalued antimalarial drug, chloroquine to find out the proficiency against ROS mediated caspase activation and apoptosis in liver during Plasmodium berghei NK65 infection." | 3.81 | Chitosan conjugated chloroquine: proficient to protect the induction of liver apoptosis during malaria. ( Chattopadhyay, S; Chowdhuri, AR; Das, S; Dash, SK; Majumdar, S; Roy, S; Sahu, SK; Tripathy, S, 2015) |
| "Protection against malaria in humans can be achieved by repeated exposure to infected mosquito bites during prophylactic chloroquine treatment (chemoprophylaxis and sporozoites (CPS))." | 3.81 | Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunization. ( Jarra, W; Langhorne, J; Lévy, P; Nahrendorf, W; Sauerwein, RW; Spence, PJ; Tumwine, I, 2015) |
| "The antimalarial activity and lipid profiles of Methyl Jasmonate (MJ) were investigated against established malaria infection in vivo using BALB/c mice." | 3.81 | Potential antimalarial activity of Methyl Jasmonate and its effect on lipid profiles in Plasmodium Berghei infected mice. ( Ademowo, OG; Emikpe, B; Falade, CO; Kosoko, AM; Oyinloye, OE, 2015) |
| "To investigate the antimalarial potential of kolaviron (KV), a biflavonoid fraction from Garcinia kola seeds, against Plasmodium berghei (P." | 3.80 | Antimalarial potential of kolaviron, a biflavonoid from Garcinia kola seeds, against Plasmodium berghei infection in Swiss albino mice. ( Aderemi, K; Ayokulehin, K; Catherine, F; Olusegun, A; Oluwatosin, A; Patricia, O; Tolulope, A, 2014) |
| "Results indicate prominent anti-malarial action of tigecycline in vitro and in vivo in combination with CQ and support further evaluation of tigecycline as a potential combination candidate for treatment of drug-resistant cases of malaria." | 3.80 | In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine. ( Sahu, R; Tekwani, BL; Walker, LA, 2014) |
| "Previously reported studies identified analogues of propafenone that had potent antimalarial activity, reduced cardiac ion channel activity, and properties that suggested the potential for clinical development for malaria." | 3.78 | Lead optimization of antimalarial propafenone analogues. ( Clark, JA; Connelly, MC; Derisi, JL; Furimsky, A; Gow, J; Guiguemde, WA; Guy, RK; Iyer, LV; Kyle, DE; Lemoff, A; Lowes, D; Mirsalis, J; Parman, T; Pradhan, A; Sigal, M; Tang, L; Wilson, E; Zhu, F, 2012) |
| "The increasing spread of chloroquine resistant malaria has intensified the search for new antimalarial treatment, especially drugs that can be used in combination." | 3.78 | Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune. ( Abiodun, OO; Gbotosho, GO; Happi, CT; Oduola, AM; Sowunmi, A; Woranola, O, 2012) |
| " After sporozoite inoculation and blood-stage cure of initial parasitemia with chloroquine, rhesus macaques were treated on subsequent relapses with chloroquine in conjunction with test regimens of approved drugs." | 3.78 | Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. ( Bennett, K; Deye, GA; Fracisco, S; Gettayacamin, M; Hansukjariya, P; Im-erbsin, R; Macareo, L; Magill, AJ; Ohrt, C; Rothstein, Y; Sattabongkot, J, 2012) |
| "An ethnopharmacological investigation was undertaken on Western Ghats plants traditionally used to treat malaria; 50 plants were very carefully selected from total of 372 plants, and 216 extracts were prepared and tested for in vivo antiplasmodial activity alone and in combination with chloroquine (CQ) against CQ-tolerant Plasmodium berghei (strain NK65)." | 3.77 | Antimalarial activity of traditionally used Western Ghats plants from India and their interactions with chloroquine against chloroquine-tolerant Plasmodium berghei. ( Kadarkari, M; Samy, K, 2011) |
| "Chloroquine (CQ) is an important antimalarial drug for the treatment of special patient groups and as a comparator for preclinical testing of new drugs." | 3.77 | Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. ( Batty, KT; Ilett, KF; Jago, JD; Moore, BR; Page-Sharp, M; Stoney, JR, 2011) |
| " They were monitored for development of Plasmodium falciparum malaria, which was treated with chloroquine (CQ) + sulfadoxine-pyrimethamine (SP) and the children followed up for 28 days." | 3.76 | Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. ( Egwang, TG; Kiyingi, HS; Nannyonga, M, 2010) |
| " We show that micromolar concentrations efficiently killed chloroquine-sensitive and -resistant Plasmodium falciparum strains in vitro; inhibited parasitemia in vivo, even after parasite establishment; and protected Plasmodium chabaudi chabaudi-infected mice from a lethal challenge." | 3.75 | Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo. ( Blanco, YC; Brocchi, M; Costa, FT; Duran, N; Facchini, G; Goelnitz, U; Justo, GZ; Lopes, SC; Nogueira, PA; Rodrigues, FL; Wunderlich, G, 2009) |
| " knowlesi infection had uncomplicated malaria that responded to chloroquine and primaquine treatment." | 3.75 | Clinical and laboratory features of human Plasmodium knowlesi infection. ( Cox-Singh, J; Daneshvar, C; Davis, TM; Divis, PC; Rafa'ee, MZ; Singh, B; Zakaria, SK, 2009) |
| "Methanolic extracts from 15 medicinal plants representing 11 families, used traditionally for malaria treatment in Kenya were screened for their in vivo antimalarial activity in mice against a chloroquine (CQ)-tolerant Plasmodium berghei NK65, either alone or in combination with CQ." | 3.74 | Antimalarial activity of methanolic extracts from plants used in Kenyan ethnomedicine and their interactions with chloroquine (CQ) against a CQ-tolerant rodent parasite, in mice. ( Amano, T; Ishih, A; Kino, H; Miyase, T; Mkoji, GM; Muregi, FW; Suzuki, T; Terada, M, 2007) |
| "The anti-malarial chloroquine can modulate the outcome of infection during the Plasmodium sporogonic development, interfering with Plasmodium gene expression and subsequently, with transmission." | 3.74 | Effect of chloroquine on gene expression of Plasmodium yoelii nigeriensis during its sporogonic development in the mosquito vector. ( Abrahamsen, MS; Abrantes, P; do Rosario, VE; Lopes, LF; Ramos, S; Silveira, H, 2007) |
| "To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria in in Dawei District, southern Myanmar." | 3.74 | Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. ( Annerberg, A; de Radiguès, X; Guthmann, JP; Imwong, M; Lesage, A; Lindegardh, N; Min Lwin, M; Nosten, F; Pittet, A; Zaw, T, 2008) |
| "Although chloroquine (CQ) monotherapy is now generally inadequate for the treatment of Plasmodium falciparum malaria in northern Ghana--recently, 58% of 225 children failed treatment by day 14--use of the drug continues because of its low cost and wide availability." | 3.73 | Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86. ( Agana-Nsiire, P; Bienzle, U; Eggelte, TA; Ehrhardt, S; Markert, M; Mathieu, A; Mockenhaupt, FP; Otchwemah, RN; Stollberg, K, 2005) |
| " Gambian children with malaria were treated with chloroquine in 28-day trials, and recovery was defined primarily as the absence of severe clinical malaria at any time and absence of parasitemia with fever after 3 days." | 3.73 | Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children. ( Hallett, R; Holder, AA; Ismaili, J; McCall, MB; Milligan, P; Ord, R; Pinder, M; Sisay-Joof, F; Sutherland, CJ, 2006) |
| "We have previously shown that both chloroquine and paracetamol (acetaminophen) have antipyretic activity during treatment of acute uncomplicated Plasmodium falciparum malaria in children 1-4 years old." | 3.73 | Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes. ( Björkman, A; Hugosson, E; Montgomery, SM; Premji, Z; Troye-Blomberg, M, 2006) |
| "In West Africa, administration of chloroquine chemoprophylaxis during pregnancy is common, but little is known about its impact on Plasmodium falciparum infection during pregnancy." | 3.72 | Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso. ( Diarra, A; Konate, A; Moran, AC; Newman, RD; Parise, ME; Sawadogo, R; Sirima, SB; Yameogo, M, 2003) |
| "Chloroquine-resistant Plasmodium vivax malaria was first reported in India in 1995." | 3.72 | Monitoring the chloroquine sensitivity of Plasmodium vivax from Calcutta and Orissa, India. ( Addy, M; Bandyopadhyay, AK; Maji, AK; Nandy, A, 2003) |
| " All recurrent parasitemias occurred with whole blood levels of chloroquine plus desethylchloroquine exceeding 100 ng/ml." | 3.72 | Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. ( Baird, JK; Fryauff, DJ; Leksana, B; Subianto, B; Sumawinata, IW; Sutamihardja, A, 2003) |
| "To study the antimalarial effect of agmatine (Agm) on chloroquine-susceptible Plasmodium berghei K173 strain (S strain) and the P berghei K173 resistant strain (R strain)." | 3.72 | Antimalarial effect of agmatine on Plasmodium berghei K173 strain. ( Li, J; Liu, Y; Su, RB; Wei, XL, 2003) |
| "A non-compartmental pharmacokinetic model was used to describe the changes in gametocytaemia in nine children with chloroquine-sensitive Plasmodium falciparum malaria in whom asexual parasitaemia cleared within 72 h of chloroquine treatment." | 3.72 | Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections. ( Fateye, BA; Sowunmi, A, 2003) |
| "In Togo, chloroquine (CQ) remains the first-line drug for the treatment of uncomplicated, Plasmodium falciparum malaria." | 3.72 | Chloroquine efficacy in the treatment of uncomplicated malaria at three sentinel sites in northern Togo. ( Adjogble, K; Agbo, K; Avodagbe, A; Dekou, K; Djadou, KE; Kassankogno, Y; Malvy, JM; Millet, P; Morgah, K; Penali, KL; Pignandi, A; Sodahlon, YK; Sukwa, T, 2003) |
| "The effects of p-chlorophenylalanine, an inhibitor of serotonin synthesis, indomethacin, an inhibitor of prostaglandin synthesis, cyproheptadine, a serotonin, bradykinin and histamine antagonist, were assessed separately and in combination with chloroquine (CQ) in Vom strains of Swiss albino mice (18-22 g) of either sex infected intraperitoneally with 1 x 10(7) Plasmodium yoelii nigeriensis-induced malaria." | 3.72 | Effects of autacoid inhibitors and of an antagonist on malaria infection in mice. ( Agbani, EO; Iwalewa, EO, 2004) |
| " Seventy patients with Plasmodium falciparum malaria were included in a study of resistance to chloroquine and sulfadoxine-pyrimethamine therapy." | 3.70 | Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela. ( Caraballo, A; Rodriguez-Acosta, A, 1999) |
| "The spectrum of antimalarial activity of the new macrolide antibiotic azithromycin was evaluated against blood- and sporozoite-induced infections with a chloroquine-resistant strain of Plasmodium yoelii nigeriensis (N-67) in Swiss mice and with simian parasite Plasmodium cynomolgi B in rhesus monkeys." | 3.70 | Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. ( Puri, SK; Singh, N, 2000) |
| "The response to standard chloroquine treatment was evaluated, by microscopical examination of blood-smears, among 81 soldiers diagnosed with Plasmodium vivax malaria in South Korea in 1996." | 3.70 | Response to chloroquine of Plasmodium vivax among South Korean soldiers. ( Kim, DS; Kim, KH; Kim, MJ; Kim, YK; Lee, KN; Lim, CS; Strickman, D, 1999) |
| "1%) took anti-malaria prophylaxis (chloroquine) in the index pregnancy, and 136 (58." | 3.70 | Effect of chloroquine prophylaxis on birthweight and malaria parasite load among pregnant women delivering in a regional hospital in Cameroon. ( Ratard, R; Salihu, HM; Tchuinguem, G, 2000) |
| "Several compounds in current clinical use as antihistaminic agents, among them cyproheptadine (CYP), have been shown, in experimental models, to reverse resistance of the asexual, intra-erythrocytic stages of rodent or human malarial parasites to chloroquine (CQ)." | 3.70 | The chemotherapy of rodent malaria. LIX. Drug combinations to impede the selection of drug resistance, Part 3: Observations on cyproheptadine, an antihistaminic agent, with chloroquine. ( Butcher, GA; Peters, W; Robinson, BL; Stewart, LB, 2000) |
| " In a cohort of pregnant women enrolled at first antenatal clinic visit in rural Malawi, we evaluated reported fever, determined parasitemia, and placed the women on antimalarial regimens containing chloroquine (CQ) or mefloquine (MQ)." | 3.69 | Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. ( Breman, JG; Heymann, DL; Khoromana, CO; Slutsker, L; Steketee, RW; Wirima, JJ, 1996) |
| "The objective of the study was to determine the efficacy of chloroquine in pregnant women with Plasmodium falciparum parasitemia at therapeutic doses of 25 mg/kg body weight divided over 3 days." | 3.69 | Resistance to chloroquine therapy in pregnant women with malaria parasitemia. ( Ojwang, SB; Oyieke, JB; Rukaria-Kaumbutho, RM, 1996) |
| "Fenozan B07, a 1,2,4-trioxane endoperoxide with potent blood schizontocidal activity against drug-sensitive and drug-resistant rodent malaria parasites, exerted a modest potentiating action when administered with chloroquine (CQ) to mice infected with parasites of the CQ-resistant P." | 3.69 | The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites. ( Fleck, SL; Peters, W; Robinson, BL, 1997) |
| "The sensitivity to chloroquine according to the degree of synchronicity of Plasmodium yoelii nigeriensis, which is considered to be the most resistant of the rodent malaria strains, was studied." | 3.69 | Plasmodium yoelii nigeriensis: biological mechanisms of resistance to chloroquine. ( Altemayer-Caillard, V; Beauté-Lafitte, A; Chabaud, AG; Landau, I, 1994) |
| " Currently, there is no established treatment for Plasmodium vivax parasitemias that are not cured by chloroquine." | 3.69 | WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. ( Cooper, RD; Kyle, DE; Nuzum, EO; Obaldia, N; Rieckmann, KH; Rossan, RN; Shanks, GD, 1997) |
| "Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P." | 2.90 | Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. ( Abdissa, A; Abebe, C; Angus, B; Batista Pereira, D; Beck, HP; Brand, F; Breton, JJ; Brito, MAM; Buathong, N; Casapía, M; Chuquiyauri, R; Clover, DD; Costa, MRF; Diro, E; Duparc, S; Espino, FEJ; Fletcher, K; Getie, S; Green, JA; Hardaker, E; Jones, SW; Kellam, LM; Kleim, JP; Koh, GCKW; Krudsood, S; Lacerda, MVG; Llanos-Cuentas, A; Lon, C; Mia, RZ; Mohamed, K; Mohammed, R; Monteiro, WM; Noedl, H; Rousell, VM; Saunders, DL; Tada, MS; Ugwuegbulam, CO; Val, F; Wubie, KM; Yilma, D; Zeynudin, A, 2019) |
| "Malaria is a parasitic disease with the highest morbidity and mortality worldwide." | 2.82 | Action mechanisms of metallic compounds on Plasmodium spp. ( Brenda, CT; Marcela, RL; Nelly, LV; Norma, RF; Teresa I, F, 2022) |
| "Chloroquine (CQ) is the first-line treatment for vivax malaria in Ethiopia, but there is evidence for its declining efficacy." | 2.80 | Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. ( Abera, A; Aseffa, A; Auburn, S; Gadisa, E; Getachew, S; Petros, B; Price, RN; Thriemer, K, 2015) |
| " Serious adverse events (AEs; all causality) were observed more frequently with MQ compared with AZCQ (four vs one, respectively), though discontinuations for AEs were similar (four vs three, respectively)." | 2.79 | Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. ( Chandra, R; Dieng, Y; Djimdé, AA; Dunne, MW; Kain, KC; Mugyenyi, P; Mulenga, M; Oduro, AR; Ogutu, B; Robbins, J; Sagara, I; Sarkar, S; Sie, A; Tiono, AB; Wasunna, M, 2014) |
| "Tinidazole is a 5-nitroimidazole approved in the USA for the treatment of indications including amoebiasis and giardiasis." | 2.78 | Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse. ( Cheah, PY; Lwin, KM; Macareo, L; Miller, RS; Nosten, F; Yuentrakul, P, 2013) |
| "A safe and reproducible Plasmodium vivax infectious challenge method is required to evaluate the efficacy of malaria vaccine candidates." | 2.76 | Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. ( Arévalo-Herrera, M; Echavarría, JF; Epstein, JE; Herrera, S; Jordán-Villegas, A; Palacios, R; Ramírez, O; Richie, TL; Rocha, L; Solarte, Y; Vélez, JD, 2011) |
| "Chloroquine was used as first-line treatment for Plasmodium falciparum or Plasmodium vivax in Indonesia before the initial launch of artemisinin combination therapy in 2004." | 2.75 | Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. ( Baird, JK; Endawati, D; Laihad, F; Ling, LH; Setiabudy, R; Sutanto, I, 2010) |
| " The main outcome measures for safety were incidences of post-treatment clinical and laboratory adverse events." | 2.74 | Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. ( Geita, J; Hiawalyer, G; Hombhanje, FW; Jones, R; Kevau, I; Kuanch, C; Linge, D; Masta, A; Sapuri, M; Saweri, A; Toraso, S, 2009) |
| "Birth weight was analyzed through multivariate linear and logistic regressions." | 2.73 | The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa. ( Barro, D; Cot, M; Cottrell, G; Mary, JY, 2007) |
| "Self-reported CQ treatment of fever episodes at home as well as referrals to health centres increased over the study period." | 2.73 | Process and effects of a community intervention on malaria in rural Burkina Faso: randomized controlled trial. ( Becher, H; Coulibaly, B; Eriksen, J; Gustafsson, L; Jahn, A; Kouyaté, B; Mueller, O; Sauerborn, R; Somé, F; Tomson, G, 2008) |
| "The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed." | 2.72 | Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. ( Al Khaja, KAJ; Sequeira, RP, 2021) |
| " We evaluated the anti-relapse efficacy of total primaquine doses of 45, 105, and 210 mg administered at a dosage of 15 mg/day in 210 adults with P." | 2.72 | Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. ( Alvarez, G; Blair, S; Carmona-Fonseca, J; Maestre, A; Piñeros, JG; Ríos, A; Tobón, A, 2006) |
| "falciparum malaria were treated with either CQ monotherapy (n=120) or the combination of CQ plus three doses of AS (CQ/AS; n=352)." | 2.71 | Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. ( Coleman, R; Drakeley, CJ; Jawara, M; Obisike, U; Pinder, M; Sutherland, CJ; Targett, GA; Walraven, G, 2004) |
| "Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia." | 2.70 | Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. ( Ayomi, E; Baird, JK; Basri, H; Fryauff, DJ; Hoffman, SL; Sutanihardja, A; Wiady, I, 2002) |
| "falciparum malaria was compared with that of CQ, each drug being given at 10 mg/kg per day for 3 days (days 0, 1 and 2)." | 2.70 | Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children. ( Adedeji, AA; Ayede, AI; Falade, AG; Falade, CO; Happi, TC; Ndikum, VN; Oduola, AM; Sowunmi, A; Sowunmi, CO, 2001) |
| "Primaquine was better tolerated than chloroquine." | 2.68 | Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Leksana, B; Masbar, S; Richie, TL; Subianto, B; Wiady, I, 1995) |
| "falciparum for at least 14 days." | 2.68 | Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. ( Alin, MH; Ashton, M; Bjorkman, A; Bwijo, BA; Kihamia, CM; Mtey, GJ; Premji, Z, 1995) |
| "The efficacy and toxicity of oral quinine combined with oral chloroquine were studied in 50 Thai men with uncomplicated falciparum malaria." | 2.68 | Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria. ( Chantra, A; Chindanond, D; Clemens, R; Phophak, N; Pukrittayakamee, S; Vanijanonta, S, 1996) |
| "Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0." | 2.68 | Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997) |
| "Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment." | 2.66 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020) |
| " knowlesi than chloroquine, as confirmed by both methods, with a mean estimated parasite clearance half-life of 2." | 1.91 | Quantification of parasite clearance in Plasmodium knowlesi infections. ( Anstey, NM; Barber, BE; Cooper, DJ; Dini, S; Grigg, MJ; Haghiri, A; Rajahram, GS; Rajasekhar, M; Sakam, SS; Simpson, JA; T Thurai Rathnam, J; William, T, 2023) |
| " Conversely, when the W2 systems were dosed with chloroquine, parasitemia levels were moderately decreased when compared to the 3D7 model." | 1.91 | Development of a human malaria-on-a-chip disease model for drug efficacy and off-target toxicity evaluation. ( Comiter, B; Hickman, JJ; Long, CJ; McAleer, CW; Rupar, MJ; Sasserath, T; Smith, E; Sriram, N, 2023) |
| "Chloroquine (CQ) was one of the first drugs used for its treatment, but was officially withdrawn from the market in 2007 following reports of high levels of chloroquine resistance." | 1.48 | Low rates of Plasmodium falciparum Pfcrt K76T mutation in three sentinel sites of malaria monitoring in Côte d'Ivoire. ( Amiah-Droh, M; Bédia-Tanoh, VA; Gnagne, PA; Ignace Eby Menan, H; Konaté, A; Tano, DK; Yavo, W, 2018) |
| " The most promising compound (13) showed a reduction in parasitemia of 96% when dosed at 30 mg/kg orally once a day for 4 days in the P." | 1.43 | Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. ( Angulo-Barturen, I; Avery, VM; Baragaña, B; Campbell, SF; Duffy, S; Fairlamb, AH; Ferrer, S; Frearson, JA; Gamo, FJ; Gilbert, IH; Gray, DW; Grimaldi, R; Hallyburton, I; Jiménez-Díaz, B; Martínez, MS; Meister, S; Norcross, NR; Norval, S; Osuna-Cabello, M; Porzelle, A; Read, KD; Riley, J; Sanz, L; Simeons, FR; Stojanovski, L; Waterson, D; Willis, P; Wilson, C; Winzeler, EA; Wittlin, S, 2016) |
| "Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P." | 1.42 | Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015) |
| " The pharmacokinetic properties of active compounds were determined using a mouse model and blood samples were collected at different time intervals and analysed using LC-MS/MS." | 1.42 | Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. ( Andayi, A; Chibale, K; Dambuza, NS; Egan, T; Evans, A; Norman, J; Smith, P; Taylor, D; Wiesner, L, 2015) |
| "The chloroquine was treated by the actual drug content of effective nanochloroquine and the nanodrug was charged with its effective dose for fifteen days, after successive infection development in Swiss mice." | 1.39 | A novel chitosan based antimalarial drug delivery against Plasmodium berghei infection. ( Chattopadhyay, S; Das, S; Dash, SK; Mahapatra, SK; Majumder, S; Pramanik, P; Roy, S; Tripathy, S, 2013) |
| "Parasitemia was 4% on day 8 when compared to that on day 0, whereas it was 9% on day 9." | 1.38 | Comparative study of chloroquine and quinine on malaria rodents and their effects on the mouse testis. ( Abolghasemi, E; Davoudi, M; Moosa-Kazemi, SH; Reisi, A; Satvat, MT, 2012) |
| "vivax malaria were successfully analyzed using both the microscopic schizont maturation inhibition and SYBR Green-I assays." | 1.37 | Assessment of in vitro sensitivity of Plasmodium vivax fresh isolates. ( Chacharoenkul, W; Muhamad, P; Na-Bangchang, K; Ruengweerayut, R; Rungsihirunrat, K, 2011) |
| "Ellagic acid is a polyphenol found in various plant products." | 1.35 | In vitro and in vivo properties of ellagic acid in malaria treatment. ( Benoit-Vical, F; Berry, A; Garcia-Alvarez, MC; Nicolau, ML; Olagnier, D; Soh, PN; Witkowski, B, 2009) |
| "Parasite recrudescences in 33 consecutive paired episodes during the same pregnancy were identified by msp1 and msp2 genotyping." | 1.35 | Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009) |
| "In addition, on the day of recurrence of parasitaemia the levels of chloroquine-desethylchloroquine (CQ-DCQ) were above the minimum effective concentration (>or=100 etag/ml) in all the three cases, showing that treatment failure could not be attributed to low level of drug in the patients blood." | 1.35 | Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. ( Bacha, K; Birhanu, T; Ketema, T; Petros, B, 2009) |
| "Here we describe high rates of P." | 1.35 | Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. ( da Silva, NS; da Silva-Nunes, M; Ferreira, MU; Orjuela-Sánchez, P, 2009) |
| "Iron supplementation is employed to treat post-malarial anaemia in environments where iron deficiency is common." | 1.35 | Iron incorporation and post-malaria anaemia. ( Abrams, SA; Austin, S; Cox, SE; Doherty, CP; Fulford, AJ; Hilmers, DC; Prentice, AM, 2008) |
| "Falciparum Malaria is hyperendemic in southern Nigeria and chloroquine resistance is an increasing problem." | 1.33 | Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. ( Göbels, K; Graupner, J; Grobusch, MP; Häussinger, D; Lund, A; Richter, J, 2005) |
| "Sulfadoxine-pyremethamine treatment alone cured 68." | 1.33 | The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis. ( A-Elbasit, IE; Alifrangis, M; Elbashir, MI; Giha, HA; Khalil, IF, 2006) |
| "Treatment with quinine dihydrochloride i." | 1.33 | [Successful management of malaria tropica with 50% parasitaemia]. ( Eiffert, H; Möller, H; Ramadori, G; Reichard, U; Schwörer, H, 2006) |
| "Ferroquine is a derivative of chloroquine and shows good activity in vitro and in animal models, but the development of cross-resistance is of concern." | 1.33 | In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. ( Dietz, K; Kreidenweiss, A; Kremsner, PG; Mordmüller, B, 2006) |
| " The study findings showed that antimalarial property of goniothalamin was enhanced by combination with chloroquine at lower dose of each drug." | 1.33 | Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice. ( Khozirah, S; Mohd Ridzuan, MA; Noor Rain, A; Ruenruetai, U; Zakiah, I, 2006) |
| "falciparum malaria were initially treated with chloroquine (CQ)." | 1.32 | Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India. ( Barman, K; Dev, V; Phookan, S, 2003) |
| "Amodiaquine was 3." | 1.31 | In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar. ( Ariey, F; Duchemin, JB; Harisoa, JL; Mauclere, P; Pietra, V; Rabarijaona, LP; Raharimalala, LA; Rakotomanana, F; Ranaivo, L; Randrianarivelojosia, M; Robert, V, 2002) |
| "Chloroquine treatment reduced the index of gametocytogenesis to 73% (5 mg/kg) and 55% (2." | 1.31 | The effects of subcurative doses of chloroquine on Plasmodium vinckei petteri gametocytes and on their infectivity to mosquitoes. ( Chabaud, AG; Coquelin, F; Gautret, P; Jacquemin, JL; Landau, I; Miltgen, F; Tailhardat, L; Voza, T, 2000) |
| " From September to December 1998, 598 children with uncomplicated malaria were treated; 135 received chloroquine (CQ) alone, 276 received pyrimethamine/sulfadoxine (Fansidar, PSD) alone, 113 received PSD with a single dose of artesunate (PSD + 1ART) and 74 received PSD combined with three doses of artesunate (PSD + 3ART)." | 1.31 | Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. ( Coleman, R; Doherty, T; Jawara, M; Targett, G; von Seidlein, L; Walraven, G, 2001) |
| "Amodiaquine was shown to be more effective than chloroquine in clinical response and ridding patients of parasites: adequate clinical response was significantly higher with amodiaquine than chloroquine [100% (27/27) versus 45% (9/20), p < 0." | 1.31 | [Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon]. ( Bouyou Akotet, M; Guiyedi, V; Koko, J; Kombila, M; Mabika Manfoumbi, M; Matsiégui, PB; Traoré, B, 2001) |
| "Chloroquine-treated and artemether-treated parasites displayed a pigment-clumping morphology and lowered the parasitaemia faster than dioncophylline B." | 1.31 | A comparison of the stage-specific efficacy of chloroquine, artemether and dioncophylline B against the rodent malaria parasite Plasmodium chabaudi chabaudi in vivo. ( Bringmann, G; Chimanuka, B; François, G; Heyden, YV; Holenz, J; Plaizier-Vercammen, J; Timperman, G, 2001) |
| "Spermidine was not detectable after inhibition." | 1.31 | Effect of drugs inhibiting spermidine biosynthesis and metabolism on the in vitro development of Plasmodium falciparum. ( Gottwald, A; Kaiser, A; Lindenthal, B; Maier, W; Seitz, HM; Wiersch, C, 2001) |
| " The dose-response relationship between the severity of parasitaemia and the risk of being anaemic (P < 0." | 1.31 | Weekly chloroquine prophylaxis and the effect on maternal haemoglobin status at delivery. ( Bosny, JP; Dagne, G; Naik, EG; Salihu, HM; Tchuinguem, G, 2002) |
| "vivax parasitemias were sensitive to chloroquine and the blood remained clear, with the exception of one case in which an asymptomatic parasitemia appeared on day 28." | 1.30 | Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia. ( Baird, JK; Candradikusuma, D; Fryauff, DJ; Leksana, B; Marwoto, H; Masbar, S; Richie, T; Romzan, A; Sutamihardja, MA; Tuti, S, 1997) |
| "One case of cerebral malaria was noted." | 1.30 | [Malaria in an urban environment: the case of the city of Rufisque in Senegal]. ( Diallo, S; Dieng, Y; Faye, O; Feller-Dansokho, E; Gaye, O; Lakh, NC; Ndir, O, 1997) |
| "Ascending parasitemias were stopped by chloroquine treatment when they were between 1." | 1.30 | Plasmodium chabaudi chabaudi: effect of low parasitemias on immunity in CB6F1 mice. ( Favila-Castillo, L; Garcia-Tapia, D; Monroy-Ostria, A, 1999) |
| "Chloroquine was prescribed at 25 mg/kg for 3 days in febrile patients with uncomplicated P." | 1.30 | [Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)]. ( Ali, I; Bendavid, C; Condomines, P; Crassard, N; Djermakoye, F; Faugère, B; Parola, P, 1999) |
| "Treatment with chloroquine did not influence the intracellular level of GSH, but it was found to significantly decrease GR activity." | 1.29 | Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. ( Dubois, VL; Pauly, G; Platel, DF; Tribouley-Duret, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.32) | 18.7374 |
| 1990's | 56 (18.12) | 18.2507 |
| 2000's | 137 (44.34) | 29.6817 |
| 2010's | 95 (30.74) | 24.3611 |
| 2020's | 20 (6.47) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, C | 1 |
| Srivastav, NC | 1 |
| Puri, SK | 4 |
| de Andrade-Neto, VF | 2 |
| da Silva, T | 1 |
| Lopes, LM | 1 |
| do Rosário, VE | 2 |
| de Pilla Varotti, F | 1 |
| Krettli, AU | 2 |
| Yoshikawa, M | 1 |
| Motoshima, K | 1 |
| Fujimoto, K | 1 |
| Tai, A | 1 |
| Kakuta, H | 1 |
| Sasaki, K | 1 |
| Soh, PN | 1 |
| Witkowski, B | 1 |
| Olagnier, D | 1 |
| Nicolau, ML | 1 |
| Garcia-Alvarez, MC | 1 |
| Berry, A | 2 |
| Benoit-Vical, F | 2 |
| Madapa, S | 1 |
| Tusi, Z | 1 |
| Sridhar, D | 1 |
| Kumar, A | 1 |
| Siddiqi, MI | 1 |
| Srivastava, K | 2 |
| Rizvi, A | 1 |
| Tripathi, R | 1 |
| Shiva Keshava, GB | 1 |
| Shukla, PK | 1 |
| Batra, S | 1 |
| Hasugian, AR | 1 |
| Tjitra, E | 4 |
| Ratcliff, A | 1 |
| Siswantoro, H | 1 |
| Kenangalem, E | 1 |
| Wuwung, RM | 1 |
| Purba, HL | 1 |
| Piera, KA | 1 |
| Chalfien, F | 1 |
| Marfurt, J | 1 |
| Penttinen, PM | 1 |
| Russell, B | 1 |
| Anstey, NM | 3 |
| Price, RN | 2 |
| Nepveu, F | 1 |
| Kim, S | 1 |
| Boyer, J | 1 |
| Chatriant, O | 1 |
| Ibrahim, H | 1 |
| Reybier, K | 1 |
| Monje, MC | 1 |
| Chevalley, S | 2 |
| Perio, P | 1 |
| Lajoie, BH | 1 |
| Bouajila, J | 1 |
| Deharo, E | 3 |
| Sauvain, M | 1 |
| Tahar, R | 1 |
| Basco, L | 1 |
| Pantaleo, A | 1 |
| Turini, F | 1 |
| Arese, P | 1 |
| Valentin, A | 3 |
| Thompson, E | 1 |
| Vivas, L | 1 |
| Petit, S | 1 |
| Nallet, JP | 1 |
| Zishiri, VK | 1 |
| Joshi, MC | 1 |
| Hunter, R | 1 |
| Chibale, K | 2 |
| Smith, PJ | 1 |
| Summers, RL | 1 |
| Martin, RE | 1 |
| Egan, TJ | 1 |
| del Olmo, E | 1 |
| Barboza, B | 1 |
| Chiaradia, LD | 1 |
| Moreno, A | 2 |
| Carrero-Lérida, J | 1 |
| González-Pacanowska, D | 1 |
| Muñoz, V | 1 |
| López-Pérez, JL | 1 |
| Giménez, A | 1 |
| Benito, A | 1 |
| Martínez, AR | 1 |
| Ruiz-Pérez, LM | 1 |
| San Feliciano, A | 1 |
| Sá, MS | 1 |
| de Menezes, MN | 1 |
| Ribeiro, IM | 1 |
| Tomassini, TC | 1 |
| Ribeiro dos Santos, R | 1 |
| de Azevedo, WF | 1 |
| Soares, MB | 2 |
| Lowes, D | 1 |
| Pradhan, A | 1 |
| Iyer, LV | 1 |
| Parman, T | 1 |
| Gow, J | 1 |
| Zhu, F | 1 |
| Furimsky, A | 1 |
| Lemoff, A | 1 |
| Guiguemde, WA | 1 |
| Sigal, M | 1 |
| Clark, JA | 1 |
| Wilson, E | 1 |
| Tang, L | 1 |
| Connelly, MC | 1 |
| Derisi, JL | 1 |
| Kyle, DE | 3 |
| Mirsalis, J | 1 |
| Guy, RK | 1 |
| Cedrón, JC | 1 |
| Gutiérrez, D | 1 |
| Flores, N | 1 |
| Ravelo, ÁG | 1 |
| Estévez-Braun, A | 1 |
| Cross, RM | 1 |
| Flanigan, DL | 1 |
| Monastyrskyi, A | 1 |
| LaCrue, AN | 1 |
| Sáenz, FE | 1 |
| Maignan, JR | 1 |
| Mutka, TS | 1 |
| White, KL | 1 |
| Shackleford, DM | 1 |
| Bathurst, I | 1 |
| Fronczek, FR | 1 |
| Wojtas, L | 1 |
| Guida, WC | 1 |
| Charman, SA | 1 |
| Burrows, JN | 1 |
| Manetsch, R | 1 |
| Leven, M | 1 |
| Held, J | 3 |
| Duffy, S | 2 |
| Tschan, S | 1 |
| Sax, S | 1 |
| Kamber, J | 1 |
| Frank, W | 1 |
| Kuna, K | 1 |
| Geffken, D | 1 |
| Siethoff, C | 1 |
| Barth, S | 1 |
| Avery, VM | 2 |
| Wittlin, S | 4 |
| Mordmüller, B | 6 |
| Kurz, T | 1 |
| Giannini, G | 1 |
| Battistuzzi, G | 1 |
| Cohen, A | 1 |
| Suzanne, P | 1 |
| Lancelot, JC | 1 |
| Verhaeghe, P | 1 |
| Lesnard, A | 1 |
| Basmaciyan, L | 1 |
| Hutter, S | 1 |
| Laget, M | 1 |
| Dumètre, A | 1 |
| Paloque, L | 1 |
| Crozet, MD | 1 |
| Rathelot, P | 1 |
| Dallemagne, P | 1 |
| Lorthiois, A | 1 |
| Sibley, CH | 1 |
| Vanelle, P | 1 |
| Mazier, D | 1 |
| Rault, S | 1 |
| Azas, N | 1 |
| Norcross, NR | 1 |
| Baragaña, B | 1 |
| Wilson, C | 1 |
| Hallyburton, I | 1 |
| Osuna-Cabello, M | 1 |
| Norval, S | 1 |
| Riley, J | 1 |
| Stojanovski, L | 1 |
| Simeons, FR | 1 |
| Porzelle, A | 1 |
| Grimaldi, R | 1 |
| Meister, S | 1 |
| Sanz, L | 1 |
| Jiménez-Díaz, B | 1 |
| Angulo-Barturen, I | 2 |
| Ferrer, S | 1 |
| Martínez, MS | 1 |
| Gamo, FJ | 2 |
| Frearson, JA | 1 |
| Gray, DW | 1 |
| Fairlamb, AH | 1 |
| Winzeler, EA | 1 |
| Waterson, D | 1 |
| Campbell, SF | 1 |
| Willis, P | 2 |
| Read, KD | 1 |
| Gilbert, IH | 1 |
| Valverde, EA | 1 |
| Romero, AH | 1 |
| Acosta, ME | 1 |
| Gamboa, N | 1 |
| Henriques, G | 1 |
| Rodrigues, JR | 1 |
| Ciangherotti, C | 1 |
| López, SE | 1 |
| Quiliano, M | 1 |
| Pabón, A | 1 |
| Moles, E | 1 |
| Bonilla-Ramirez, L | 1 |
| Fabing, I | 1 |
| Fong, KY | 1 |
| Nieto-Aco, DA | 1 |
| Wright, DW | 1 |
| Pizarro, JC | 1 |
| Vettorazzi, A | 1 |
| López de Cerain, A | 1 |
| Fernández-Busquets, X | 2 |
| Garavito, G | 1 |
| Aldana, I | 1 |
| Galiano, S | 1 |
| Mallaupoma, LRC | 1 |
| Dias, BKM | 1 |
| Singh, MK | 1 |
| Honorio, RI | 1 |
| Nakabashi, M | 1 |
| Kisukuri, CM | 1 |
| Paixão, MW | 1 |
| Garcia, CRS | 1 |
| Brenda, CT | 1 |
| Norma, RF | 1 |
| Marcela, RL | 1 |
| Nelly, LV | 1 |
| Teresa I, F | 1 |
| Ojueromi, OO | 1 |
| Oboh, G | 1 |
| Ademosun, AO | 1 |
| Morais, CMG | 1 |
| Brito, RMM | 1 |
| Weselucha-Birczyńska, A | 1 |
| Pereira, VSS | 1 |
| Pereira-Silva, JW | 1 |
| Menezes, A | 1 |
| Pessoa, FAC | 1 |
| Kucharska, M | 1 |
| Birczyńska-Zych, M | 1 |
| Ríos-Velásquez, CM | 1 |
| T Thurai Rathnam, J | 1 |
| Grigg, MJ | 1 |
| Dini, S | 1 |
| William, T | 2 |
| Sakam, SS | 1 |
| Cooper, DJ | 1 |
| Rajahram, GS | 1 |
| Barber, BE | 1 |
| Haghiri, A | 1 |
| Rajasekhar, M | 1 |
| Simpson, JA | 2 |
| Mekonnen, DA | 1 |
| Abadura, GS | 1 |
| Behaksra, SW | 1 |
| Taffese, HS | 1 |
| Bayissa, GA | 1 |
| Bulto, MG | 1 |
| Tessema, TS | 1 |
| Tadesse, FG | 1 |
| Gadisa, E | 2 |
| Ariefta, NR | 1 |
| Pagmadulam, B | 1 |
| Hatano, M | 1 |
| Ikeda, N | 1 |
| Isshiki, K | 1 |
| Matoba, K | 1 |
| Igarashi, M | 1 |
| Nihei, CI | 1 |
| Nishikawa, Y | 1 |
| Rupar, MJ | 1 |
| Sasserath, T | 1 |
| Smith, E | 1 |
| Comiter, B | 1 |
| Sriram, N | 1 |
| Long, CJ | 1 |
| McAleer, CW | 1 |
| Hickman, JJ | 1 |
| Nguyen, TT | 2 |
| Nzigou Mombo, B | 1 |
| Lalremruata, A | 2 |
| Koehne, E | 1 |
| Zoleko Manego, R | 1 |
| Dimessa Mbadinga, LB | 1 |
| Adegnika, AA | 1 |
| Agnandji, ST | 1 |
| Lell, B | 1 |
| Kremsner, PG | 4 |
| Velavan, TP | 1 |
| Ramharter, M | 1 |
| Mombo-Ngoma, G | 1 |
| Pukáncsik, M | 1 |
| Molnár, P | 1 |
| Orbán, Á | 1 |
| Butykai, Á | 1 |
| Marton, L | 1 |
| Kézsmárki, I | 1 |
| Vértessy, BG | 1 |
| Kamil, M | 1 |
| Abraham, A | 1 |
| Aly, ASI | 1 |
| Orabueze, CI | 1 |
| Obi, E | 1 |
| Adesegun, SA | 1 |
| Coker, HA | 1 |
| Sahu, S | 1 |
| Ghosh, SK | 1 |
| Kalita, JM | 1 |
| Ginjupalli, MC | 1 |
| K, KR | 1 |
| Nutmakul, T | 1 |
| Pattanapanyasat, K | 1 |
| Soonthornchareonnon, N | 1 |
| Shiomi, K | 1 |
| Mori, M | 1 |
| Prathanturarug, S | 1 |
| Rodrigo, C | 1 |
| Rajapakse, S | 1 |
| Fernando, D | 1 |
| Jongo, SA | 1 |
| Urbano, V | 1 |
| Church, LWP | 1 |
| Olotu, A | 1 |
| Manock, SR | 1 |
| Schindler, T | 1 |
| Mtoro, A | 1 |
| Kc, N | 2 |
| Hamad, A | 2 |
| Nyakarungu, E | 1 |
| Mpina, M | 1 |
| Deal, A | 1 |
| Bijeri, JR | 1 |
| Ondo Mangue, ME | 1 |
| Ntutumu Pasialo, BE | 1 |
| Nguema, GN | 1 |
| Owono, SN | 1 |
| Rivas, MR | 1 |
| Chemba, M | 1 |
| Kassim, KR | 1 |
| James, ER | 1 |
| Stabler, TC | 1 |
| Abebe, Y | 1 |
| Saverino, E | 1 |
| Sax, J | 1 |
| Hosch, S | 1 |
| Tumbo, AM | 1 |
| Gondwe, L | 1 |
| Segura, JL | 1 |
| Falla, CC | 1 |
| Phiri, WP | 1 |
| Hergott, DEB | 1 |
| García, GA | 1 |
| Schwabe, C | 1 |
| Maas, CD | 1 |
| Murshedkar, T | 1 |
| Billingsley, PF | 1 |
| Tanner, M | 1 |
| Ayekaba, MO | 1 |
| Sim, BKL | 2 |
| Daubenberger, C | 1 |
| Richie, TL | 8 |
| Abdulla, S | 1 |
| Hoffman, SL | 5 |
| Al Khaja, KAJ | 1 |
| Sequeira, RP | 1 |
| Zaid, OI | 1 |
| Abd Majid, R | 1 |
| Sidek, HM | 1 |
| Noor, SM | 1 |
| Abd Rachman-Isnadi, MF | 1 |
| Bello, RO | 1 |
| Chin, VK | 1 |
| Basir, R | 1 |
| Usman, MA | 1 |
| Usman, FI | 1 |
| Abubakar, MS | 1 |
| Salman, AA | 1 |
| Adamu, A | 1 |
| Ibrahim, MA | 1 |
| Sulyok, Z | 1 |
| Fendel, R | 1 |
| Eder, B | 1 |
| Lorenz, FR | 1 |
| Karnahl, M | 1 |
| Adjadi, FAC | 1 |
| Klockenbring, T | 1 |
| Flügge, J | 1 |
| Woldearegai, TG | 1 |
| Lamsfus Calle, C | 1 |
| Ibáñez, J | 1 |
| Rodi, M | 1 |
| Egger-Adam, D | 1 |
| Kreidenweiss, A | 2 |
| Köhler, C | 1 |
| Esen, M | 1 |
| Sulyok, M | 1 |
| Manoj, A | 1 |
| Nuwagira, C | 1 |
| Peter, EL | 1 |
| Ajayi, CO | 1 |
| Adriko, J | 1 |
| Kagoro, GR | 1 |
| Olet, EA | 1 |
| Ogwang, PE | 1 |
| Tolo, CU | 1 |
| Mahajan, E | 1 |
| Sinha, S | 1 |
| Bhatia, A | 1 |
| Sehgal, R | 1 |
| Medhi, B | 1 |
| Toukam, LL | 1 |
| Tatsinkou Fossi, B | 1 |
| Taiwe, GS | 1 |
| Bila, RB | 1 |
| Feugaing Sofeu, DD | 1 |
| Ivo, EP | 1 |
| Achidi, EA | 1 |
| Gunawardena, S | 1 |
| Daniels, RF | 1 |
| Yahathugoda, TC | 1 |
| Weerasooriya, MV | 1 |
| Durfee, K | 1 |
| Volkman, SK | 1 |
| Wirth, DF | 1 |
| Karunaweera, ND | 1 |
| McLean, ARD | 1 |
| Boel, M | 1 |
| McGready, R | 2 |
| Ataide, R | 1 |
| Drew, D | 1 |
| Tsuboi, T | 1 |
| Beeson, JG | 1 |
| Nosten, F | 5 |
| Fowkes, FJI | 1 |
| Agarwal, P | 1 |
| Soni, A | 1 |
| Perumal, P | 1 |
| Sowmiya, R | 1 |
| Prasanna Kumar, S | 1 |
| Ravikumar, S | 1 |
| Deepak, P | 1 |
| Balasubramani, G | 1 |
| Sandoval, E | 1 |
| Lafuente-Monasterio, MJ | 1 |
| Almela, MJ | 1 |
| Castañeda, P | 1 |
| Jiménez Díaz, MB | 1 |
| Martínez-Martínez, MS | 1 |
| Vidal, J | 1 |
| Bamborough, P | 1 |
| Burrows, J | 1 |
| Cammack, N | 1 |
| Chaparro, MJ | 1 |
| Coterón, JM | 1 |
| de Cozar, C | 1 |
| Crespo, B | 1 |
| Díaz, B | 1 |
| Drewes, G | 1 |
| Fernández, E | 1 |
| Ferrer-Bazaga, S | 1 |
| Fraile, MT | 1 |
| Ghidelli-Disse, S | 1 |
| Gómez, R | 1 |
| Haselden, J | 1 |
| Huss, S | 1 |
| León, ML | 1 |
| de Mercado, J | 1 |
| Macdonald, SJF | 1 |
| Martín Hernando, JI | 1 |
| Prats, S | 1 |
| Puente, M | 1 |
| Rodríguez, A | 1 |
| de la Rosa, JC | 1 |
| Rueda, L | 1 |
| Selenski, C | 1 |
| Wilson, DM | 1 |
| Witty, M | 1 |
| Calderón, F | 1 |
| Sortica, VA | 1 |
| Lindenau, JD | 1 |
| Cunha, MG | 1 |
| O Ohnishi, MD | 1 |
| R Ventura, AM | 1 |
| Ribeiro-Dos-Santos, ÂK | 1 |
| Santos, SE | 1 |
| Guimarães, LS | 1 |
| Hutz, MH | 1 |
| Chu, CS | 2 |
| Phyo, AP | 1 |
| Lwin, KM | 2 |
| Win, HH | 1 |
| San, T | 1 |
| Aung, AA | 1 |
| Raksapraidee, R | 1 |
| Carrara, VI | 1 |
| Bancone, G | 2 |
| Watson, J | 1 |
| Moore, KA | 1 |
| Wiladphaingern, J | 1 |
| Proux, S | 1 |
| Sriprawat, K | 1 |
| Winterberg, M | 1 |
| Cheah, PY | 2 |
| Chue, AL | 1 |
| Tarning, J | 1 |
| Imwong, M | 2 |
| White, NJ | 2 |
| Reis, PA | 1 |
| Pais, KC | 1 |
| Pereira, MF | 1 |
| Douradinha, B | 1 |
| Costa, NF | 1 |
| Kaiser, CR | 1 |
| Bozza, PT | 1 |
| Areas, ALL | 1 |
| Zalis, MG | 1 |
| de Lima Ferreira, M | 1 |
| de Souza, MVN | 1 |
| da Silva Frutuoso, V | 1 |
| de Castro-Faria-Neto, HC | 1 |
| Konaté, A | 2 |
| Gnagne, PA | 1 |
| Bédia-Tanoh, VA | 1 |
| Amiah-Droh, M | 1 |
| Tano, DK | 1 |
| Ignace Eby Menan, H | 1 |
| Yavo, W | 2 |
| Lacerda, MVG | 2 |
| Llanos-Cuentas, A | 2 |
| Krudsood, S | 3 |
| Lon, C | 1 |
| Saunders, DL | 1 |
| Mohammed, R | 1 |
| Yilma, D | 1 |
| Batista Pereira, D | 1 |
| Espino, FEJ | 1 |
| Mia, RZ | 1 |
| Chuquiyauri, R | 2 |
| Val, F | 2 |
| Casapía, M | 2 |
| Monteiro, WM | 2 |
| Brito, MAM | 2 |
| Costa, MRF | 2 |
| Buathong, N | 1 |
| Noedl, H | 1 |
| Diro, E | 1 |
| Getie, S | 1 |
| Wubie, KM | 1 |
| Abdissa, A | 1 |
| Zeynudin, A | 2 |
| Abebe, C | 1 |
| Tada, MS | 1 |
| Brand, F | 1 |
| Beck, HP | 1 |
| Angus, B | 2 |
| Duparc, S | 3 |
| Kleim, JP | 1 |
| Kellam, LM | 1 |
| Rousell, VM | 2 |
| Jones, SW | 2 |
| Hardaker, E | 2 |
| Mohamed, K | 2 |
| Clover, DD | 2 |
| Fletcher, K | 1 |
| Breton, JJ | 2 |
| Ugwuegbulam, CO | 1 |
| Green, JA | 2 |
| Koh, GCKW | 2 |
| Hien, TT | 1 |
| Vélez, ID | 1 |
| Namaik-Larp, C | 1 |
| Villegas, MF | 1 |
| Nguyen, CH | 1 |
| Aruachan, S | 1 |
| Papwijitsil, R | 1 |
| Nosten, FH | 1 |
| Craig, G | 1 |
| Kendall, L | 1 |
| Wilches, VM | 1 |
| Ye, Z | 1 |
| Van Dyke, K | 1 |
| Rossan, RN | 2 |
| Muhamad, P | 1 |
| Chacharoenkul, W | 1 |
| Rungsihirunrat, K | 1 |
| Ruengweerayut, R | 1 |
| Na-Bangchang, K | 1 |
| Abolghasemi, E | 1 |
| Moosa-Kazemi, SH | 1 |
| Davoudi, M | 1 |
| Reisi, A | 1 |
| Satvat, MT | 1 |
| Olanlokun, JO | 1 |
| Bolaji, OM | 1 |
| Agbedahunsi, JM | 1 |
| Olorunsogo, OO | 1 |
| Hwang, J | 1 |
| Alemayehu, BH | 1 |
| Reithinger, R | 1 |
| Tekleyohannes, SG | 1 |
| Birhanu, SG | 1 |
| Demeke, L | 1 |
| Hoos, D | 1 |
| Melaku, Z | 1 |
| Kassa, M | 1 |
| Jima, D | 1 |
| Malone, JL | 1 |
| Nettey, H | 1 |
| Green, M | 1 |
| Poe, A | 1 |
| Akinyi, S | 1 |
| Udhayakumar, V | 1 |
| Kachur, SP | 1 |
| Filler, S | 1 |
| Macareo, L | 2 |
| Yuentrakul, P | 1 |
| Miller, RS | 1 |
| Kikueta, CM | 1 |
| Kambu, OK | 1 |
| Mbenza, AP | 1 |
| Mavinga, ST | 1 |
| Mbamu, BM | 1 |
| Cos, P | 1 |
| Maes, L | 1 |
| Apers, S | 1 |
| Pieters, L | 1 |
| Cimanga, RK | 1 |
| Tripathy, S | 2 |
| Mahapatra, SK | 1 |
| Chattopadhyay, S | 2 |
| Das, S | 2 |
| Dash, SK | 2 |
| Majumder, S | 1 |
| Pramanik, P | 1 |
| Roy, S | 2 |
| Sharma, L | 1 |
| Shukla, G | 1 |
| Bustos, MD | 1 |
| Wongsrichanalai, C | 2 |
| Delacollette, C | 1 |
| Burkholder, B | 1 |
| Doll, KL | 1 |
| Butler, NS | 1 |
| Harty, JT | 1 |
| Urbán, P | 1 |
| Valle-Delgado, JJ | 1 |
| Mauro, N | 1 |
| Marques, J | 1 |
| Manfredi, A | 1 |
| Rottmann, M | 1 |
| Ranucci, E | 1 |
| Ferruti, P | 1 |
| Lopes, SC | 3 |
| Albrecht, L | 2 |
| Carvalho, BO | 1 |
| Siqueira, AM | 3 |
| Thomson-Luque, R | 1 |
| Nogueira, PA | 2 |
| Fernandez-Becerra, C | 1 |
| Del Portillo, HA | 1 |
| Russell, BM | 1 |
| Rénia, L | 3 |
| Lacerda, MV | 4 |
| Costa, FT | 3 |
| Oluwatosin, A | 1 |
| Tolulope, A | 1 |
| Ayokulehin, K | 1 |
| Patricia, O | 1 |
| Aderemi, K | 1 |
| Catherine, F | 1 |
| Olusegun, A | 1 |
| Sohsuebngarm, D | 1 |
| Sasipreeyajan, J | 1 |
| Nithiuthai, S | 1 |
| Chansiripornchai, N | 1 |
| Laothamatas, J | 1 |
| Sammet, CL | 1 |
| Golay, X | 1 |
| Van Cauteren, M | 1 |
| Lekprasert, V | 1 |
| Tangpukdee, N | 2 |
| Leowattana, W | 1 |
| Wilairatana, P | 4 |
| Swaminathan, SV | 1 |
| DeLaPaz, RL | 1 |
| Brown, TR | 1 |
| Looareesuwan, S | 3 |
| Brittenham, GM | 1 |
| Dos-Santos, JC | 1 |
| Angerami, RN | 1 |
| Castiñeiras, CM | 1 |
| Garcia, MT | 1 |
| Levy, CE | 1 |
| Moretti, ML | 1 |
| Coutinho, LI | 1 |
| Gurgel, RL | 1 |
| Su, WC | 1 |
| Carvalho, LM | 1 |
| Benzecry, SG | 1 |
| Alencar, AC | 2 |
| Alexandre, MA | 1 |
| Alecrim, MG | 1 |
| Gebru, T | 1 |
| Kalesse, M | 1 |
| Jansen, R | 1 |
| Gerth, K | 1 |
| Müller, R | 1 |
| Raccurt, CP | 1 |
| Brasseur, P | 2 |
| Lemoine, F | 1 |
| Cicéron, M | 1 |
| Existe, A | 1 |
| Boncy, J | 1 |
| Sahu, R | 1 |
| Walker, LA | 1 |
| Tekwani, BL | 1 |
| Price, C | 1 |
| Ashbaugh, C | 1 |
| Miller, AL | 1 |
| Loscalzo, J | 1 |
| Sagara, I | 1 |
| Oduro, AR | 2 |
| Mulenga, M | 1 |
| Dieng, Y | 2 |
| Ogutu, B | 1 |
| Tiono, AB | 1 |
| Mugyenyi, P | 2 |
| Sie, A | 2 |
| Wasunna, M | 1 |
| Kain, KC | 2 |
| Djimdé, AA | 1 |
| Sarkar, S | 1 |
| Chandra, R | 1 |
| Robbins, J | 2 |
| Dunne, MW | 2 |
| Chowdhuri, AR | 1 |
| Sahu, SK | 1 |
| Majumdar, S | 1 |
| Nahrendorf, W | 1 |
| Spence, PJ | 1 |
| Tumwine, I | 1 |
| Lévy, P | 1 |
| Jarra, W | 1 |
| Sauerwein, RW | 2 |
| Langhorne, J | 1 |
| Schats, R | 1 |
| Bijker, EM | 1 |
| van Gemert, GJ | 2 |
| Graumans, W | 1 |
| van de Vegte-Bolmer, M | 2 |
| van Lieshout, L | 1 |
| Haks, MC | 1 |
| Hermsen, CC | 2 |
| Scholzen, A | 1 |
| Visser, LG | 1 |
| Bankole, AE | 1 |
| Adekunle, AA | 1 |
| Sowemimo, AA | 1 |
| Umebese, CE | 1 |
| Abiodun, O | 2 |
| Gbotosho, GO | 7 |
| Basu, A | 1 |
| Saha, S | 1 |
| Guha, SK | 1 |
| Dambuza, NS | 1 |
| Smith, P | 1 |
| Evans, A | 1 |
| Norman, J | 1 |
| Taylor, D | 1 |
| Andayi, A | 1 |
| Egan, T | 1 |
| Wiesner, L | 1 |
| Getachew, S | 1 |
| Thriemer, K | 1 |
| Auburn, S | 1 |
| Abera, A | 1 |
| Aseffa, A | 2 |
| Petros, B | 3 |
| Cheruiyot, AC | 1 |
| Auschwitz, JM | 1 |
| Lee, PJ | 1 |
| Yeda, RA | 1 |
| Okello, CO | 1 |
| Leed, SE | 1 |
| Talwar, M | 1 |
| Murthy, T | 1 |
| Gaona, HW | 1 |
| Hickman, MR | 1 |
| Akala, HM | 1 |
| Kamau, E | 1 |
| Johnson, JD | 1 |
| Oyinloye, OE | 1 |
| Kosoko, AM | 1 |
| Emikpe, B | 1 |
| Falade, CO | 3 |
| Ademowo, OG | 1 |
| Mavondo, GA | 2 |
| Mkhwananzi, BN | 2 |
| Mabandla, MV | 3 |
| Lobo, L | 1 |
| Sousa, Bd | 1 |
| Cabral, L | 1 |
| Cristiano, ML | 1 |
| Nogueira, F | 1 |
| Macedo, TS | 1 |
| Colina-Vegas, L | 1 |
| DA Paixão, M | 1 |
| Navarro, M | 1 |
| Barreto, BC | 1 |
| Oliveira, PC | 1 |
| Macambira, SG | 1 |
| Machado, M | 1 |
| Prudêncio, M | 1 |
| D'Alessandro, S | 1 |
| Basilico, N | 1 |
| Moreira, DR | 1 |
| Batista, AA | 1 |
| Cysne, DN | 1 |
| Fortes, TS | 1 |
| Reis, AS | 1 |
| de Paulo Ribeiro, B | 1 |
| Dos Santos Ferreira, A | 1 |
| do Amaral, FM | 1 |
| Guerra, RN | 1 |
| Marinho, CR | 1 |
| Nicolete, R | 1 |
| Nascimento, FR | 1 |
| Musabayane, CT | 2 |
| Chukwuocha, UM | 1 |
| Fernández-Rivera, O | 1 |
| Legorreta-Herrera, M | 1 |
| Phiri, K | 1 |
| Kimani, J | 1 |
| Mtove, GA | 1 |
| Zhao, Q | 1 |
| Rojo, R | 1 |
| Ayoub, A | 1 |
| Vandenbroucke, P | 1 |
| Sibiya, HP | 1 |
| Melo, GC | 1 |
| Magalhaes, BL | 1 |
| Machado, K | 1 |
| Alencar Filho, AC | 1 |
| Kuehn, A | 1 |
| Marques, MM | 1 |
| Manso, MC | 1 |
| Felger, I | 1 |
| Vieira, JL | 1 |
| Lameyre, V | 1 |
| Daniel-Ribeiro, CT | 1 |
| Pisciotta, JM | 1 |
| Scholl, PF | 1 |
| Shuman, JL | 1 |
| Shualev, V | 1 |
| Sullivan, DJ | 1 |
| Seifu, S | 1 |
| Zemene, E | 1 |
| Suleman, S | 1 |
| Biruksew, A | 1 |
| Adam, I | 2 |
| Elmardi, KA | 1 |
| Malik, EM | 1 |
| Collins, WE | 5 |
| Sullivan, JS | 5 |
| Nace, D | 2 |
| Williams, T | 2 |
| Williams, A | 2 |
| Barnwell, JW | 2 |
| Teka, H | 1 |
| Yamuah, L | 1 |
| Tesfaye, G | 1 |
| Elhassan, I | 1 |
| Muchohi, S | 1 |
| Kokwaro, G | 1 |
| Engers, H | 1 |
| Okokon, JE | 1 |
| Nwafor, PA | 1 |
| Laranjeiras, RF | 1 |
| Brant, LC | 1 |
| Lima, AC | 1 |
| Coelho, PM | 1 |
| Braga, EM | 1 |
| Mayor, A | 1 |
| Serra-Casas, E | 1 |
| Bardají, A | 1 |
| Sanz, S | 1 |
| Puyol, L | 1 |
| Cisteró, P | 1 |
| Sigauque, B | 1 |
| Mandomando, I | 1 |
| Aponte, JJ | 1 |
| Alonso, PL | 1 |
| Menéndez, C | 1 |
| Rogers, WO | 2 |
| Sem, R | 1 |
| Tero, T | 1 |
| Chim, P | 1 |
| Lim, P | 1 |
| Muth, S | 1 |
| Socheat, D | 1 |
| Ariey, F | 2 |
| Ogunfowokan, O | 1 |
| Dankyau, M | 1 |
| Madaki, AJ | 1 |
| Thacher, TD | 3 |
| Silveira, P | 1 |
| Vashist, U | 2 |
| Cabral, A | 1 |
| Amaral, KB | 1 |
| Soares, GL | 1 |
| Dagosto, M | 1 |
| Blanco, YC | 1 |
| Justo, GZ | 1 |
| Rodrigues, FL | 1 |
| Goelnitz, U | 1 |
| Wunderlich, G | 1 |
| Facchini, G | 1 |
| Brocchi, M | 1 |
| Duran, N | 1 |
| Periyanayagam, K | 1 |
| Nirmala Devi, K | 1 |
| Suseela, L | 1 |
| Uma, A | 1 |
| Ismail, M | 1 |
| Kiboi, DM | 1 |
| Irungu, BN | 1 |
| Langat, B | 1 |
| Brun, R | 2 |
| Chollet, J | 1 |
| Nganga, JK | 1 |
| Nyambati, VC | 1 |
| Rukunga, GM | 1 |
| Bell, A | 1 |
| Nzila, A | 1 |
| Daneshvar, C | 2 |
| Davis, TM | 2 |
| Cox-Singh, J | 2 |
| Rafa'ee, MZ | 2 |
| Zakaria, SK | 2 |
| Divis, PC | 2 |
| Singh, B | 2 |
| Roestenberg, M | 1 |
| McCall, M | 1 |
| Hopman, J | 1 |
| Wiersma, J | 1 |
| Luty, AJ | 1 |
| van Schaijk, B | 1 |
| Teelen, K | 1 |
| Arens, T | 1 |
| Spaarman, L | 1 |
| de Mast, Q | 1 |
| Roeffen, W | 1 |
| Snounou, G | 2 |
| van der Ven, A | 1 |
| Sauerwein, R | 1 |
| Ketema, T | 2 |
| Bacha, K | 2 |
| Birhanu, T | 1 |
| Hombhanje, FW | 1 |
| Linge, D | 1 |
| Saweri, A | 1 |
| Kuanch, C | 1 |
| Jones, R | 1 |
| Toraso, S | 1 |
| Geita, J | 1 |
| Masta, A | 1 |
| Kevau, I | 1 |
| Hiawalyer, G | 1 |
| Sapuri, M | 1 |
| Carvalhaes, R | 1 |
| D'agosto, M | 1 |
| da Silva, AD | 1 |
| Yeshiwondim, AK | 1 |
| Tekle, AH | 1 |
| Dengela, DO | 1 |
| Yohannes, AM | 1 |
| Teklehaimanot, A | 1 |
| Nakibuuka, V | 1 |
| Ndeezi, G | 1 |
| Nakiboneka, D | 1 |
| Ndugwa, CM | 1 |
| Tumwine, JK | 1 |
| Moneriz, C | 2 |
| Marín-García, P | 2 |
| Bautista, JM | 2 |
| Diez, A | 2 |
| Puyet, A | 2 |
| Orjuela-Sánchez, P | 1 |
| da Silva, NS | 1 |
| da Silva-Nunes, M | 1 |
| Ferreira, MU | 1 |
| Coste, A | 1 |
| Lopez, A | 1 |
| Pipy, B | 1 |
| Sutanto, I | 1 |
| Endawati, D | 1 |
| Ling, LH | 1 |
| Laihad, F | 1 |
| Setiabudy, R | 1 |
| Baird, JK | 8 |
| Min-Oo, G | 1 |
| Ayi, K | 1 |
| Bongfen, SE | 1 |
| Tam, M | 1 |
| Radovanovic, I | 1 |
| Gauthier, S | 1 |
| Santiago, H | 1 |
| Rothfuchs, AG | 1 |
| Roffê, E | 1 |
| Sher, A | 1 |
| Mullick, A | 1 |
| Fortin, A | 1 |
| Stevenson, MM | 1 |
| Gros, P | 1 |
| Kinzer, MH | 1 |
| Chand, K | 1 |
| Basri, H | 5 |
| Lederman, ER | 1 |
| Susanti, AI | 1 |
| Elyazar, I | 1 |
| Taleo, G | 1 |
| Bangs, MJ | 5 |
| Maguire, JD | 1 |
| Herbas, MS | 1 |
| Ueta, YY | 1 |
| Ichikawa, C | 1 |
| Chiba, M | 1 |
| Ishibashi, K | 1 |
| Shichiri, M | 1 |
| Fukumoto, S | 1 |
| Yokoyama, N | 1 |
| Takeya, M | 1 |
| Xuan, X | 1 |
| Arai, H | 1 |
| Suzuki, H | 1 |
| Samy, K | 1 |
| Kadarkari, M | 1 |
| Lekana-Douki, JB | 1 |
| Dinzouna Boutamba, SD | 1 |
| Zatra, R | 1 |
| Zang Edou, SE | 1 |
| Ekomy, H | 1 |
| Bisvigou, U | 1 |
| Toure-Ndouo, FS | 1 |
| Herrera, S | 1 |
| Solarte, Y | 1 |
| Jordán-Villegas, A | 1 |
| Echavarría, JF | 1 |
| Rocha, L | 1 |
| Palacios, R | 1 |
| Ramírez, O | 1 |
| Vélez, JD | 1 |
| Epstein, JE | 1 |
| Arévalo-Herrera, M | 1 |
| Nurul Aiezzah, Z | 1 |
| Noor, E | 1 |
| Hasidah, MS | 1 |
| Getahun, K | 1 |
| García-Granados, A | 1 |
| Moore, BR | 1 |
| Page-Sharp, M | 1 |
| Stoney, JR | 1 |
| Ilett, KF | 1 |
| Jago, JD | 1 |
| Batty, KT | 1 |
| Menon, J | 1 |
| Rajahram, G | 1 |
| Chan, L | 1 |
| Ma, G | 1 |
| Donaldson, S | 1 |
| Khoo, S | 1 |
| Frederick, C | 1 |
| Jelip, J | 1 |
| Yeo, TW | 1 |
| Friesen, J | 1 |
| Matuschewski, K | 1 |
| Happi, CT | 2 |
| Woranola, O | 1 |
| Abiodun, OO | 1 |
| Sowunmi, A | 13 |
| Oduola, AM | 8 |
| Kiyingi, HS | 1 |
| Egwang, TG | 1 |
| Nannyonga, M | 1 |
| Okuboyejo, TM | 1 |
| Oróstegui-Pinilla, D | 1 |
| Rodríguez-Morales, AJ | 1 |
| Congpuon, K | 1 |
| Satimai, W | 2 |
| Sujariyakul, A | 1 |
| Intanakom, S | 1 |
| Harnpitakpong, W | 1 |
| Pranuth, Y | 1 |
| Cholpol, S | 1 |
| Bualombai, P | 1 |
| Srivastava, HC | 1 |
| Chandrashekar, P | 1 |
| Kurien, G | 1 |
| Sreehari, U | 1 |
| Yadav, RS | 2 |
| Deye, GA | 1 |
| Gettayacamin, M | 1 |
| Hansukjariya, P | 1 |
| Im-erbsin, R | 1 |
| Sattabongkot, J | 1 |
| Rothstein, Y | 1 |
| Fracisco, S | 1 |
| Bennett, K | 1 |
| Magill, AJ | 1 |
| Ohrt, C | 1 |
| Wijayalath, W | 1 |
| Cheesman, S | 1 |
| Tanabe, K | 1 |
| Handunnetti, S | 1 |
| Carter, R | 1 |
| Pathirana, S | 1 |
| Dai, M | 1 |
| Freeman, B | 1 |
| Shikani, HJ | 1 |
| Bruno, FP | 1 |
| Collado, JE | 1 |
| Macias, R | 1 |
| Reznik, SE | 1 |
| Davies, P | 1 |
| Spray, DC | 1 |
| Tanowitz, HB | 1 |
| Weiss, LM | 1 |
| Desruisseaux, MS | 1 |
| Ishih, A | 2 |
| Kawakami, C | 1 |
| Todoroki, A | 1 |
| Hirai, H | 1 |
| Ohori, K | 1 |
| Kobayashi, F | 1 |
| Wiady, I | 3 |
| Sutanihardja, A | 1 |
| Ayomi, E | 2 |
| Fryauff, DJ | 9 |
| Phan, GT | 1 |
| de Vries, PJ | 1 |
| Tran, BQ | 1 |
| Le, HQ | 1 |
| Nguyen, NV | 1 |
| Nguyen, TV | 1 |
| Heisterkamp, SH | 1 |
| Kager, PA | 1 |
| Randrianarivelojosia, M | 1 |
| Harisoa, JL | 1 |
| Rabarijaona, LP | 1 |
| Raharimalala, LA | 1 |
| Ranaivo, L | 1 |
| Pietra, V | 2 |
| Duchemin, JB | 1 |
| Rakotomanana, F | 1 |
| Robert, V | 2 |
| Mauclere, P | 1 |
| de Suremain, N | 1 |
| Marc, E | 1 |
| Moulin, F | 1 |
| Yera, H | 1 |
| Dupouy-Camet, J | 1 |
| Brunet, F | 1 |
| Gendrel, D | 1 |
| Sirima, SB | 1 |
| Sawadogo, R | 1 |
| Moran, AC | 1 |
| Diarra, A | 1 |
| Yameogo, M | 1 |
| Parise, ME | 2 |
| Newman, RD | 2 |
| Hoelscher, M | 1 |
| Löscher, T | 3 |
| Nandy, A | 1 |
| Addy, M | 1 |
| Maji, AK | 1 |
| Bandyopadhyay, AK | 1 |
| Sumawinata, IW | 1 |
| Leksana, B | 3 |
| Sutamihardja, A | 1 |
| Subianto, B | 4 |
| Zucker, JR | 1 |
| Ruebush, TK | 4 |
| Obonyo, C | 1 |
| Otieno, J | 1 |
| Campbell, CC | 1 |
| Bouyou-Akotet, MK | 1 |
| Ionete-Collard, DE | 1 |
| Mabika-Manfoumbi, M | 1 |
| Kendjo, E | 1 |
| Matsiegui, PB | 2 |
| Mavoungou, E | 1 |
| Kombila, M | 2 |
| Fateye, BA | 8 |
| Happi, TC | 6 |
| Su, RB | 1 |
| Wei, XL | 1 |
| Liu, Y | 1 |
| Li, J | 1 |
| Machado, RL | 1 |
| de Figuereido Filho, AF | 1 |
| Calvosa, VS | 1 |
| Figueredo, MC | 1 |
| Nascimento, JM | 1 |
| Póvoa, MM | 1 |
| Plowe, CV | 1 |
| Barcus, MJ | 1 |
| Marwoto, H | 2 |
| Elyazar, IR | 1 |
| Ndyomugyenyi, R | 3 |
| Magnussen, P | 3 |
| Clarke, S | 1 |
| Drakeley, CJ | 1 |
| Jawara, M | 2 |
| Targett, GA | 1 |
| Walraven, G | 3 |
| Obisike, U | 1 |
| Coleman, R | 2 |
| Pinder, M | 4 |
| Sutherland, CJ | 3 |
| Dev, V | 2 |
| Phookan, S | 1 |
| Barman, K | 1 |
| Sodahlon, YK | 1 |
| Agbo, K | 1 |
| Morgah, K | 1 |
| Adjogble, K | 1 |
| Avodagbe, A | 1 |
| Djadou, KE | 1 |
| Dekou, K | 1 |
| Pignandi, A | 1 |
| Kassankogno, Y | 1 |
| Sukwa, T | 1 |
| Penali, KL | 1 |
| Millet, P | 2 |
| Malvy, JM | 1 |
| van den Broek, IV | 1 |
| van der Wardt, S | 1 |
| Talukder, L | 1 |
| Chakma, S | 1 |
| Brockman, A | 1 |
| Nair, S | 1 |
| Anderson, TC | 1 |
| Legesse, M | 1 |
| Erko, B | 1 |
| Balcha, F | 1 |
| Kamtekar, KD | 1 |
| Gogtay, NJ | 1 |
| Dalvi, SS | 1 |
| Karnad, DR | 1 |
| Chogle, AR | 1 |
| Aigal, U | 1 |
| Kshirsagar, NA | 1 |
| Ibrahim, MH | 1 |
| Elbashir, MI | 2 |
| Naser, A | 1 |
| Aelbasit, IA | 1 |
| Kheir, MM | 1 |
| Oliveira, MF | 1 |
| d'Avila, JC | 1 |
| Tempone, AJ | 1 |
| Soares, JB | 1 |
| Rumjanek, FD | 1 |
| Ferreira-Pereira, A | 1 |
| Ferreira, ST | 1 |
| Oliveira, PL | 1 |
| Iwalewa, EO | 1 |
| Agbani, EO | 1 |
| Ranjit, MR | 1 |
| Das, A | 1 |
| Chhotray, GP | 1 |
| Das, BP | 1 |
| Das, BN | 1 |
| Acharya, AS | 1 |
| Vessière, A | 1 |
| Fabre, R | 1 |
| Marchou, B | 1 |
| Massip, P | 1 |
| Magnaval, JF | 1 |
| Adedeji, AA | 8 |
| Fehintola, FA | 5 |
| Babalola, CP | 1 |
| Perch, M | 1 |
| Kofoed, P | 1 |
| Fischer, TK | 1 |
| Có, F | 1 |
| Rombo, L | 1 |
| Aaby, P | 1 |
| Eugen-Olsen, J | 1 |
| Hou, LJ | 1 |
| Raju, SS | 1 |
| Abdulah, MS | 1 |
| Nor, NM | 1 |
| Ravichandran, M | 1 |
| Ajayi, AA | 1 |
| Kolawole, BA | 1 |
| Udoh, SJ | 1 |
| Kayentao, K | 2 |
| Kodio, M | 2 |
| Maiga, H | 1 |
| Doumtabe, D | 1 |
| Ongoiba, A | 1 |
| Coulibaly, D | 2 |
| Keita, AS | 2 |
| Maiga, B | 2 |
| Mungai, M | 2 |
| Doumbo, O | 1 |
| Vijaykadga, S | 1 |
| Rojanawatsirivej, C | 1 |
| Congpoung, K | 1 |
| Uaekowitchai, C | 1 |
| Pumborplub, B | 1 |
| Sittimongkol, S | 1 |
| Pinyorattanachote, A | 1 |
| Prigchoo, P | 1 |
| Anyorigiya, T | 1 |
| Hodgson, A | 1 |
| Ansah, P | 1 |
| Anto, F | 1 |
| Ansah, NA | 1 |
| Atuguba, F | 1 |
| Mumuni, G | 1 |
| Amankwa, J | 1 |
| Tamez, PA | 1 |
| Lantvit, D | 1 |
| Lim, E | 1 |
| Pezzuto, JM | 1 |
| Pitmang, SL | 1 |
| Madaki, JK | 2 |
| Egah, DZ | 1 |
| Fischer, PR | 1 |
| Graupner, J | 1 |
| Göbels, K | 1 |
| Grobusch, MP | 1 |
| Lund, A | 1 |
| Richter, J | 1 |
| Häussinger, D | 1 |
| Nakazawa, S | 1 |
| Khalil, IF | 2 |
| Alifrangis, M | 2 |
| Tarimo, DS | 2 |
| Staalsø, T | 1 |
| Satti, GM | 1 |
| Theander, TG | 1 |
| Rønn, AM | 1 |
| Bygbjerg, IC | 2 |
| Tambo, E | 2 |
| Meerman, L | 1 |
| Ord, R | 3 |
| Bousema, JT | 1 |
| van Niekerk, M | 1 |
| Osman, E | 1 |
| Hallett, R | 2 |
| Adjetey, TA | 1 |
| Affoumou, GB | 1 |
| Loukou, DD | 1 |
| Nebavi, NG | 1 |
| Barro-Kiki, P | 1 |
| Menan, EI | 1 |
| Kone, M | 1 |
| Mockenhaupt, FP | 3 |
| Ehrhardt, S | 2 |
| Eggelte, TA | 3 |
| Agana-Nsiire, P | 1 |
| Stollberg, K | 1 |
| Mathieu, A | 1 |
| Markert, M | 1 |
| Otchwemah, RN | 1 |
| Bienzle, U | 4 |
| Nsimba, SE | 1 |
| Rimoy, GH | 1 |
| Singh, N | 2 |
| Shukla, M | 1 |
| Valecha, N | 1 |
| Bhattacharyya, PC | 1 |
| Patel, K | 1 |
| Mohapatra, MK | 1 |
| Lakhani, J | 1 |
| Devi, CU | 1 |
| Adak, T | 1 |
| Lele, C | 1 |
| Patki, K | 1 |
| Eggena, MP | 1 |
| Hopkins, H | 1 |
| Barugahare, B | 1 |
| Okello, M | 1 |
| Ssali, F | 1 |
| Rosenthal, PJ | 1 |
| Cao, H | 1 |
| Dorsey, G | 1 |
| Udeinya, IJ | 1 |
| Brown, N | 1 |
| Shu, EN | 1 |
| Udeinya, FI | 1 |
| Quakeyie, I | 1 |
| Kocken, CH | 1 |
| van der Wel, A | 1 |
| Arbe-Barnes, S | 1 |
| Matile, H | 1 |
| Scheurer, C | 1 |
| Thomas, AW | 1 |
| Pedroni, HC | 1 |
| Bettoni, CC | 1 |
| Spalding, SM | 1 |
| Dalla Costa, T | 1 |
| Sisay-Joof, F | 1 |
| Ismaili, J | 1 |
| McCall, MB | 1 |
| Holder, AA | 1 |
| Milligan, P | 1 |
| A-Elbasit, IE | 1 |
| Giha, HA | 1 |
| Nyakeriga, AM | 1 |
| Perlmann, H | 1 |
| Hagstedt, M | 1 |
| Berzins, K | 1 |
| Troye-Blomberg, M | 2 |
| Zhivotovsky, B | 1 |
| Perlmann, P | 1 |
| Grandien, A | 1 |
| Reichard, U | 1 |
| Möller, H | 1 |
| Eiffert, H | 1 |
| Ramadori, G | 1 |
| Schwörer, H | 1 |
| Hugosson, E | 1 |
| Montgomery, SM | 1 |
| Premji, Z | 2 |
| Björkman, A | 2 |
| Alvarez, G | 1 |
| Piñeros, JG | 1 |
| Tobón, A | 1 |
| Ríos, A | 1 |
| Maestre, A | 1 |
| Blair, S | 1 |
| Carmona-Fonseca, J | 1 |
| Abosl, AO | 1 |
| Mbukwa, E | 1 |
| Majinda, RR | 1 |
| Raserok, BH | 1 |
| Yenesew, A | 1 |
| Midiwo, JO | 1 |
| Akala, H | 1 |
| Liyala, P | 1 |
| Waters, NC | 1 |
| Muregi, FW | 1 |
| Miyase, T | 1 |
| Suzuki, T | 1 |
| Kino, H | 1 |
| Amano, T | 1 |
| Mkoji, GM | 1 |
| Terada, M | 1 |
| Dietz, K | 1 |
| Ozkaya, G | 1 |
| Yildirim, T | 1 |
| Aydin, K | 1 |
| Ergüven, S | 1 |
| Unal, S | 1 |
| Villegas, L | 1 |
| Htway, M | 1 |
| Paw, MK | 1 |
| Pimanpanarak, M | 1 |
| Arunjerdja, R | 1 |
| Viladpai-Nguen, SJ | 1 |
| Greenwood, B | 1 |
| Mohd Ridzuan, MA | 1 |
| Ruenruetai, U | 1 |
| Noor Rain, A | 1 |
| Khozirah, S | 1 |
| Zakiah, I | 1 |
| Ma, SH | 1 |
| Zheng, L | 1 |
| Liu, YJ | 1 |
| Guo, SY | 1 |
| Feng, H | 1 |
| Chen, G | 1 |
| Li, DM | 1 |
| Wang, JC | 1 |
| Cao, YM | 1 |
| Foronda, P | 1 |
| Santana-Morales, MA | 1 |
| Orós, J | 1 |
| Abreu-Acosta, N | 1 |
| Ortega-Rivas, A | 1 |
| Lorenzo-Morales, J | 1 |
| Valladares, B | 1 |
| Cottrell, G | 1 |
| Mary, JY | 1 |
| Barro, D | 1 |
| Cot, M | 2 |
| Diallo, DA | 1 |
| Sutherland, C | 1 |
| Nebie, I | 3 |
| Konate, AT | 1 |
| Ilboudo-Sanogo, E | 1 |
| Greenwood, BM | 1 |
| Cousens, SN | 1 |
| Parise, M | 1 |
| Traoré, B | 3 |
| Doumbo, OK | 1 |
| Tukur, IU | 1 |
| Sagay, AS | 1 |
| Kaiser, S | 1 |
| Adjei, L | 1 |
| Burchard, GD | 1 |
| Anemana, SD | 1 |
| Muangnoicharoen, S | 1 |
| Thanachartwet, V | 1 |
| Luplertlop, N | 1 |
| Srivilairit, S | 1 |
| Kano, S | 1 |
| Ringwald, P | 4 |
| Silveira, H | 2 |
| Ramos, S | 1 |
| Abrantes, P | 1 |
| Lopes, LF | 1 |
| Abrahamsen, MS | 1 |
| Hall, P | 1 |
| Grady, KK | 1 |
| Bounngaseng, A | 1 |
| Huber, C | 1 |
| Galland, GG | 4 |
| Sullivan, JJ | 1 |
| Barnadas, C | 1 |
| Ratsimbasoa, A | 1 |
| Ranaivosoa, H | 1 |
| Ralaizandry, D | 1 |
| Raveloariseheno, D | 1 |
| Rabekotonorina, V | 1 |
| Picot, S | 2 |
| Ménard, D | 1 |
| Guthmann, JP | 1 |
| Pittet, A | 1 |
| Lesage, A | 1 |
| Lindegardh, N | 1 |
| Min Lwin, M | 1 |
| Zaw, T | 1 |
| Annerberg, A | 1 |
| de Radiguès, X | 1 |
| Kouyaté, B | 2 |
| Somé, F | 2 |
| Jahn, A | 1 |
| Coulibaly, B | 1 |
| Eriksen, J | 1 |
| Sauerborn, R | 2 |
| Gustafsson, L | 1 |
| Tomson, G | 2 |
| Becher, H | 1 |
| Mueller, O | 1 |
| Pfeiffer, K | 1 |
| Müller, O | 1 |
| Haefeli, WE | 1 |
| Zoungrana, A | 1 |
| Gustafsson, LL | 1 |
| Chung, IM | 1 |
| Kim, MY | 1 |
| Moon, HI | 1 |
| Doherty, CP | 1 |
| Cox, SE | 1 |
| Fulford, AJ | 1 |
| Austin, S | 1 |
| Hilmers, DC | 1 |
| Abrams, SA | 1 |
| Prentice, AM | 1 |
| Farooq, MA | 1 |
| Salamat, A | 1 |
| Iqbal, MA | 1 |
| Astagneau, P | 1 |
| Steketee, RW | 5 |
| Wirima, JJ | 5 |
| Khoromana, CO | 3 |
| Masbar, S | 2 |
| Srivastava, P | 1 |
| Arif, AJ | 1 |
| Pandey, VC | 1 |
| Cooper, RD | 3 |
| Dubois, VL | 1 |
| Platel, DF | 1 |
| Pauly, G | 1 |
| Tribouley-Duret, J | 1 |
| Del Nero, L | 1 |
| Lamizana, L | 1 |
| Mehta, SR | 1 |
| Hogh, B | 1 |
| Thompson, R | 1 |
| Hetzel, C | 1 |
| Fleck, SL | 2 |
| Kruse, NA | 1 |
| Jones, I | 1 |
| Dgedge, M | 1 |
| Barreto, J | 1 |
| Sinden, RE | 1 |
| Hess, FI | 1 |
| Kilian, A | 1 |
| Söllner, W | 1 |
| Nothdurft, HD | 2 |
| Pröll, S | 2 |
| Basco, LK | 3 |
| Marquet, F | 1 |
| Makler, MM | 1 |
| Le Bras, J | 1 |
| Cranfield, MR | 1 |
| Graczyk, TK | 1 |
| Beall, FB | 1 |
| Ialeggio, DM | 1 |
| Shaw, ML | 1 |
| Skjoldager, ML | 1 |
| Umotong, AB | 1 |
| Amanor-Boadu, SD | 1 |
| Okerengwo, AA | 1 |
| Hedo, CC | 1 |
| Schultz, LJ | 1 |
| Macheso, A | 1 |
| Kazembe, P | 1 |
| Chitsulo, L | 1 |
| Alin, MH | 1 |
| Kihamia, CM | 1 |
| Bwijo, BA | 1 |
| Mtey, GJ | 1 |
| Ashton, M | 1 |
| Metzger, W | 1 |
| Graninger, W | 1 |
| Slutsker, L | 3 |
| Breman, JG | 3 |
| Heymann, DL | 3 |
| Roberts, JM | 1 |
| Vanijanonta, S | 1 |
| Chantra, A | 1 |
| Phophak, N | 1 |
| Chindanond, D | 1 |
| Clemens, R | 1 |
| Pukrittayakamee, S | 1 |
| Loureiro, LF | 1 |
| Cesário, AM | 1 |
| Franco, AS | 1 |
| Rosário, VE | 1 |
| Ibhanesebhor, SE | 1 |
| Otobo, ES | 1 |
| Ladipo, OA | 1 |
| Rukaria-Kaumbutho, RM | 1 |
| Ojwang, SB | 1 |
| Oyieke, JB | 1 |
| Carme, B | 1 |
| Gay, F | 2 |
| Ndounga, M | 1 |
| Hayette-Gorremans, MP | 1 |
| Bouquety, JC | 1 |
| Awalludin, M | 1 |
| Jones, T | 1 |
| Wignall, FS | 1 |
| Candradikusuma, D | 1 |
| Sutamihardja, MA | 1 |
| Tuti, S | 1 |
| Richie, T | 1 |
| Romzan, A | 1 |
| Harjosuwarno, S | 1 |
| Robinson, BL | 2 |
| Peters, W | 2 |
| Cambie, G | 1 |
| Verdier, F | 1 |
| Gaudebout, C | 1 |
| Clavier, F | 1 |
| Ginsburg, H | 2 |
| Beauté-Lafitte, A | 1 |
| Altemayer-Caillard, V | 1 |
| Chabaud, AG | 3 |
| Landau, I | 3 |
| Nkwelle Akede, A | 1 |
| Chaulet, JF | 1 |
| Tetanye, E | 1 |
| Prévosto, JM | 1 |
| Boudin, C | 2 |
| Ambroise-Thomas, P | 1 |
| Obaldia, N | 1 |
| Nuzum, EO | 1 |
| Rieckmann, KH | 1 |
| Shanks, GD | 1 |
| Nayar, JK | 1 |
| Baker, RH | 1 |
| Knight, JW | 1 |
| Morris, CL | 3 |
| Richardson, BB | 2 |
| le Hesran, JY | 2 |
| Personne, P | 1 |
| Chambon, R | 1 |
| Foumane, V | 1 |
| Verhave, JP | 1 |
| de Vries, C | 1 |
| al-Yaman, F | 1 |
| Genton, B | 1 |
| Mokela, D | 1 |
| Narara, A | 1 |
| Raiko, A | 1 |
| Alpers, MP | 1 |
| Buchachart, K | 1 |
| Chalermrut, K | 1 |
| Rattanapong, Y | 1 |
| Amradee, S | 1 |
| Siripiphat, S | 1 |
| Chullawichit, S | 1 |
| Thimasan, K | 1 |
| Ittiverakul, M | 1 |
| Triampon, A | 1 |
| Walsh, DS | 1 |
| Hoshen, MB | 1 |
| Stein, WD | 1 |
| Barat, LM | 2 |
| Himonga, B | 2 |
| Nkunika, S | 1 |
| Ettling, M | 1 |
| Kapelwa, W | 1 |
| Bloland, PB | 2 |
| Kazembe, PN | 1 |
| Oloo, AJ | 1 |
| Gaye, O | 1 |
| Faye, O | 2 |
| Ndir, O | 1 |
| Feller-Dansokho, E | 1 |
| Lakh, NC | 1 |
| Diallo, S | 1 |
| Ellman, R | 1 |
| Maxwell, C | 1 |
| Finch, R | 1 |
| Shayo, D | 1 |
| Favila-Castillo, L | 1 |
| Monroy-Ostria, A | 1 |
| Garcia-Tapia, D | 1 |
| Sumawinata, I | 1 |
| Kadir, A | 1 |
| Ingkokusumo, G | 1 |
| Caraballo, A | 1 |
| Rodriguez-Acosta, A | 1 |
| Jennings, VM | 1 |
| Kendall, J | 2 |
| Jelinek, T | 1 |
| Kilian, AH | 1 |
| Westermeier, A | 1 |
| Kabagambe, G | 1 |
| von Sonnenburg, F | 1 |
| Meche, FS | 1 |
| Dow, GS | 1 |
| Reynoldson, JA | 1 |
| Andrew Thompson, RC | 1 |
| Rosa, R | 1 |
| Seixas, E | 1 |
| Rolão, N | 1 |
| Santos-Gomes, G | 1 |
| do Rosário, V | 1 |
| Hoffmann, JJ | 1 |
| Pennings, JM | 1 |
| Verhoef, H | 1 |
| Hodgins, E | 1 |
| Carter, JY | 1 |
| Lema, O | 1 |
| West, CE | 1 |
| Kok, FJ | 1 |
| Duraisingh, MT | 1 |
| Jones, P | 1 |
| Sambou, I | 1 |
| von Seidlein, L | 2 |
| Warhurst, DC | 1 |
| Vuong, PN | 1 |
| Richard, F | 1 |
| Coquelin, F | 2 |
| Gonnet, F | 1 |
| Parola, P | 1 |
| Ali, I | 1 |
| Djermakoye, F | 1 |
| Crassard, N | 1 |
| Bendavid, C | 1 |
| Faugère, B | 1 |
| Condomines, P | 1 |
| Lim, CS | 1 |
| Kim, YK | 1 |
| Lee, KN | 1 |
| Kim, MJ | 1 |
| Kim, KH | 1 |
| Kim, DS | 1 |
| Strickman, D | 1 |
| Babiker, HA | 1 |
| Abdel-Muhsin, AA | 1 |
| Mackinnon, MJ | 1 |
| Hill, WG | 1 |
| Walliker, D | 1 |
| McCutcheon, KR | 1 |
| Freese, JA | 1 |
| Frean, JA | 1 |
| Veale, RB | 1 |
| Sharp, BL | 1 |
| Markus, MB | 1 |
| Awono-Ambene, HP | 1 |
| Trape, JF | 1 |
| Falade, AG | 3 |
| Akinyinka, OO | 1 |
| Salihu, HM | 2 |
| Tchuinguem, G | 2 |
| Ratard, R | 1 |
| Gautret, P | 1 |
| Tailhardat, L | 1 |
| Miltgen, F | 1 |
| Voza, T | 1 |
| Jacquemin, JL | 1 |
| Sowunmi, CO | 2 |
| Sijuade, AO | 1 |
| Stewart, LB | 1 |
| Butcher, GA | 1 |
| Jennings, V | 1 |
| Rab, MA | 1 |
| Freeman, TW | 1 |
| Durrani, N | 1 |
| de Poerck, D | 1 |
| Rowland, MW | 1 |
| Doherty, T | 1 |
| Targett, G | 1 |
| May, J | 1 |
| Bergqvist, Y | 1 |
| Meyer, CG | 1 |
| Falusi, AG | 1 |
| Cuzin-Ouattara, N | 1 |
| Sanon, S | 1 |
| Druilhe, P | 1 |
| Staalsoe, T | 1 |
| Megnekou, R | 1 |
| Fievét, N | 1 |
| Ricke, CH | 1 |
| Zornig, HD | 1 |
| Leke, R | 1 |
| Taylor, DW | 1 |
| Deloron, P | 1 |
| Hviid, L | 1 |
| Soto, J | 1 |
| Toledo, J | 1 |
| Gutierrez, P | 1 |
| Luzz, M | 1 |
| Llinas, N | 1 |
| Cedeño, N | 1 |
| Dunne, M | 1 |
| Berman, J | 1 |
| Ayede, AI | 1 |
| Ndikum, VN | 1 |
| Guiyedi, V | 1 |
| Koko, J | 1 |
| Bouyou Akotet, M | 1 |
| Mabika Manfoumbi, M | 1 |
| Chimanuka, B | 1 |
| François, G | 1 |
| Timperman, G | 1 |
| Heyden, YV | 1 |
| Holenz, J | 1 |
| Plaizier-Vercammen, J | 1 |
| Bringmann, G | 1 |
| Okafor, HU | 1 |
| Nwaiwu, O | 1 |
| Kaiser, A | 1 |
| Gottwald, A | 1 |
| Wiersch, C | 1 |
| Lindenthal, B | 1 |
| Maier, W | 1 |
| Seitz, HM | 1 |
| Ghalib, HW | 1 |
| Al-Ghamdi, S | 1 |
| Akood, M | 1 |
| Haridi, AE | 1 |
| Ageel, AA | 1 |
| Abdalla, RE | 1 |
| Bourke, AT | 1 |
| Jankowski, EA | 1 |
| Naik, EG | 1 |
| Bosny, JP | 1 |
| Dagne, G | 1 |
| Minjas, JN | 1 |
| Bustos, DG | 1 |
| Lazaro, JE | 1 |
| Pottier, A | 1 |
| Laracas, CJ | 1 |
| Diquet, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing Safety and Protective Efficacy of the Whole Plasmodium Falciparum Sporozoite Chemoprophylaxis Vaccine Candidate PfSPZ-CVac and Prime- Target Vaccination With Viral Vectored Vaccine Candidate Regime MVA ME-TRAP/ ChAd63 ME-TRAP in Malaria-naïve, H[NCT05441410] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | ||
| A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border[NCT01074905] | Phase 3 | 655 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.[NCT01376167] | Phase 2 | 851 participants (Actual) | Interventional | 2014-04-24 | Completed | ||
| FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru[NCT05690841] | Phase 3 | 7,700 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | ||
| A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria[NCT02216123] | Phase 3 | 251 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection[NCT01052584] | 354 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax[NCT00811096] | Phase 2 | 20 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Phase II/III, Randomized, Double-Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa[NCT00082576] | Phase 2/Phase 3 | 238 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| A Phase 3, Randomized, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa[NCT00367653] | Phase 3 | 397 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Re-exposure of Previously Immunized and Challenged Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites[NCT01660854] | 21 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria[NCT01378286] | Phase 3 | 380 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| [NCT01075945] | Phase 4 | 140 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis[NCT00442377] | 15 participants (Anticipated) | Interventional | 2007-01-31 | Completed | |||
| Safety and Protective Efficacy of Genetically Attenuated Pf∆mei2 (Also Referred to as GA2) Malaria Parasites in Healthy Dutch Volunteers.[NCT04577066] | Phase 1/Phase 2 | 43 participants (Actual) | Interventional | 2021-09-27 | Completed | ||
| Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum I[NCT03952650] | Phase 1/Phase 2 | 252 participants (Actual) | Interventional | 2019-05-23 | Completed | ||
| Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum[NCT03083847] | Phase 1 | 55 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis[NCT02080026] | 15 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection[NCT02098590] | 40 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers[NCT02925403] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2016-08-26 | Completed | ||
| Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis[NCT01783340] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2013-04-30 | Withdrawn (stopped due to No funding) | ||
| Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual Blood Stag[NCT02511054] | Phase 1 | 57 participants (Actual) | Interventional | 2015-07-21 | Completed | ||
| Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis[NCT01236612] | 25 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial[NCT00124267] | Phase 3 | 108 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099] | Phase 3 | 723 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.[NCT01585077] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax[NCT02083068] | Phase 2 | 32 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali[NCT00127998] | 1,011 participants | Interventional | 2005-07-31 | Completed | |||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients[NCT02524444] | Phase 1 | 142 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380] | Phase 2 | 18 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participants who received blood transfusion as a result of hemoglobin decline has been summarized. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 0 |
| TQ + CQ | 0 |
| PQ + CQ | 0 |
There were no participants with acute renal failure in the study. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 0 |
| TQ + CQ | 0 |
| PQ + CQ | 0 |
A participant (par) was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Par had non-zero P vivax asexual parasite count at Baseline. b) Par showed initial clearance of P vivax parasitemia. c) Par had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Par did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Par is parasite-free at 4 months defined as a negative asexual P vivax parasite count at the first parasite assessment performed after Study Day 109 (up to and including Study Day 130). Par were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites or did not have a 4 month assessment. The number of par with recurrence-free efficacy at 4 months has been summarized. (NCT01376167)
Timeframe: 4 months post dose
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 47 |
| TQ + CQ | 177 |
| PQ + CQ | 90 |
A participant was considered to have demonstrated recurrence-free efficacy at 6 months if: a) Participant had non-zero P vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P vivax parasitemia defined as two negative asexual P vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. Participants were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites, or did not have a 6 month assessment. The number of participants with recurrence-free efficacy at 6 months has been summarized. (NCT01376167)
Timeframe: 6 months post dose
| Intervention | Participants (Number) |
|---|---|
| CQ Only | 35 |
| TQ + CQ | 155 |
| PQ + CQ | 83 |
Apparent population oral clearance of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60
| Intervention | Liters per hour (Median) |
|---|---|
| Participants in TQ Only Arms | 2.96 |
Fever clearance time was defined as time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.40 degree Celsius is reduced to a value less than or equal to 37.40 degree Celsius and in the absence of value more than 37.40 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed using Kaplan Meier Methodology. The median fever clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| CQ Only | 7 |
| TQ + CQ | 7 |
| PQ + CQ | 8 |
Parasite clearance time was defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours. The time taken to achieve parasite clearance was analyzed using Kaplan Meier Methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| CQ Only | 43 |
| TQ + CQ | 45 |
| PQ + CQ | 42 |
Recurrence was defined as the first confirmed presence of P vivax asexual stage parasites after clearance of initial parasitemia following CQ treatment. Time to recurrence was defined as the time (in days) from initial parasite clearance to recurrence. The time to recurrence was analyzed by the Kaplan-Meier method. NA indicates data was not available due to insufficient number of participants with events during the follow up period in the study. The median number of days to recurrence along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Days (Median) |
|---|---|
| CQ Only | 86 |
| TQ + CQ | NA |
| PQ + CQ | NA |
Apparent population central volume of distribution of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60
| Intervention | Liters (Median) |
|---|---|
| Participants in TQ Only Arms | 915 |
Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine (Masimo). The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The last assessment performed prior to the first dose of study medication (CQ or randomized treatment) was considered as Baseline. Change from Baseline was calculated as the post baseline assessment minus the Baseline assessment for percent methemoglobin. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 120
| Intervention | Percent Methemoglobin (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2, Male | Day 2, Female | Day 3, Male | Day 3, Female | Day 5, Male | Day 5, Female | Day 8, Male | Day 8, Female | Day 11, Male | Day 11, Female | Day 15, Male | Day 15, Female | Day 22, Male | Day 22, Female | Day 29, Male | Day 29, Female | Day 60, Male | Day 60, Female | Day 120, Male | Day 120, Female | |
| CQ Only | -0.18 | -0.22 | -0.15 | -0.20 | -0.28 | -0.20 | -0.12 | -0.16 | -0.07 | -0.13 | 0.12 | -0.08 | 0.07 | -0.05 | -0.10 | -0.18 | 0.44 | 0.19 | 0.20 | 0.10 |
| PQ + CQ | -0.10 | -0.01 | -0.02 | 0.11 | 1.28 | 0.90 | 3.01 | 2.58 | 3.61 | 3.41 | 3.51 | 3.63 | 1.96 | 1.86 | 0.58 | 0.49 | 0.20 | 0.16 | 0.37 | 0.37 |
| TQ + CQ | -0.03 | 0.10 | -0.01 | 0.26 | 0.42 | 1.37 | 0.98 | 2.04 | 1.17 | 2.13 | 0.94 | 1.67 | 0.54 | 0.93 | 0.23 | 0.24 | -0.10 | 0.03 | 0.07 | -0.03 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Brazil (Drug shop for care) | Brazil (Enrollment clinic for care) | Brazil (other location for care) | Peru (Drug shop for care) | Peru (Enrollment clinic for care) | Peru (Attended another clinic) | Peru (Other location for care) | Thailand (Drug shop for care) | Thailand (Enrollment clinic for care) | Thailand (In-hospital care) | |
| First Malaria Recurrence | 4.76 | 6.17 | 4.23 | 1.47 | 8.78 | 2.71 | 0.72 | 4.60 | 19.15 | 6.13 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | |||
|---|---|---|---|---|
| Brazil (Enrollment clinic for care) | Peru (Enrollment clinic for care) | Peru (Attended another clinic) | Peru (Other location for care) | |
| First Malaria Recurrence Follow-up | 6.15 | 8.54 | 3.94 | 1.30 |
"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180
| Intervention | USD (Mean) |
|---|---|
| Peru, n=23, 3 | |
| First Malaria Recurrence Follow-up | 0.32 |
"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180
| Intervention | USD (Mean) | |
|---|---|---|
| Peru, n=23, 3 | Brazil, n=6, 0 | |
| First Malaria Recurrence | 0.49 | 1.70 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | logMAR scores (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | |
| CQ Only | 0.041 | 0.048 | 0.039 | 0.032 | 0.044 | 0.041 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | logMAR scores (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | Day 180; right eye | Day 180; left eye | |
| PQ + CQ | 0.029 | 0.048 | 0.021 | 0.045 | 0.016 | 0.041 | 0.000 | 0.000 |
| TQ + CQ | 0.046 | 0.039 | 0.049 | 0.032 | 0.038 | 0.028 | 0.033 | 0.033 |
Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Nothing | Brazil, Drug shop | Brazil, Trial clinic | Brazil, Other | Cambodia, Nothing | Ethiopia, Nothing | Ethiopia, Another clinic | Ethiopia, Other | Ethiopia, Trial clinic | Peru, Nothing | Peru, Drug shop | Peru, Trial clinic | Peru, Another clinic | Peru, Other | Thailand, Nothing | Thailand, Drug shop | Thailand, Trial clinic | Thailand, In hospital | |
| First Malaria Recurrence Follow-up | 5 | 0 | 76 | 0 | 14 | 13 | 0 | 0 | 1 | 0 | 0 | 63 | 54 | 1 | 16 | 0 | 0 | 0 |
Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Nothing | Brazil, Drug shop | Brazil, Trial clinic | Brazil, Other | Cambodia, Nothing | Ethiopia, Nothing | Ethiopia, Another clinic | Ethiopia, Other | Ethiopia, Trial clinic | Peru, Nothing | Peru, Drug shop | Peru, Trial clinic | Peru, Another clinic | Peru, Other | Philippines, Nothing | Thailand, Nothing | Thailand, Drug shop | Thailand, Trial clinic | Thailand, In hospital | |
| First Malaria Recurrence | 21 | 2 | 62 | 2 | 13 | 12 | 1 | 1 | 0 | 1 | 8 | 61 | 10 | 15 | 1 | 1 | 1 | 13 | 1 |
Blood samples were collected for the evaluation of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk. Phos), Aspartate Aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ALT, High | Alk Phos, High | AST, High | Bilirubin, High | Creatine kinase, High | Creatinine, High | GFR, Low | Indirect bilirubin | Urea, High | |
| CQ Only | 11 | 3 | 5 | 18 | 8 | 0 | 0 | 11 | 42 |
| PQ + CQ | 5 | 1 | 2 | 12 | 8 | 0 | 0 | 8 | 46 |
| TQ + CQ | 10 | 1 | 7 | 23 | 5 | 1 | 1 | 22 | 85 |
Gastrointestinal tolerability was analyzed by the number of par experiencing gastrointestinal disorders such as abdominal pain, heartburn, diarrhea, constipation, nausea, and vomiting. The number of participants with gastrointestinal disorders for each treatment group has been summarized. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Nausea | Vomiting | Abdominal pain upper | Diarrhoea | Abdominal pain | Dyspepsia | |
| CQ Only | 12 | 9 | 13 | 6 | 5 | 5 |
| PQ + CQ | 9 | 11 | 7 | 5 | 6 | 2 |
| TQ + CQ | 21 | 22 | 11 | 15 | 8 | 6 |
Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood eosinophils, High | Blood leukocytes, Low | Blood lymphocytes, Low | Blood lymphocytes, High | Blood neutrophils, Low | Blood platelets, Low | Blood reticulocytes, High | Methemoglobin, High | |
| CQ Only | 18 | 0 | 7 | 23 | 2 | 14 | 72 | 4 |
| PQ + CQ | 28 | 2 | 0 | 13 | 7 | 15 | 85 | 11 |
| TQ + CQ | 38 | 3 | 4 | 32 | 5 | 35 | 141 | 5 |
Glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines. Blood samples were collected for the evaluation of hemoglobin levels. Hemoglobin decreases of >=30% or >3 grams/deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs). Number of participants with maximum hemoglobin decline from Baseline over first 29 days of study has been summarized. Safety Population consisted of all randomized participants who received at least one dose of study medication. (NCT01376167)
Timeframe: Baseline and up to Day 29
| Intervention | Participants (Number) | ||
|---|---|---|---|
| <=20 grams/liter (g/L) | >20g/L to <=30 g/L | >30 g/L or >=30% | |
| CQ Only | 120 | 11 | 2 |
| PQ + CQ | 114 | 12 | 3 |
| TQ + CQ | 214 | 31 | 14 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 1; right eye | Day 1; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | Any time post Baseline; right eye | Any time post Baseline; left eye | |
| CQ Only | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; right eye | Baseline; left eye | Day 1; right eye | Day 1; left eye | Day 29; right eye | Day 29; left eye | Day 90; right eye | Day 90; left eye | Day 180; right eye | Day 180; left eye | Any time post Baseline; right eye | Any time post Baseline; left eye | |
| PQ + CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ + CQ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 29, Definite change, right eye | Day 29, Ques change, right eye | Day 29, Definite change, left eye | Day 29, Ques change, left eye | Day 90, Definite change, right eye | Day 90, Ques change, right eye | Day 90, Definite change, left eye | Day 90, Ques change, left eye | Day 180, Definite change, right eye | Day 180, Ques change, right eye | Day 180, Definite change, left eye | Day 180, Ques change, left eye | |
| CQ Only | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| TQ + CQ | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Day 29, Definite change, right eye | Day 29, Ques change, right eye | Day 29, Definite change, left eye | Day 29, Ques change, left eye | Day 90, Definite change, right eye | Day 90, Ques change, right eye | Day 90, Definite change, left eye | Day 90, Ques change, left eye | |
| PQ + CQ | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with possible drug induced liver injury with hyperbilirubinemia. TEAEs is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| CQ Only | 86 | 6 |
| PQ + CQ | 76 | 4 |
| TQ + CQ | 164 | 21 |
An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with AEs based on severity has been presented. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Mild or Grade 1 | Moderate or Grade 2 | Severe or Grade 3 | Grade 4 | Grade 5 | |
| CQ Only | 30 | 52 | 3 | 1 | 0 |
| PQ + CQ | 38 | 37 | 1 | 0 | 0 |
| TQ + CQ | 70 | 89 | 2 | 0 | 1 |
TEAEs are defined as adverse events (AEs) with an onset date and time on or after that of the start of first dose of study medication (including CQ). The number of participants with TEAEs potentially related to hemoglobin decrease has been presented. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Haemoglobin decreased | Fatigue | Hyperbilirubinaemia | Pallor | |
| CQ Only | 2 | 2 | 1 | 0 |
| PQ + CQ | 2 | 0 | 0 | 0 |
| TQ + CQ | 14 | 1 | 0 | 1 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Days (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Housework | Brazil, Farming | Brazil, paid employment | Brazil, Other | Cambodia, Farming | Ethiopia, Housework | Ethiopia, Farming | Ethiopia, Student | Ethiopia, Paid employment | Ethiopia, Other | Peru, Housework | Peru, Farming | Peru, Student | Peru, Paid employment | Peru, Other | Thailand, paid employment | Thailand, Other | |
| First Malaria Recurrence Follow-up | 0 | 0 | 0 | 5 | 24 | 3 | 3 | 0 | 4 | 7 | 29 | 28 | 6 | 8.5 | 32 | 0 | 0 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180
| Intervention | Days (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil, Housework | Brazil, Farming | Brazil, paid employment | Brazil, Other | Cambodia, Farming | Ethiopia, Housework | Ethiopia, Farming | Ethiopia, Student | Ethiopia, Paid employment | Ethiopia, Other | Peru, Housework | Peru, Farming | Peru, Student | Peru, Paid employment | Peru, Other | Philippines, Farming | Thailand, paid employment | Thailand, Other | |
| First Malaria Recurrence | 1 | 8 | 8 | 3 | 17 | 4 | 2.5 | 3 | 2 | 1 | 24 | 19 | 1 | 6 | 26 | 0 | 20 | 1 |
Health outcomes were evaluated based on cost incurred due to clinically relevant hemolysis. The total cost was evaluated based on the amount spent on treatment, transport, medication and test. The costs associated with hemolysis event has been presented. The aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major cost differences with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | USD (Mean) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 9.174 |
"Health outcomes were evaluated based on the cost of medications purchased. The total medication cost associated with hemolysis event has been presented. Medications recorded as Other and medications without costs are excluded from the analysis. The aim of this outcome measure was to determine the cost to a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major cost differences with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan." (NCT02216123)
Timeframe: Up to Day 180
| Intervention | USD (Mean) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 0 |
Health outcomes were evaluated based on total time lost by participants or care givers due to a hemolysis event. The number of participants or care givers who took days off from work due to a hemolysis event has been presented based on the normal occupation. The aim of this outcome measure was to determine the time taken off by participants due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major differences in time taken off by participants with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 0 |
Health outcomes were evaluated based on the actions taken by the participants to treat hemolysis events. The number of participants in Brazil who attended the trial clinic to treat a hemolysis event has been presented. The aim of this outcome measure was to determine the action taken by a participant due to an event of hemolysis, regardless of treatment received in the study. It was not expected there would be major differences in action taken by the participants with hemoglobin decrease between the treatment arms. This was pre-specified in the statistical analysis plan. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| Participants With Clinically Relevant Hemolysis | 1 |
Microscopic blood slides (two thick film and one thin film slide) were prepared and examined for asexual parasite count. The number of participants with positive P. falciparum asexual parasite count post Baseline has been summarized for each treatment arm. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) |
|---|---|
| TQ+CQ | 4 |
| PQ+CQ | 3 |
Recrudescence is defined as any P. vivax parasitemia occurring on or before Day 32 (that is, blood stage treatment failure). A participant was considered to have had a recrudescence if both of the following were true: a) Participant had a positive P. vivax asexual parasite count at Baseline and demonstrated clearance (that is, did not have two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval). b) Participant had a positive genetically homologous asexual P. vivax parasite count, after their zero count in Days 1 to 5, but on or before Study Day 32. The number of participants with recrudescence before Study Day 33 has been presented. (NCT02216123)
Timeframe: Up to Day 32
| Intervention | Participants (Number) |
|---|---|
| TQ+CQ | 0 |
| PQ+CQ | 0 |
Apparent population oral clearance of TQ (NCT02216123)
Timeframe: Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180
| Intervention | Liters per hour (Median) |
|---|---|
| Participants in TQ Only Arms | 2.96 |
Clinically relevant hemolysis is defined as a decrease in hemoglobin of >=30% or >3 grams per deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL at any visit after the first dose of study medication. The percentage of participants with clinically relevant hemolysis has been summarized. Safety Population comprised of all randomized participants who received at least one dose of blinded study medication. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Percentage of participants (Number) |
|---|---|
| TQ+CQ | 2.41 |
| PQ+CQ | 1.18 |
A participant was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P. vivax parasitemia. c) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Participant is parasite-free at 4 months. The rate of relapse-free efficacy was estimated by Kaplan-Meier methodology. The percentage of participants who were relapse-free at 4 months post dose has been presented along with 95% confidence interval. (NCT02216123)
Timeframe: 4 months post dose
| Intervention | Percentage of participants (Number) |
|---|---|
| TQ+CQ | 82.3 |
| PQ+CQ | 79.7 |
A participant was considered to have demonstrated relapse-free efficacy at 6 months if: a) Participant had non-zero P. vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P. vivax parasitemia defined as two negative asexual P. vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P. vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. The rate of relapse-free efficacy was estimated by Kaplan-Meier methodology. The percentage of participants who were relapse-free at 6 months post dose has been presented along with 95% confidence interval. (NCT02216123)
Timeframe: 6 months post dose
| Intervention | Percentage of participants (Number) |
|---|---|
| TQ+CQ | 72.7 |
| PQ+CQ | 75.1 |
Fever clearance time is defined as the time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.4 degree Celsius is reduced to a value less than or equal to 37.4 degree Celsius, in the absence of value more than 37.4 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed by Kaplan-Meier method. (NCT02216123)
Timeframe: Up to Day 9
| Intervention | Hours (Median) |
|---|---|
| TQ+CQ | 10 |
| PQ+CQ | 13 |
Gametocyte clearance time is defined as time from first dose until the first slide that was gametocyte negative and remained so at the next slide reading. The time taken to achieve gametocyte clearance was analyzed by Kaplan-Meier method. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| TQ+CQ | 38 |
| PQ+CQ | 41 |
Parasite clearance time is defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours later. The time to achieve parasite clearance was analyzed by Kaplan-Meier methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Hours (Median) |
|---|---|
| TQ+CQ | 41 |
| PQ+CQ | 44 |
Relapse is defined by a positive blood smear with or without vivax symptoms. Relapse is described as any recurrence of malaria that occurred after Day 32 of the study. The time to relapse was analyzed by the Kaplan-Meier method. The median number of days to relapse along with 95% confidence interval has been presented for each treatment group. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Days (Median) |
|---|---|
| TQ+CQ | NA |
| PQ+CQ | NA |
Apparent population central volume of distribution of TQ (NCT02216123)
Timeframe: Day 2, Day 3, Day 8, Day 15, Day 29, Day 60 and Day 180
| Intervention | Liters (Median) |
|---|---|
| Participants in TQ Only Arms | 915 |
Methemoglbin is an oxidized and inactive form of hemoglobin. Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine. The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo) was considered as Baseline value. Change from Baseline is the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 120
| Intervention | Percent change (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 2, Male, n=114, 53 | Day 2, Female, n=52, 32 | Day 3, Male, n=114, 53 | Day 3, Female, n=52, 32 | Day 5, Male, n=113, 53 | Day 5, Female, n=52, 32 | Day 8, Male, n=112, 52 | Day 8, Female, n=52, 32 | Day 11, Male, n=112, 52 | Day 11, Female, n=51, 32 | Day 15, Male, n=113, 52 | Day 15, Female, n=52, 32 | Day 22, Male, n=112, 52 | Day 22, Female, n=52, 32 | Day 29, Male, n=111, 52 | Day 29, Female, n=52, 32 | Day 60, Male, n=107, 51 | Day 60, Female, n=52, 32 | Day 120, Male, n=109, 50 | Day 120, Female, n=50, 31 | |
| PQ+CQ | 0.02 | -0.06 | 0.03 | 0.17 | 0.89 | 1.32 | 2.63 | 2.81 | 3.30 | 3.44 | 3.26 | 3.61 | 1.58 | 2.30 | 0.46 | 0.84 | 0.20 | 0.14 | -0.01 | 0.04 |
| TQ+CQ | 0.02 | -0.16 | 0.18 | 0.08 | 0.77 | 0.63 | 1.22 | 1.00 | 1.16 | 1.04 | 1.01 | 0.81 | 0.61 | 0.32 | 0.24 | -0.02 | 0.05 | -0.09 | 0.06 | 0.14 |
Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements. The mean and standard deviation of pulse rate has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | beats per minute (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 assessment 4; n=161, 84 | Day 2 assessment 1; n=166, 85 | Day 2 assessment 4; n=166, 85 | Day 3 assessment 1; n=166, 83 | Day 3 assessment 4; n=166, 82 | Day 8; n=164, 84 | Day 11; n=163, 84 | Day15; n=165, 84 | Day 22; n=164, 84 | Day 29; n=163, 84 | Day 60; n=160, 83 | Day 90; n=160, 82 | Day 120; n=159, 81 | Day 150; n=161, 82 | Day180; n=160, 83 | |
| PQ+CQ | -9.3 | -9.9 | -11.8 | -18.2 | -17.5 | -14.6 | -15.5 | -16.9 | -16.8 | -17.5 | -18.5 | -18.6 | -19.1 | -17.9 | -18.3 |
| TQ+CQ | -10.8 | -9.9 | -11.9 | -15.1 | -16.5 | -12.7 | -13.4 | -13.5 | -14.7 | -16.9 | -16.7 | -16.3 | -16.7 | -16.8 | -18.0 |
Vital signs were measured twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to pharmacokinetic (PK) measurements. MAP was calculated as the sum of SBP and two times DBP divided by 3. The mean and standard deviation of SBP, DBP and MAP has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | millimeter of mercury (mmHg) (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBP, Day 1 assessment 4; n=161, 84 | SBP, Day 2 assessment 1; n=166, 85 | SBP, Day 2 assessment 4; n=166, 85 | SBP, Day 3 assessment 1; n=166, 83 | SBP, Day 3 assessment 4; n=166, 82 | SBP, Day 8; n=164, 84 | SBP, Day 11; n=163, 84 | SBP, Day15; n=165, 84 | SBP, Day 22; n=164, 84 | SBP, Day 29; n=163, 84 | SBP, Day 60; n=160, 83 | SBP, Day 90; n=160, 82 | SBP, Day 120; n=159, 81 | SBP, Day 150; n=161, 82 | SBP, Day180; n=160, 83 | DBP, Day 1 assessment 4; n=161, 84 | DBP, Day 2 assessment 1; n=166, 85 | DBP, Day 2 assessment 4; n=166, 85 | DBP, Day 3 assessment 1; n=166, 83 | DBP, Day 3 assessment 4; n=166, 82 | DBP, Day 8; n=164, 84 | DBP, Day 11; n=163, 84 | DBP, Day15; n=165, 84 | DBP, Day 22; n=164, 84 | DBP, Day 29; n=163, 84 | DBP, Day 60; n=160, 83 | DBP, Day 90; n=160, 82 | DBP, Day 120; n=159, 81 | DBP, Day 150; n=161, 82 | DBP, Day180; n=160, 83 | MAP, Day 1 assessment 4; n=161, 84 | MAP, Day 2 assessment 1; n=166, 85 | MAP, Day 2 assessment 4; n=166, 85 | MAP, Day 3 assessment 1; n=166, 83 | MAP, Day 3 assessment 4; n=166, 82 | MAP, Day 8; n=164, 84 | MAP, Day 11; n=163, 84 | MAP, Day15; n=165, 84 | MAP, Day 22; n=164, 84 | MAP, Day 29; n=163, 84 | MAP, Day 60; n=160, 83 | MAP, Day 90; n=160, 82 | MAP, Day 120; n=159, 81 | MAP, Day 150; n=161, 82 | MAP, Day180; n=160, 83 | |
| PQ+CQ | -0.9 | -2.3 | -2.7 | -2.1 | -2.2 | 0.8 | 1.2 | 2.5 | 2.9 | 4.4 | 4.3 | 5.3 | 3.1 | 4.9 | 5.7 | -1.5 | -2.2 | -2.6 | -1.3 | -1.9 | 1.1 | -0.5 | 0.4 | 1.3 | 1.5 | 1.9 | 3.5 | 2.4 | 4.1 | 3.7 | -1.3 | -2.2 | -2.6 | -1.6 | -2.0 | 1.0 | 0.1 | 1.1 | 1.8 | 2.4 | 2.7 | 4.1 | 2.6 | 4.4 | 4.4 |
| TQ+CQ | 1.2 | 0.4 | -0.8 | -0.6 | -2.7 | 2.2 | 1.3 | 3.2 | 3.3 | 2.6 | 4.4 | 3.8 | 3.8 | 4.4 | 3.7 | 1.1 | -0.1 | -0.8 | -0.2 | -1.9 | 0.9 | -0.0 | 1.5 | 1.2 | 0.9 | 3.1 | 2.7 | 3.3 | 3.2 | 2.9 | 1.1 | 0.0 | -0.8 | -0.3 | -2.2 | 1.3 | 0.4 | 2.0 | 1.9 | 1.5 | 3.5 | 3.1 | 3.5 | 3.6 | 3.2 |
Vital signs were performed twice a day on Days 1 through 3, at least 4 hours apart, and immediately prior to PK measurements. The mean and standard deviation of pulse rate has been presented. The values presented does not include Day 3 assessments for participant number 570. Baseline value is defined as the latest pre-treatment assessment where treatment is their first dose of study medication (CQ/PQ/TQ/Placebo). Change from Baseline is the value at post dose minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | Celsius (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 assessment 4; n=161, 84 | Day 2 assessment 1; n=166, 85 | Day 2 assessment 4; n=166, 85 | Day 3 assessment 1; n=166, 83 | Day 3 assessment 4; n=166, 82 | Day 8; n=164, 84 | Day 11; n=163, 84 | Day15; n=165, 84 | Day 22; n=164, 84 | Day 29; n=163, 84 | Day 60; n=160, 83 | Day 90; n=160, 82 | Day 120; n=159, 81 | Day 150; n=161, 82 | Day180; n=160, 83 | |
| PQ+CQ | -0.5 | -0.6 | -0.6 | -0.9 | -1.0 | -0.9 | -0.9 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -0.9 | -1.0 | -1.0 |
| TQ+CQ | -0.6 | -0.6 | -0.6 | -1.0 | -1.0 | -1.0 | -1.0 | -0.9 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other). The costs associated with a relapse episode of P. vivax malaria has been presented. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Brazil; enrollment clinic for care; n=19, 17 | Colombia; hospital emergency center; n=1,1 | Peru; enrollment clinic for care; n=32, 33 | Peru; attended another clinic; n=8, 30 | Thailand; enrollment clinic for care; n=0, 1 | Vietnam; drug shop for care;n=1, 2 | Vietnam; attended another clinic; n=0, 1 | |
| First Malaria Relapse Follow-up | 8.032 | 16.775 | 8.815 | 3.959 | 1.534 | 2.809 | 0.936 |
Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital emergency center, other). The costs associated with a relapse episode of P. vivax malaria has been presented. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | US Dollars (USD) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Brazil; enrollment clinic for care; n=19, 17 | Colombia; enrollment clinic for care; n=1,0 | Colombia; attended another clinic; n=1,0 | Colombia; hospital emergency center; n=1,1 | Peru; enrollment clinic for care; n=32, 33 | Peru; attended another clinic; n=8, 30 | Peru; Other; n=8, 0 | Vietnam; drug shop for care;n=1, 2 | Vietnam; Other; n=1, 0 | |
| First Malaria Relapse | 8.208 | 42.776 | 4.194 | 16.775 | 9.244 | 1.677 | 0.818 | 0.702 | 1.873 |
"Health outcomes were evaluated based on the cost of medications purchased. The total medication cost for paracetamol associated with relapse episode of P vivax malaria has been presented. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title)." (NCT02216123)
Timeframe: Up to Day 180
| Intervention | USD (Mean) | ||
|---|---|---|---|
| Colombia; n=2, 1 | Peru; n=6, 2 | Vietnam; n=1, 1 | |
| First Malaria Relapse | 2.516 | 0.491 | 0.468 |
| First Malaria Relapse Follow-up | 4.194 | 0.327 | 2.341 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil; Housework; n=2, 1 | Brazil; Farming; n=1, 1 | Brazil; Student; n=1, 1 | Brazil; Paid employment; n=7, 7 | Brazil; Other; n=8, 7 | Colombia; Farming; n=2, 2 | Colombia; Paid employment; n=1, 1 | Peru; Housework; n=18, 18 | Peru, Farming; n=4, 4 | Peru; Student; n=3, 3 | Peru; Paid employment; n=1, 1 | Peru; Other; n=7, 7 | Thailand; Farming; n=1, 1 | Vietnam; Farming; n=4, 4 | Vietnam; Paid employment; n=0, 3 | |
| First Malaria Relapse Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 15 | 4 | 2 | 1 | 6 | 1 | 1 | 2 |
Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The number of participants or care givers who had taken off from their normal occupation due to relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil; Housework; n=2, 1 | Brazil; Farming; n=1, 1 | Brazil; Student; n=1, 1 | Brazil; Paid employment; n=7, 7 | Brazil; Other; n=8, 7 | Colombia; Housework; n=1, 0 | Colombia; Farming; n=2, 2 | Colombia; Paid employment; n=1, 1 | Peru; Housework; n=18, 18 | Peru, Farming; n=4, 4 | Peru; Student; n=3, 3 | Peru; Paid employment; n=1, 1 | Peru; Other; n=7, 7 | Thailand; Farming; n=1, 1 | Vietnam; Farming; n=4, 4 | |
| First Malaria Relapse | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 14 | 4 | 2 | 1 | 7 | 1 | 3 |
Mid-stream urine was collected and analyzed for bilirubin, glucose, ketones, leukocyte esterase (LE), nitrites, occult blood, proteins and urobilinogen by dipstick method. The number of participants with abnormal urinalysis results (Trace, +, ++, +++, ++++) has been presented. Only those participants with data available at the specified data points were analyzed. (NCT02216123)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bilirubin, Day 1, Trace | Bilirubin, Day 1, + | Bilirubin, Day1, ++ | Bilirubin, Day 3, + | Bilirubin, Day 3, ++ | Bilirubin, Day 5, Trace | Bilirubin, Day 5, + | Bilirubin, Day 8, + | Bilirubin, Day 11, Trace | Bilirubin, Day 22, Trace | Bilirubin, Day 22, + | Bilirubin, Day 60, Trace | Bilirubin, Day 60, + | Bilirubin, Day 90, + | Bilirubin, Day 120, + | Glucose, Day 1, + | Glucose, Day 1, ++ | Glucose, Day1, +++ | Glucose, Day1, ++++ | Glucose, Day 3, + | Glucose, Day 3, ++ | Glucose, Day 3, +++ | Glucose, Day 3, ++++ | Glucose, Day 5, ++ | Glucose, Day 5, +++ | Glucose, Day 8, + | Glucose, Day 8, ++ | Glucose, Day 8,+++ | Glucose, Day 11, Trace | Glucose, Day 11, + | Glucose, Day 11, ++ | Glucose, Day 11, +++ | Glucose, Day 15, ++ | Glucose, Day 15, +++ | Glucose, Day 15, ++++ | Glucose, Day 22, + | Glucose, Day 22, +++ | Glucose, Day 29, Trace | Glucose, Day 29, ++ | Glucose, Day 60, + | Glucose, Day 60, ++ | Glucose, Day 90, + | Glucose, Day 90, ++ | Glucose, Day 90, +++ | Glucose, Day 120, Trace | Glucose, Day 120, + | Glucose, Day 120, ++ | Glucose, Day 120, +++ | Glucose, Day 120, ++++ | Ketones, Day 1, Trace | Ketones, Day 1, + | Ketones, Day1, ++ | Ketones, Day1, +++ | Ketones, Day 3, Trace | Ketones, Day 3, + | Ketones, Day 3, ++ | Ketones, Day 3, +++ | Ketones, Day 5, + | Ketones, Day 8, + | Ketones, Day 11, Trace | Ketones, Day 22, Trace | Ketones, Day 22, + | Ketones, Day 90, Trace | Ketones, Day 90, + | Ketones, Day 90, ++ | Ketones, Day 120, Trace | Ketones, Day 120, + | Ketones, Day 120, ++ | LE, Day 1, Trace | LE, Day 1, + | LE, Day1, ++ | LE, Day1, +++ | LE, Day 3, Trace | LE, Day 3, + | LE, Day 3, ++ | LE, Day 3, +++ | LE, Day 5, Trace | LE, Day 5, + | LE, Day 5, ++ | LE, Day 5, +++ | LE, Day 8, Trace | LE, Day 8, + | LE, Day 8, ++ | LE, Day 8, +++ | LE, Day 11, Trace | LE, Day 11, + | LE, Day 11, ++ | LE, Day 11, +++ | LE, Day 15, Trace | LE, Day 15, + | LE, Day 15, ++ | LE, Day 15, +++ | LE, Day 22, Trace | LE, Day 22, + | LE, Day 22, ++ | LE, Day 22, +++ | LE, Day 29, Trace | LE, Day 29, + | LE, Day 29, ++ | LE, Day 29, +++ | LE, Day 60, Trace | LE, Day 60, + | LE, Day 60, ++ | LE, Day 60, +++ | LE, Day 90, Trace | LE, Day 90, + | LE, Day 90, ++ | LE, Day 90, +++ | LE, Day 120, Trace | LE, Day 120, + | LE, Day 120, ++ | LE, Day 120, +++ | Nitrite, Day 1, Trace | Nitrite, Day 1, + | Nitrite, Day 3, + | Nitrite, Day 5, + | Nitrite, Day 5, +++ | Nitrite, Day 8, +++ | Nitrite, Day 11, + | Nitrite, Day 15, + | Nitrite, Day 22, Trace | Nitrite, Day 29, + | Nitrite, Day 60, + | Nitrite, Day 90, Trace | Nitrite, Day 90, + | Nitrite, Day 120, + | Nitrite, Day 120, ++ | Occult blood, Day 1, Trace | Occult blood, Day 1, + | Occult blood, Day 1, ++ | Occult blood, Day1, +++ | Occult blood, Day1, ++++ | Occult blood, Day 3, Trace | Occult blood, Day 3, + | Occult blood, Day 3, ++ | Occult blood, Day 3, +++ | Occult blood, Day 3, ++++ | Occult blood, Day 5, Trace | Occult blood, Day 5, + | Occult blood, Day 5, ++ | Occult blood, Day 5, +++ | Occult blood, Day 5, ++++ | Occult blood, Day 8, Trace | Occult blood, Day 8, + | Occult blood, Day 8, ++ | Occult blood, Day 8,+++ | Occult blood, Day 11, Trace | Occult blood, Day 11, + | Occult blood, Day 11, ++ | Occult blood, Day 11, +++ | Occult blood, Day 11, ++++ | Occult blood, Day 15, Trace | Occult blood, Day 15, + | Occult blood, Day 15, ++ | Occult blood, Day 15, +++ | Occult blood, Day 15, ++++ | Occult blood, Day 22, Trace | Occult blood, Day 22, + | Occult blood, Day 22, ++ | Occult blood, Day 22, +++ | Occult blood, Day 22, ++++ | Occult blood, Day 29, Trace | Occult blood, Day 29, + | Occult blood, Day 29, ++ | Occult blood, Day 29, +++ | Occult blood, Day 29, ++++ | Occult blood, Day 60, Trace | Occult blood, Day 60, + | Occult blood, Day 60, ++ | Occult blood, Day 60, +++ | Occult blood, Day 60, ++++ | Occult blood, Day 90, Trace | Occult blood, Day 90, + | Occult blood, Day 90, ++ | Occult blood, Day 90, +++ | Occult blood, Day 90, ++++ | Occult blood, Day 120, Trace | Occult blood, Day 120, + | Occult blood, Day 120, ++ | Occult blood, Day 120, +++ | Occult blood, Day 120, ++++ | Protein, Day 1, Trace | Protein, Day 1, + | Protein, Day1, ++ | Protein, Day 3, Trace | Protein, Day 3, + | Protein, Day 3, ++ | Protein, Day 5, Trace | Protein, Day 5, + | Protein, Day 5, ++ | Protein, Day 8, Trace | Protein, Day 8, + | Protein, Day 8,++ | Protein, Day 11, Trace | Protein, Day 11, + | Protein, Day 11, ++ | Protein, Day 15, + | Protein, Day 15, ++ | Protein, Day 22, Trace | Protein, Day 22, + | Protein, Day 22, ++ | Protein, Day 29, Trace | Protein, Day 29, + | Protein, Day 29, ++ | Protein, Day 60, Trace | Protein, Day 60, + | Protein, Day 60, ++ | Protein, Day 90, Trace | Protein Day 90, + | Protein, Day 120, Trace | Protein, Day 120, + | Protein, Day 120, ++ | Urobilinogen, Day 1, Trace | Urobilinogen, Day 1, + | Urobilinogen, Day1, ++ | Urobilinogen, Day1, +++ | Urobilinogen, Day 3, Trace | Urobilinogen, Day 3, + | Urobilinogen, Day 3, ++ | Urobilinogen Day 3, +++ | Urobilinogen, Day 3, ++++ | Urobilinogen, Day 5, Trace | Urobilinogen, Day 5, + | Urobilinogen, Day 8, Trace | Urobilinogen, Day 8, + | Urobilinogen, Day 8, ++ | Urobilinogen, Day 8,+++ | Urobilinogen, Day 11, Trace | Urobilinogen, Day 11, + | Urobilinogen, Day 11, ++ | Urobilinogen, Day 15, Trace | Urobilinogen, Day 15, + | Urobilinogen, Day 15, ++ | Urobilinogen, Day 22, Trace | Urobilinogen, Day 29, Trace | Urobilinogen, Day 29, + | Urobilinogen, Day 60, Trace | Urobilinogen, Day 60, + | Urobilinogen, Day 90, Trace | Urobilinogen, Day 90, + | Urobilinogen, Day 120, Trace | Urobilinogen, Day 120, + | Urobilinogen, Day 120, ++ | |
| PQ+CQ | 1 | 2 | 0 | 3 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 2 | 4 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 0 | 0 | 2 | 3 | 1 | 1 | 3 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 9 | 2 | 2 | 0 | 5 | 1 | 0 | 1 | 4 | 2 | 2 | 3 | 4 | 1 | 2 | 2 | 3 | 3 | 1 | 2 | 8 | 3 | 1 | 2 | 4 | 0 | 1 | 0 | 6 | 4 | 0 | 3 | 4 | 2 | 1 | 1 | 7 | 2 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 4 | 7 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 1 | 1 | 3 | 3 | 2 | 2 | 4 | 4 | 0 | 2 | 1 | 3 | 2 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 5 | 1 | 1 | 1 | 2 | 5 | 1 | 4 | 0 | 0 | 7 | 3 | 0 | 0 | 1 | 7 | 2 | 3 | 2 | 2 | 5 | 3 | 0 | 2 | 8 | 8 | 1 | 6 | 13 | 1 | 5 | 1 | 1 | 4 | 2 | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 4 | 1 | 2 | 11 | 4 | 3 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| TQ+CQ | 1 | 9 | 3 | 8 | 2 | 1 | 4 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 3 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 3 | 4 | 4 | 2 | 0 | 5 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 3 | 19 | 5 | 1 | 4 | 13 | 2 | 1 | 3 | 11 | 3 | 3 | 7 | 10 | 6 | 2 | 6 | 11 | 3 | 3 | 8 | 4 | 4 | 2 | 4 | 13 | 3 | 1 | 5 | 11 | 1 | 4 | 8 | 8 | 5 | 2 | 6 | 13 | 2 | 0 | 5 | 12 | 5 | 0 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 0 | 2 | 2 | 1 | 2 | 18 | 9 | 12 | 6 | 4 | 14 | 9 | 5 | 3 | 4 | 7 | 6 | 4 | 3 | 4 | 12 | 3 | 3 | 2 | 8 | 3 | 3 | 1 | 2 | 11 | 3 | 2 | 0 | 4 | 11 | 4 | 2 | 1 | 5 | 17 | 3 | 3 | 1 | 5 | 15 | 2 | 3 | 1 | 4 | 13 | 7 | 4 | 2 | 2 | 13 | 3 | 6 | 0 | 15 | 19 | 4 | 8 | 21 | 3 | 5 | 4 | 2 | 6 | 6 | 1 | 1 | 4 | 1 | 2 | 1 | 2 | 2 | 1 | 3 | 4 | 1 | 3 | 3 | 1 | 4 | 3 | 2 | 6 | 1 | 8 | 23 | 10 | 3 | 6 | 14 | 8 | 0 | 0 | 3 | 3 | 2 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 1 | 1 | 3 | 4 | 2 | 3 | 1 | 4 | 3 | 2 | 2 | 0 |
Health outcomes were evaluated based on the actions taken by the participants to treat relapse episode of P vivax malaria. The number of participants with the type of action taken to treat relapse episode of P vivax malaria has been presented by country. Participants may be represented in more than one category, so the total number of participants may be less than the number quoted. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brazil; Trial clinic; n=19, 17 | Brazil; Other; n=19, 17 | Colombia; Nothing; n=4, 3 | Colombia; Trial clinic; n=4, 3 | Colombia; Another clinic; n=4, 3 | Colombia; Hospital emergency center; n=4, 3 | Peru; Trial clinic; n=33, 33 | Peru; Another clinic; n=33, 33 | Peru; Other; n=33, 33 | Thailand; Nothing; n=1, 1 | Thailand; Trial Clinic; n=1, 1 | Vietnam; Nothing; n=4, 7 | Vietnam; Drug Shop; n=4, 7 | Vietnam; Other; n=4, 7 | Vietnam; Another clinic; n=4, 7 | |
| First Malaria Relapse | 19 | 5 | 2 | 1 | 1 | 1 | 32 | 8 | 9 | 1 | 0 | 1 | 2 | 1 | 0 |
| First Malaria Relapse Follow-up | 17 | 0 | 2 | 0 | 0 | 1 | 33 | 33 | 0 | 0 | 1 | 5 | 2 | 0 | 1 |
Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline is the value at post dose visit minus the Baseline value. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The number of participants with change in Best Corrected Visual Acuity Test Scores from Baseline has been presented where possible change is defined as a change from Baseline >=0.12 to <0.3 and definite change is defined as a change from Baseline >=0.3 logMAR score. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum change; possible; right eye; n=27, 13 | Maximum change; definite; right eye; n=27, 13 | Maximum change; possible; left eye; n=27, 13 | Maximum change; definite; left eye; n=27, 13 | Day 29; possible change; right eye; n=27, 13 | Day 29; definite change; right eye; n=27, 13 | Day 29; possible change; left eye; n=27, 13 | Day 29; definite change; left eye; n=27, 13 | Day 90; possible change; right eye; n=27, 12 | Day 90; definite change; right eye; n=27, 12 | Day 90; possible change; left eye; n=27, 12 | Day 90; definite change; left eye; n=27, 12 | Day 180; possible change; right eye; n=2, 2 | Day 180; definite change; right eye; n=2, 2 | Day 180; possible change; left eye; n=2, 2 | Day 180; definite change; left eye; n=2, 2 | |
| PQ+CQ | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TQ+CQ | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
Plasma or serum samples were anlalyzed to evaluate clinical chemistry parameters such as alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory values outside the extended normal range (F3) has been presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Safety Population consisted of all randomized participants who received at least one dose of blinded study medication. (NCT02216123)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ALT, High | ALP, High | AST, High | Bilirubin, High | Creatine kinase, High | Creatinine, High | GFR, Low | Indirect bilirubin, High | Urea, High | |
| PQ+CQ | 0 | 1 | 3 | 18 | 4 | 0 | 0 | 21 | 19 |
| TQ+CQ | 8 | 0 | 6 | 28 | 3 | 0 | 0 | 36 | 40 |
12 lead ECG was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes. ECG assessments were performed in triplicate at screening followed by single ECGs 12 hours after the first dose of study medication and at Day 29. The number of participants with abnormal-clinically significant ECG findings have been presented. The 12 Hour Post Randomized Treatment (11.5-12.5 Hours) timepoint included all readings taken between 11.5 and 12.5 hours post randomized treatment. The 12 Hour Post Randomized Treatment (8-72 Hours) timepoint is a sensitivity analysis of the 12 Hour post randomized treatment timepoint, including all readings taken between 8 and 72 hours post randomized treatment. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 29
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 11.5 to 12.5 hours Day 1, Assessment 1; n=143, 75 | 11.5 to 12.5 hours Day 1 Assessment 2; n=6, 6 | 11.5 to 12.5 hours Day 1 Assessment 3; n=5, 5 | 8 to 72 hours Day 1 Assessment 1; n=166, 85 | 8 to 72 hours Day 1 Assessment 2; n=6, 6 | 8 to 72 hours Day 1 Assessment 3; n=5, 5 | Day 29; n=161, 84 | |
| PQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Two drops of peripheral blood were collected onto pre-printed filter paper for subsequent deoxyribonucleic acid (DNA) extraction and polymerase chain reaction (PCR) analysis of Plasmodium species on all participants at screening (Day 1; pre-dose) and; if necessary, at the time of the first recrudescence/relapse or re-infection. PCR of the P. vivax genes, was used to distinguish between genetically homologous and genetically heterologous infection. The number of participants with genetically homologous and genetically heterologous P. vivax infections has been summarized for each treatment group. Only those participants with an infection occuring on or after Study Day 33 were analyzed. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Heterologous P. vivax | Homologous P. vivax | Unknown genetic classification | |
| PQ+CQ | 9 | 10 | 1 |
| TQ+CQ | 8 | 29 | 5 |
Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) has been presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Participants having both High and Low values for Normal Ranges at any post-baseline visits for safety parameters were counted in both the High and Low categories. (NCT02216123)
Timeframe: Up to Day 120
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Blood eosinophils, High | Blood leukocytes, Low | Blood lymphocytes, Low | Blood lymphocytes, High | Blood neutrophils, Low | Blood platelets, Low | Blood reticulocytes, High | Methemoglobin, High | |
| PQ+CQ | 15 | 0 | 1 | 4 | 3 | 8 | 39 | 3 |
| TQ+CQ | 32 | 0 | 8 | 11 | 5 | 13 | 80 | 2 |
Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up visit. Assessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye has been summarized for each visit. The number of participants with new keratopathy at any time post Baseline is also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; right eye; n=27, 13 | Baseline; left eye; n=27, 13 | Day 1; right eye; n=27, 13 | Day 1; left eye; n=27, 13 | Day 29; right eye; n=27, 13 | Day 29; left eye; n=27, 13 | Day 90; right eye; n=27, 12 | Day 90; left eye; n=27, 12 | Day 180; right eye; n=2, 2 | Day 180; left eye; n=2, 2 | Any time post Baseline; right eye; n=27, 13 | Any time post Baseline; left eye; n=27, 13 | |
| PQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ+CQ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Ophthalmic assessments were carried out at pre-qualified sites prior to randomization and at Days 29 and 90 and at withdrawal follow-up. Assessments were carried out at Day 180 (and up to resolution) if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the value at post dose visit minus the Baseline value. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline has been presented. The number of participants with maximum change post-Baseline (definite when absent or questionable at Baseline) has been presented for either eye. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title). (NCT02216123)
Timeframe: Baseline and up to Day 180
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 29, Definite change, right eye; n=22, 13 | Day 29, Ques change, right eye; n=22, 13 | Day 29, Definite change, left eye; n=22, 13 | Day 29, Ques change, left eye; n=22, 13 | Day 90, Definite change, right eye; n=24, 11 | Day 90, Ques change, right eye; n=24, 11 | Day 90, Definite change, left eye; n=24, 11 | Day 90, Ques change, left eye; n=24, 11 | Day 180, Definite change, right eye; n=3, 2 | Day 180, Ques change, right eye; n=3, 2 | Day 180, Definite change, left eye; n=3, 2 | Day 180, Ques change, left eye; n=3, 2 | Maximum change post-Baseline; either eye; n=27, 13 | |
| PQ+CQ | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TQ+CQ | 0 | 2 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant under clinical investigation, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations such as important medical events and events of possible drug induced liver injury with hyperbilirubinemia. TEAEs are defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT02216123)
Timeframe: Up to Day 180
| Intervention | Participants (Number) | |
|---|---|---|
| TEAEs | Serious TEAEs | |
| PQ+CQ | 64 | 1 |
| TQ+CQ | 119 | 6 |
Count of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) occurring after PfSPZ-CVac immunization. This outcome measure applies to main phase arms 1b, 2b, 4a, and 4b. Arms 5b and 6b were not performed as patent parasitemia with the higher dose of PfSPZ was not observed in the pilot phase (Arms 1a, 2a). (NCT03952650)
Timeframe: For the main phase: from the day of inoculation to approximately 6 months post-3rd inoculation. For the booster phase: from the time of inoculation to approximately 6 months post-booster inoculation
| Intervention | Participants (Count of Participants) |
|---|---|
| 1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 88 |
| 2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 57 | 59 |
| 4a - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 51 |
| 4b - Safety Comparator: Dosing Interval on Days: 1, 29, 57 | 36 |
Count of participants with local and systemic grade 3 signs or symptoms lasting more than 48 hours despite adequate management and serious adverse events (SAEs) occurring after PfSPZ-CVac DVI. Only arm 3a was analyzed for this outcome measure, per the protocol objectives. (NCT03952650)
Timeframe: From day of inoculation to 14 days post-inoculation
| Intervention | Participants (Count of Participants) |
|---|---|
| 3a - Pilot/Safety: Dosing Interval on Days: 1 | 0 |
Count of participants with positive sensitive blood smear (sBS) occurring after PfSPZ-CVac immunization starting on day 7 post DVI. Only pilot phase arms (Arms 1a, 2a) were analyzed for this outcome measure. Arms 5a and 6a were not performed, as no patent parasitemia was observed in either Arms 1a or 2a, per the protocol. (NCT03952650)
Timeframe: 7 -12 days post-inoculation
| Intervention | Participants (Count of Participants) |
|---|---|
| 1a - Pilot/Safety: Dosing Interval on Days: 1 | 0 |
| 2a - Pilot/Safety: Dosing Interval on Days: 1 | 0 |
Incidence of a clinical malaria diagnosis occurring after PfSPZ-Cvac challenge requiring treatment with atovaquone/proguanil (Malarone). (NCT03083847)
Timeframe: 12 days post PfSPZ Challenge injection
| Intervention | participants (Number) |
|---|---|
| Main (3): 3 Doses of 2x10^5 PfSPZ + Chloroquine + 7G8 CHMI | 0 |
| Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine | 0 |
| Pilot (5b): 1 Dose of 2x10^5 PfSPZ Challenge + Chloroquine | 0 |
Participants who had one or more episodes of related or/and unrelated adverse events (AEs). An AE is defined as any untoward medical occurrence temporarily associated with the subject's participation in research, whether or not considered related or not. Refer to adverse event table for specific AE. (NCT03083847)
Timeframe: 7 months
| Intervention | participants (Number) |
|---|---|
| Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine | 2 |
| Pilot (1b):1 Injection of 1x10^5 PfSPZ Challenge+Pyrimethamine | 2 |
| Pilot (1d):1 Injection of 2x10^5 PfSPZ Challenge+Pyrimethamine | 3 |
| Main (2a):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+NF54 | 8 |
| Main (2b):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+7G8 | 9 |
| Main (3):3 Doses of 2x10^5 PfSPZ Challenge+Chloroquine+7G8 | 10 |
| Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine | 2 |
| Pilot (5b): 1 Injection of 2x10^5 PfSPZ Challenge+Chloroquine | 4 |
Participants with P. falciparum blood stage infection defined as detection of P. falciparum parasites by qPCR (real time NIH qPCR and sensitive retrospective Laboratory of Malaria Immunology & Vaccinology (LMIV) qPCR) following Sanaria® PfSPZ Challenge (NF54) via direct venous injection (DVI). (NCT03083847)
Timeframe: 14 days post PfSPZ Challenge injection
| Intervention | Participants (Number) |
|---|---|
| Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine | 0 |
| Pilot (1b): 1 Dose of 1x10^5 PfSPZ Challenge + Pyrimethamine | 0 |
| Pilot (1d): 1 Dose of 2x10^5 PfSPZ Challenge + Pyrimethamine | 0 |
| Main (2a): 3 Doses of 2x10^5 PfSPZ + Pyrimethamine + NF54 CHMI | 0 |
| Main (2b): 3 Doses of 2x10^5 PfSPZ + Pyrimethamine + 7G8 CHMI | 0 |
Participants who had one or more episodes of serious adverse events (SAEs). SAE is defined as a life-threatening reaction or event that results in death. (NCT03083847)
Timeframe: 7 months
| Intervention | participants (Number) |
|---|---|
| Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine | 0 |
| Pilot (1b):1 Injection of 1x10^5 PfSPZ Challenge+Pyrimethamine | 0 |
| Pilot (1d):1 Injection of 2x10^5 PfSPZ Challenge+Pyrimethamine | 0 |
| Main (2a):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+NF54 | 0 |
| Main (2b):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+7G8 | 0 |
| Main (3):3 Doses of 2x10^5 PfSPZ Challenge+Chloroquine+7G8 | 2 |
| Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine | 0 |
| Pilot (5b): 1 Injection of 2x10^5 PfSPZ Challenge+Chloroquine | 0 |
Occurrence of solicited local and systemic adverse events (i.e: pain, redness, swelling and pruritus at injection site and temperature, feverishness, myalgia, arthralgia, malaise, headache and nausea). (NCT02925403)
Timeframe: Assessment of solicited AEs in the first 7 days post vaccination.
| Intervention | Number of adverse events (Number) |
|---|---|
| Group 1 | 10 |
| Group 2 | 0 |
Occurrence of laboratory adverse events defined as clinically significant changes from baseline. Haematology (Full Blood Count) and Biochemistry (Kidney and Liver Function Tests) will be assessed. (NCT02925403)
Timeframe: At Day 0 (baseline), day 7 and day 28 post vaccination.
| Intervention | Laboratory AEs (Number) |
|---|---|
| Group 1 | 18 |
| Group 2 | 15 |
Occurrence of serious adverse events will be collected from enrolment until the end of the follow-up period. (NCT02925403)
Timeframe: 6 months
| Intervention | SAEs (Number) |
|---|---|
| Group 1 | 0 |
| Group 2 | 0 |
Occurrence of unsolicited local and systemic adverse events. This will be done by recording the number of participants who experience unsolicited adverse events. (NCT02925403)
Timeframe: Unsolicited AEs to be assessed up to 28 days post vaccination.
| Intervention | participants (Number) |
|---|---|
| Group 1 | 8 |
| Group 2 | 5 |
Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days
| Intervention | days (Mean) |
|---|---|
| Group 1 | 11 |
| Group 2 | 11 |
| Group 3 | 9 |
5 reviews available for chloroquine and Parasitemia
| Article | Year |
|---|---|
Action mechanisms of metallic compounds on Plasmodium spp.
Topics: Antimalarials; Chloroquine; Humans; Malaria; Parasitemia; Plasmodium | 2022 |
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate D | 2020 |
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine | 2021 |
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Asia, Southeastern; Chloroquine; Directly Obser | 2013 |
Monitoring antimalarial drug resistance: making the most of the tools at hand.
Topics: Animals; Antimalarials; Chloroquine; Drug Monitoring; Drug Resistance; Folic Acid Antagonists; Genet | 2003 |
73 trials available for chloroquine and Parasitemia
| Article | Year |
|---|---|
Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Preschool; Chl | 2021 |
Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial.
Topics: Adult; Antimalarials; Cell Line; Chemoprevention; Chloroquine; Female; Humans; Immunoglobulin G; Mal | 2021 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co | 2018 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Disease-Fre | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Aminoquinolines; Antimalarials; Chloroquine; Disease-Free Survival; Double-Blind | 2019 |
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroqui | 2013 |
Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse.
Topics: Adult; Antimalarials; Chemoprevention; Chloroquine; Drug Therapy, Combination; Female; Humans; Malar | 2013 |
The efficacy of artesunate, chloroquine, doxycycline, primaquine and a combination of artesunate and primaquine against avian malaria in broilers.
Topics: Analysis of Variance; Animals; Antimalarials; Artemisinins; Artesunate; Body Weight; Chickens; Chlor | 2014 |
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, | 2014 |
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, | 2014 |
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, | 2014 |
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, | 2014 |
Heterologous Protection against Malaria after Immunization with Plasmodium falciparum Sporozoites.
Topics: Adult; Chloroquine; Humans; Immunization; Malaria, Falciparum; Parasitemia; Plasmodium falciparum; S | 2015 |
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Ethio | 2015 |
Pre-infection administration of asiatic acid retards parasitaemia induction in Plasmodium berghei murine malaria infected Sprague-Dawley rats.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Malaria; Male; Mice; Parasitemia; Penta | 2016 |
Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Asymptomatic Diseases; Azithromycin; Chloroquine; Dru | 2016 |
Fixed-Dose Artesunate-Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Brazil; Child; Child, Preschool; | 2017 |
Short report: comparison of chlorproguanil-dapsone with a combination of sulfadoxine-pyrimethamine and chloroquine in children with malaria in northcentral Nigeria.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Com | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Protection against a malaria challenge by sporozoite inoculation.
Topics: Adult; Animals; Anopheles; Antibodies, Protozoan; Antimalarials; Biomarkers; Blood; Chloroquine; Dou | 2009 |
Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Blood; Chloroquine; Drug Combinations; Huma | 2009 |
Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug | 2010 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Fe | 2010 |
Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections.
Topics: Administration, Oral; Adult; Antimalarials; Borneo; Chloroquine; Drug Therapy, Combination; Female; | 2010 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Duffy Blood-Group System; Female; Fever; Humans; Malaria | 2011 |
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Ethiopia; Female; Humans; In | 2011 |
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
Topics: Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Incidence; Indonesia; Malaria, Falcip | 2002 |
Effect of zinc on the treatment of Plasmodium falciparum malaria in children: a randomized controlled trial.
Topics: Animals; Child, Preschool; Chloroquine; Double-Blind Method; Ecuador; Fever; Ghana; Hospitalization; | 2002 |
Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Chloroquine; Double-Blind Method; Drug Resi | 2002 |
Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2003 |
Malaria in a cohort of Javanese migrants to Indonesian Papua.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Cross-Sectional Studies; Female; Follow-Up Stu | 2003 |
The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi | 2004 |
Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes.
Topics: Acute Disease; Age Factors; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate; Child; Chil | 2004 |
A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2004 |
Low-dose quinine is effective in the treatment of chloroquine-resistant Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc | 2004 |
Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Chloroquine; Chlorpheni | 2004 |
Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2004 |
Endogenous opioids, mu-opiate receptors and chloroquine-induced pruritus: a double-blind comparison of naltrexone and promethazine in patients with malaria fever who have an established history of generalized chloroquine-induced itching.
Topics: Administration, Oral; Adult; Animals; Antimalarials; Antipruritics; Area Under Curve; Chloroquine; D | 2004 |
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anemia; Birth Weight; Chemoprevention; Chloroquine; Drug A | 2005 |
A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Fever; Ghana; | 2005 |
Comparison of sulfadoxine-pyrimethamine with and without chloroquine for uncomplicated malaria in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Body Weight; Child; Chloroquine; Drug Therapy, Combination; Female | 2005 |
Predictors of the failure of treatment with chloroquine plus chlorpheniramine, in children with acute, uncomplicated, Plasmodium falciparum malaria.
Topics: Acute Disease; Age Factors; Antimalarials; Child; Child, Preschool; Chloroquine; Chlorpheniramine; D | 2005 |
Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com | 2005 |
[Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire].
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug Combinations | 2005 |
A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.
Topics: Adult; Aged; Animals; Antimalarials; Azithromycin; Chloroquine; Double-Blind Method; Drug Administra | 2005 |
Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
Topics: Adult; Animals; Antimalarials; Chloroquine; Colombia; Female; Follow-Up Studies; Humans; Malaria, Vi | 2006 |
Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Anemia; Antimalarials; Child Development; Chloroquine; Double-Blind Method; Femal | 2007 |
The importance of the period of malarial infection during pregnancy on birth weight in tropical Africa.
Topics: Adolescent; Adult; Africa; Animals; Antimalarials; Birth Weight; Burkina Faso; Chloroquine; Female; | 2007 |
Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug-resistant parasites better than unprotected children.
Topics: Animals; Antimalarials; Bedding and Linens; Burkina Faso; Child, Preschool; Chloroquine; Drug Resist | 2007 |
A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women.
Topics: Adult; Animals; Antimalarials; Birth Weight; Chloroquine; Drug Combinations; Female; Hematocrit; Hum | 2007 |
Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Topics: Adolescent; Aged; Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Therapy, Combi | 2007 |
Short report: prevalence and chloroquine sensitivity of Plasmodium malariae in Madagascar.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Female; Humans; Inf | 2007 |
Process and effects of a community intervention on malaria in rural Burkina Faso: randomized controlled trial.
Topics: Anemia; Animals; Burkina Faso; Child, Preschool; Chloroquine; Female; Fever; Humans; Infant; Malaria | 2008 |
Antibodies to ring-infected erythrocyte surface antigen (Pf155/RESA) protect against P. falciparum parasitemia in highly exposed multigravidas women in Malawi.
Topics: Adult; Amino Acid Sequence; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antigens, Surface; | 1994 |
Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Animals; Anopheles; Child; Chloroquine; Confounding Factors, Epidemiologic; Drug | 1995 |
Specific and nonspecific responses to Plasmodium falciparum blood-stage parasites and observations on the gametocytemia in schoolchildren living in a malaria-endemic area of Mozambique.
Topics: Adolescent; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Blotting, Western; C | 1995 |
The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi.
Topics: Analysis of Variance; Antimalarials; Chi-Square Distribution; Chloroquine; Drug Combinations; Drug T | 1994 |
Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Chloroqui | 1995 |
Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria.
Topics: Adolescent; Animals; Anti-Bacterial Agents; Antimalarials; Child; Child, Preschool; Chloroquine; Cli | 1995 |
Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Humans; Malaria, Falciparum; Malawi; Mefloqui | 1996 |
Malaria parasite infection during pregnancy and at delivery in mother, placenta, and newborn: efficacy of chloroquine and mefloquine in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Fetal Blood; Humans; Malaria, Falciparum; Mal | 1996 |
Therapeutic effects of chloroquine in combination with quinine in uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimalarials; Chloroquine; Drug Therapy, Combination; Fev | 1996 |
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis.
Topics: Antimalarials; Chloroquine; Disease Susceptibility; Follow-Up Studies; Humans; Incidence; Indonesia; | 1997 |
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia; | 1997 |
Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Monitoring; Drug Resistance; F | 1998 |
Population structure of recrudescent Plasmodium falciparum isolates from western Uganda.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antigens, Protozoan; Antimalarials; Child; Chil | 1999 |
Short report: effects of pyronaridine on gametocytes in patients with acute uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1999 |
Molecular epidemiology of malaria in Yaounde, Cameroon V. analysis of the omega repetitive region of the plasmodium falciparum CG2 gene and chloroquine resistance.
Topics: Adolescent; Adult; Animals; Antimalarials; Cameroon; Child; Chloroquine; DNA Primers; DNA, Protozoan | 1999 |
Comparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children.
Topics: Animals; Antimalarials; Antipruritics; Child; Child, Preschool; Chloroquine; Chlorpheniramine; Drug | 2000 |
Chloroquine prophylaxis, iron/folic-acid supplementation or case management of malaria attacks in primigravidae in western Uganda: effects on congenital malaria and infant haemoglobin concentrations.
Topics: Analysis of Variance; Anemia, Neonatal; Antimalarials; Birth Weight; Chloroquine; Double-Blind Metho | 2000 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Plasmodium vivax clinically resistant to chloroquine in Colombia.
Topics: Animals; Antimalarials; Chloroquine; Colombia; Drug Therapy, Combination; Humans; Malaria, Vivax; Ma | 2001 |
Randomized comparison of chloroquine and amodiaquine in the treatment of acute, uncomplicated, Plasmodium falciparum malaria in children.
Topics: Age Factors; Amodiaquine; Analysis of Variance; Antimalarials; Child; Child, Preschool; Chloroquine; | 2001 |
Anemia of persistent malarial parasitemia in Nigerian children.
Topics: Anemia; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu | 2001 |
Therapeutic efficacy of chloroquine against uncomplicated, Plasmodium falciparum malaria in south-western Saudi Arabia.
Topics: Acute Disease; Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Chloroquine | 2001 |
Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy.
Topics: Acetaminophen; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Dru | 2002 |
Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Area Under Curve; Child; Chloroquine; Drug Administ | 2002 |
231 other studies available for chloroquine and Parasitemia
| Article | Year |
|---|---|
In vivo active antimalarial isonitriles.
Topics: Animals; Antimalarials; Drug Resistance, Multiple; Mice; Microbial Sensitivity Tests; Nitriles; Para | 2002 |
Antiplasmodial activity of aryltetralone lignans from Holostylis reniformis.
Topics: Animals; Antimalarials; Aristolochiaceae; Cell Line, Tumor; Chromatography, High Pressure Liquid; Ci | 2007 |
Pyridinium cationic-dimer antimalarials, unlike chloroquine, act selectively between the schizont stage and the ring stage of Plasmodium falciparum.
Topics: Animals; Antimalarials; Cations; Cell Line, Tumor; Chloroquine; Dimerization; Drug Resistance; Eryth | 2008 |
In vitro and in vivo properties of ellagic acid in malaria treatment.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atovaquone; Chloroquine; Dose-Response Relationshi | 2009 |
Search for new pharmacophores for antimalarial activity. Part I: synthesis and antimalarial activity of new 2-methyl-6-ureido-4-quinolinamides.
Topics: Amides; Aminoquinolines; Animals; Anti-Bacterial Agents; Antimalarials; Inhibitory Concentration 50; | 2009 |
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals | 2009 |
Synthesis and antiplasmodial activity of new indolone N-oxide derivatives.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Resistance; Humans; Indoles; Oxides; Parasitemia; Par | 2010 |
Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT).
Topics: Animals; Antimalarials; Biological Transport; Cell Survival; Chloroquine; CHO Cells; Cricetinae; Cri | 2011 |
Antimalarial activity of imidazo[2,1-a]isoindol-5-ol derivatives and related compounds.
Topics: Animals; Antimalarials; Benzene; Cell Line; Imidazoles; Inhibitory Concentration 50; Isoindoles; Mal | 2011 |
Antimalarial activity of physalins B, D, F, and G.
Topics: Animals; Antimalarials; Immunosuppressive Agents; Malaria; Mice; Mice, Inbred BALB C; Parasitemia; P | 2011 |
Lead optimization of antimalarial propafenone analogues.
Topics: Administration, Oral; Animals; Antimalarials; Chloroquine; Cytochrome P-450 CYP2D6; Cytochrome P-450 | 2012 |
Preparation and antimalarial activity of semisynthetic lycorenine derivatives.
Topics: Amaryllidaceae Alkaloids; Antimalarials; Dimerization; Humans; Inhibitory Concentration 50; Models, | 2013 |
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Paras | 2014 |
Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
Topics: Animals; Antimalarials; Chloroquine; Malaria; Mice; Parasitemia; Parasitic Sensitivity Tests; Phenan | 2014 |
Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Disease Models, Animal; HSP90 Heat-Shock Proteins; | 2015 |
Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
Topics: Animals; Antimalarials; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Eryth | 2015 |
Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials.
Topics: Animals; Antimalarials; Humans; Malaria; Malaria, Falciparum; Mice, SCID; Parasitemia; Plasmodium be | 2016 |
Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Erythrocytes; Humans; Macrophages; Mice; Paras | 2018 |
Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery.
Topics: Animals; Antimalarials; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Hep | 2018 |
Decoding the Role of Melatonin Structure on
Topics: Animals; Chloroquine; Humans; Indoles; Malaria; Malaria, Falciparum; Melatonin; Parasitemia; Parasit | 2022 |
Effect of black seeds (Nigella sativa) on inflammatory and immunomodulatory markers in Plasmodium berghei-infected mice.
Topics: Animals; Antimalarials; Antioxidants; Biomarkers; Chloroquine; Glutathione; Immunity; Immunoglobulin | 2022 |
Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
Topics: Animals; Antimalarials; Chloroquine; Copper; Malaria, Falciparum; Malaria, Vivax; Mice; Oocysts; Par | 2022 |
Quantification of parasite clearance in Plasmodium knowlesi infections.
Topics: Animals; Antimalarials; Artemisinins; Bayes Theorem; Chloroquine; Humans; Malaria; Parasitemia; Para | 2023 |
Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response.
Topics: Antimalarials; Chloroquine; Ethiopia; Humans; Malaria, Vivax; Parasitemia; Plasmodium vivax; Primaqu | 2023 |
Antiplasmodial Activity Evaluation of a Bestatin-Related Aminopeptidase Inhibitor, Phebestin.
Topics: Aminopeptidases; Animals; Antimalarials; Chloroquine; Humans; Malaria; Malaria, Falciparum; Mice; Pa | 2023 |
Development of a human malaria-on-a-chip disease model for drug efficacy and off-target toxicity evaluation.
Topics: Antimalarials; Chloroquine; Endothelial Cells; Humans; Lab-On-A-Chip Devices; Malaria; Malaria, Falc | 2023 |
DNA recovery from archived RDTs for genetic characterization of Plasmodium falciparum in a routine setting in Lambaréné, Gabon.
Topics: Adolescent; Adult; Biological Specimen Banks; Body Temperature; Child; Child, Preschool; Chloroquine | 2019 |
Highly Sensitive and Rapid Characterization of the Development of Synchronized Blood Stage Malaria Parasites Via Magneto-Optical Hemozoin Quantification.
Topics: Animals; Blood Chemical Analysis; Chloroquine; Disease Models, Animal; Early Diagnosis; Female; Heme | 2019 |
Potential antimalarial activity of Coccinia barteri leaf extract and solvent fractions against Plasmodium berghei infected mice.
Topics: Animals; Antimalarials; Chloroquine; Cucurbitaceae; Disease Models, Animal; Female; Malaria; Male; M | 2020 |
Discovery of potential 1,3,5-Triazine compounds against strains of Plasmodium falciparum using supervised machine learning models.
Topics: Antimalarials; Chloroquine; Machine Learning; Malaria; Parasitemia; Plasmodium falciparum; Triazines | 2020 |
Speed of action and stage specificity of Bencha-loga-wichian, a Thai traditional antipyretic formulation, against Plasmodium falciparum and the chloroquine-potentiating activity of its active compounds, tiliacorinine and yanangcorinine.
Topics: Antimalarials; Antipyretics; Benzylisoquinolines; Chloroquine; Drug Resistance; Drug Synergism; Drug | 2020 |
Progression of malaria induced pathogenicity during chloroquine therapy.
Topics: Animals; Antimalarials; Chloroquine; Disease Progression; Malaria; Mice, Inbred ICR; Parasitemia; Pl | 2020 |
Phytol suppresses parasitemia and ameliorates anaemia and oxidative brain damage in mice infected with Plasmodium berghei.
Topics: Analysis of Variance; Anemia; Animals; Antimalarials; Brain; Chloroquine; Dose-Response Relationship | 2021 |
Developmental stages influence in vivo antimalarial activity of aerial part extracts of Schkuhria pinnata.
Topics: Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Asteraceae; Chloroquine; Dose-Res | 2021 |
Evaluation of the effect of probiotic as add-on therapy with conventional therapy and alone in malaria induced mice.
Topics: Antimalarials; Chloroquine; Humans; Malaria; Mice; Parasitemia; Probiotics | 2021 |
In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA.
Topics: Animals; Antimalarials; Cameroon; Chloroquine; Disease Models, Animal; Drug Combinations; Fermented | 2021 |
Case report of Plasmodium ovale curtisi malaria in Sri Lanka: relevance for the maintenance of elimination status.
Topics: Adult; Antimalarials; Chloroquine; Fever; Humans; Liberia; Malaria; Malaria, Vivax; Male; Molecular | 2017 |
Antibody Responses to
Topics: Adaptive Immunity; Antibodies, Protozoan; Antimalarials; Artemisinins; Artesunate; Chloroquine; Coho | 2017 |
Correlation between in vitro and in vivo antimalarial activity of compounds using CQ-sensitive and CQ-resistant strains of Plasmodium falciparum and CQ-resistant strain of P. yoelii.
Topics: Animals; Antimalarials; Chloroquine; Malaria, Falciparum; Mice; Parasitemia; Plasmodium falciparum | 2017 |
Isolation, structural elucidation and antiplasmodial activity of fucosterol compound from brown seaweed, Sargassum linearifolium against malarial parasite Plasmodium falciparum.
Topics: Animals; Antimalarials; Chloroquine; Drug Evaluation, Preclinical; Erythrocytes; India; Inhibitory C | 2018 |
The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold.
Topics: 2,2'-Dipyridyl; Animals; Antimalarials; Atovaquone; Chloroquine; Drug Design; Female; Humans; Hydraz | 2017 |
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Topics: Adult; Antimalarials; Brazil; Chloroquine; Drug Therapy, Combination; Female; Genotype; Humans; Live | 2017 |
In vivo and in vitro antimalarial effect and toxicological evaluation of the chloroquine analogue PQUI08001/06.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Male; Mice; Parasitemia; Plas | 2018 |
Low rates of Plasmodium falciparum Pfcrt K76T mutation in three sentinel sites of malaria monitoring in Côte d'Ivoire.
Topics: Adolescent; Adult; Age Distribution; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Cote | 2018 |
Effective treatment with a tetrandrine/chloroquine combination for chloroquine-resistant falciparum malaria in Aotus monkeys.
Topics: Administration, Oral; Animals; Antimalarials; Aotus trivirgatus; Benzylisoquinolines; Chloroquine; D | 2013 |
Assessment of in vitro sensitivity of Plasmodium vivax fresh isolates.
Topics: Antimalarials; Benzothiazoles; Chloroquine; Diamines; Humans; Inhibitory Concentration 50; Malaria, | 2011 |
Comparative study of chloroquine and quinine on malaria rodents and their effects on the mouse testis.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Malaria; Male; Mice; Orchitis; Parasite | 2012 |
Therapeutic effects of various solvent fractions of Alstonia boonei (apocynaceae) stem bark on Plasmodium berghei-induced malaria.
Topics: Alstonia; Animals; Antimalarials; Chemical Fractionation; Chloroquine; Dose-Response Relationship, D | 2012 |
In vitro and in vivo antimalarial activity and cytotoxicity of extracts and fractions from the leaves, root-bark and stem-bark of Triclisia gilletii.
Topics: Animals; Antimalarials; Cell Line; Cell Survival; Chloroquine; Drug Resistance, Multiple; Humans; Ma | 2013 |
A novel chitosan based antimalarial drug delivery against Plasmodium berghei infection.
Topics: Animals; Antimalarials; Chitosan; Chloroquine; Disease Models, Animal; DNA Damage; Drug Carriers; Dr | 2013 |
Treatment of pregnant BALB/c mice with sulphadoxine pyrimethamine or chloroquine abrogates Plasmodium berghei induced placental pathology.
Topics: Animals; Antimalarials; Antioxidants; Chloroquine; DNA Fragmentation; Drug Combinations; Female; Lip | 2014 |
CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii.
Topics: Animals; Antibodies, Protozoan; Antimalarials; CD8-Positive T-Lymphocytes; Chloroquine; Female; Mala | 2014 |
Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium.
Topics: Animals; Antimalarials; Chloroquine; Drug Carriers; Erythrocytes; Female; Malaria; Mice; Mice, Inbre | 2014 |
Paucity of Plasmodium vivax mature schizonts in peripheral blood is associated with their increased cytoadhesive potential.
Topics: Antimalarials; Cell Adhesion; Chloroquine; Erythrocytes; Humans; Malaria, Vivax; Parasitemia; Plasmo | 2014 |
Antimalarial potential of kolaviron, a biflavonoid from Garcinia kola seeds, against Plasmodium berghei infection in Swiss albino mice.
Topics: Analysis of Variance; Animals; Antimalarials; Antioxidants; Body Weight; Chloroquine; Flavonoids; Ga | 2014 |
Transient lesion in the splenium of the corpus callosum in acute uncomplicated falciparum malaria.
Topics: Acute Disease; Adult; Antimalarials; Artemisinins; Chloroquine; Corpus Callosum; Drug Therapy, Combi | 2014 |
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini | 2014 |
Slow clearance of Plasmodium vivax with chloroquine amongst children younger than six months of age in the Brazilian Amazon.
Topics: Age Factors; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; H | 2014 |
Antimalarial activity of the myxobacterial macrolide chlorotonil a.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Hydrocarbons, Chlorinated; Macrolides | 2014 |
[Epidemiological characteristics of malaria in the village of Corail, Grand'Anse, Haiti].
Topics: Adolescent; Adult; Aged; Antimalarials; Asymptomatic Diseases; Child; Child, Preschool; Chloroquine; | 2014 |
In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Malaria; Male; Mice; Minocycline; Paras | 2014 |
Clinical problem-solving. A chilly fever.
Topics: Adult; Antimalarials; Blood; Chloroquine; Circadian Rhythm; Diagnosis, Differential; Fever; Humans; | 2014 |
Chitosan conjugated chloroquine: proficient to protect the induction of liver apoptosis during malaria.
Topics: Animals; Antimalarials; Apoptosis; Caspase 3; Caspase 9; Chitosan; Chloroquine; Drug Carriers; Gluta | 2015 |
Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunization.
Topics: Animals; Antimalarials; Chemoprevention; Chloroquine; Culicidae; Erythrocytes; Host-Parasite Interac | 2015 |
Phytochemical screening and in vivo antimalarial activity of extracts from three medicinal plants used in malaria treatment in Nigeria.
Topics: Animals; Antimalarials; Bignoniaceae; Chloroquine; Drug Resistance; Female; Malaria; Male; Meliaceae | 2016 |
Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu | 2015 |
Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model.
Topics: Animals; Antimalarials; Blood Chemical Analysis; Chloroquine; Chromatography, Liquid; Disease Models | 2015 |
Assessment of the Worldwide Antimalarial Resistance Network Standardized Procedure for In Vitro Malaria Drug Sensitivity Testing Using SYBR Green Assay for Field Samples with Various Initial Parasitemia Levels.
Topics: Antimalarials; Artemisinins; Atovaquone; Benzothiazoles; Biological Assay; Chloroquine; Diamines; DN | 2016 |
Potential antimalarial activity of Methyl Jasmonate and its effect on lipid profiles in Plasmodium Berghei infected mice.
Topics: Acetates; Animals; Antimalarials; Artemisinins; Chloroquine; Cyclopentanes; Malaria; Mice; Oxylipins | 2015 |
Highly active ozonides selected against drug resistant malaria.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Disease Models, Animal; Female; Human | 2016 |
Chloroquine-containing organoruthenium complexes are fast-acting multistage antimalarial agents.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Malaria; Mice; Organometallic Compounds | 2016 |
Antimalarial potential of leaves of Chenopodium ambrosioides L.
Topics: Animals; Antimalarials; Chenopodium ambrosioides; Chloroquine; Erythrocytes; Humans; Malaria; Mice; | 2016 |
Asiatic acid influences parasitaemia reduction and ameliorates malaria anaemia in P. berghei infected Sprague-Dawley male rats.
Topics: Anemia; Animals; Antimalarials; Chloroquine; Malaria; Male; Parasitemia; Pentacyclic Triterpenes; Pl | 2016 |
Exploring the antimalarial potential of whole Cymbopogon citratus plant therapy.
Topics: Animals; Antimalarials; Chloroquine; Cymbopogon; Disease Models, Animal; Dose-Response Relationship, | 2016 |
The Effects of Transdermally Delivered Oleanolic Acid on Malaria Parasites and Blood Glucose Homeostasis in P. berghei-Infected Male Sprague-Dawley Rats.
Topics: Administration, Cutaneous; Animals; Antimalarials; Blood Glucose; Chloroquine; Drug Therapy, Combina | 2016 |
Quantitative characterization of hemozoin in Plasmodium berghei and vivax.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Hemeproteins; Liver; Malaria; Malaria, Vivax; | 2017 |
Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Shawa Robit Health Care Centre, North-East Ethiopia.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Ethiopia; Female; Hematocrit; Humans; Infant; M | 2017 |
Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan.
Topics: Adolescent; Age Factors; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Studie | 2009 |
Transmission of different strains of Plasmodium cynomolgi to Aotus nancymaae monkeys and relapse.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Insect Vectors; Malaria; Monkey Diseases; P | 2009 |
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.
Topics: Adolescent; Adult; Animals; Antimalarials; Blood; Child; Child, Preschool; Chloroquine; Chromatograp | 2008 |
Antiplasmodial activity of root extract and fractions of Croton zambesicus.
Topics: Animals; Antimalarials; Chloroquine; Croton; Female; Lethal Dose 50; Malaria; Male; Mice; Parasitemi | 2009 |
Reduced protective effect of Plasmodium berghei immunization by concurrent Schistosoma mansoni infection.
Topics: Animals; Antimalarials; Chloroquine; Female; Malaria; Mice; Mice, Inbred BALB C; Parasitemia; Plasmo | 2008 |
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.
Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Drug Combinations; Female; Genotype | 2009 |
Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia.
Topics: Adult; Animals; Antimalarials; Artemisinins; Artesunate; Cambodia; Child; Chloroquine; Drug Therapy, | 2009 |
Effect of rutin and chloroquine on White Leghorn chickens infected with Plasmodium (Bennettinia) juxtanucleare.
Topics: Adrenal Cortex Hormones; Analysis of Variance; Animals; Antimalarials; Body Temperature; Body Weight | 2009 |
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
Topics: Animals; Antimalarials; Chloroquine; Chromobacterium; Drug Resistance; Humans; Indoles; Malaria; Mal | 2009 |
In vivo antimalarial activity of leaves of Plectranthus amboinicus (lour) spreng on Plasmodium berghei yoelii.
Topics: Animals; Antimalarials; Chloroquine; Coleus; Female; Malaria; Male; Mice; Parasitemia; Parasitic Sen | 2008 |
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Drug Resista | 2009 |
Clinical and laboratory features of human Plasmodium knowlesi infection.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Blood Chemical Analysis; Chloroquine; Female; Hemog | 2009 |
Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia.
Topics: Adolescent; Adult; Animals; Antimalarials; Blood Chemical Analysis; Child; Child, Preschool; Chloroq | 2009 |
Antimalarial activity of the novel quinoline/6-thiopurine conjugate in Gallus gallus Linnaeus, infected experimentally by Plasmodium (Novyella) juxtanucleare.
Topics: Animals; Antimalarials; Chickens; Chloroquine; Disease Models, Animal; Malaria, Avian; Parasitemia; | 2009 |
Haemoglobin interference and increased sensitivity of fluorimetric assays for quantification of low-parasitaemia Plasmodium infected erythrocytes.
Topics: Animals; Benzothiazoles; Cell Separation; Chloroquine; Cytophotometry; Diamines; DNA, Protozoan; Ery | 2009 |
Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Resistance; Haplotypes; Humans; Malaria, Vivax; Mi | 2009 |
Flow cytometry for the evaluation of anti-plasmodial activity of drugs on Plasmodium falciparum gametocytes.
Topics: Anti-Infective Agents; Antimalarials; Artemisinins; Chloroquine; Drug Evaluation, Preclinical; Flow | 2010 |
Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.
Topics: Amidohydrolases; Animals; Antimalarials; Candidiasis; Chagas Disease; Chloroquine; Cysteamine; Cytok | 2010 |
Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
Topics: Adolescent; Adult; Antigens, Protozoan; Antimalarials; Case-Control Studies; Child; Child, Preschool | 2010 |
Alpha-tocopherol transfer protein disruption confers resistance to malarial infection in mice.
Topics: Animals; Antimalarials; Carrier Proteins; Chloroquine; Immunity, Innate; Malaria; Mice; Mice, Inbred | 2010 |
Antimalarial activity of traditionally used Western Ghats plants from India and their interactions with chloroquine against chloroquine-tolerant Plasmodium berghei.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Synergism; Ethnopharmacology; India; Inje | 2011 |
Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Child; Child, Pr | 2011 |
Suppression of Plasmodium berghei parasitemia by LiCl in an animal infection model.
Topics: Animals; Antimalarials; Chemoprevention; Chloroquine; Disease Models, Animal; Glycogen Synthase Kina | 2010 |
Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages.
Topics: Antimalarials; Atovaquone; Chloroquine; Erythrocytes; Malaria, Falciparum; Parasitemia; Plasmodium f | 2011 |
Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.
Topics: Animals; Antimalarials; Artemisinins; Chloroquine; Chromatography, High Pressure Liquid; Disease Mod | 2011 |
Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia.
Topics: Acute Kidney Injury; Adult; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Ethano | 2011 |
Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite.
Topics: Animals; Azithromycin; CD8-Positive T-Lymphocytes; Chloroquine; Erythrocytes; Female; Liver; Malaria | 2011 |
Interaction between ciprofloxacin and chloroquine in mice infected with chloroquine resistant Plasmodium berghei: interaction between ciprofloxacin and chloroqune.
Topics: Animals; Antimalarials; Chloroquine; Ciprofloxacin; Disease Models, Animal; Drug Resistance; Drug Th | 2012 |
Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Chloroquine; Disease Progression; Drug | 2010 |
Plasmodium falciparum gametocyte carriage, sex ratios and asexual parasite rates in Nigerian children before and after a treatment protocol policy change instituting the use of artemisinin-based combination therapies.
Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Therapy, Combina | 2011 |
Neonatal Plasmodium vivax malaria.
Topics: Antimalarials; Chloroquine; Humans; Infant, Newborn; Malaria, Vivax; Male; Parasitemia; Plasmodium v | 2011 |
In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru | 2011 |
Malaria in seasonal migrant population in Southern Gujarat, India.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Animals; Antimalarials; Blood; Child; | 2011 |
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Evaluation, Preclinical; Macaca mu | 2012 |
Strain-specific protective effect of the immunity induced by live malarial sporozoites under chloroquine cover.
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Female; Genes, Protozoan; Immunity, Active; Macaca; | 2012 |
Altered regulation of Akt signaling with murine cerebral malaria, effects on long-term neuro-cognitive function, restoration with lithium treatment.
Topics: Acute Disease; Animals; Chloroquine; Cognition; Female; Fluorescent Antibody Technique; Glycogen Syn | 2012 |
Outcome of primary lethal and nonlethal Plasmodium yoelii malaria infection in BALB/c and IFN-γ receptor-deficient mice following chloroquine treatment.
Topics: Animals; Antibodies, Protozoan; Antimalarials; Chloroquine; Immunoglobulin G; Interferon gamma Recep | 2013 |
In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Humans | 2002 |
Parasitemia in children with Plasmodium falciparum malaria receiving chemoprophylaxis.
Topics: Adolescent; Age Distribution; Animals; Chemoprevention; Child; Child, Preschool; Chloroquine; Cohort | 2003 |
Failure of a chloroquine chemoprophylaxis program to adequately prevent malaria during pregnancy in Koupéla District, Burkina Faso.
Topics: Adolescent; Adult; Animals; Antimalarials; Burkina Faso; Chemoprevention; Chloroquine; Cross-Section | 2003 |
[Malaria--case report].
Topics: Adult; Anti-Infective Agents; Antidiarrheals; Antimalarials; Chloroquine; Ciprofloxacin; Diarrhea; E | 2003 |
Monitoring the chloroquine sensitivity of Plasmodium vivax from Calcutta and Orissa, India.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; India; Malaria, Falciparum; Malaria, V | 2003 |
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Humans; Indonesia; Life Tabl | 2003 |
The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Resistance; Humans; Infant; Infant, Newb | 2003 |
Prevalence of Plasmodium falciparum infection in pregnant women in Gabon.
Topics: Adolescent; Adult; Age Factors; Animals; Chloroquine; Female; Fever; Gabon; Gravidity; Hemoglobin, S | 2003 |
Plasmodium falciparum gametocytaemia in Nigerian children: Peripheral immature gametocytaemia as an indicator of a poor response to chloroquine treatment, and its relationship to molecular determinants of chloroquine resistance.
Topics: Acute Disease; Administration, Oral; Adolescent; Animals; Antimalarials; ATP-Binding Cassette Transp | 2003 |
Antimalarial effect of agmatine on Plasmodium berghei K173 strain.
Topics: Agmatine; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Eflornithine | 2003 |
Correlation between Plasmodium vivax variants in Belém, Pará State, Brazil and symptoms and clearance of parasitaemia.
Topics: Animals; Antimalarials; Brazil; Chloroquine; Genetic Variation; Genotype; Humans; Malaria, Vivax; Pa | 2003 |
Changes in Plasmodium falciparum gametocytaemia in children with chloroquine-sensitive asexual infections.
Topics: Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Kinet | 2003 |
Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India.
Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Child, | 2003 |
Chloroquine efficacy in the treatment of uncomplicated malaria at three sentinel sites in northern Togo.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Infant; Mala | 2003 |
Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh.
Topics: Adolescent; Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Bangladesh; Child; Chi | 2004 |
Increased parasitaemia and delayed parasite clearance in Schistosoma mansoni and Plasmodium berghei co-infected mice.
Topics: Animals; Antimalarials; Chloroquine; Malaria; Male; Mice; Parasitemia; Plasmodium berghei; Random Al | 2004 |
Inhibition of heme aggregation by chloroquine reduces Schistosoma mansoni infection.
Topics: Animals; Cell Fractionation; Chloroquine; Cohort Studies; Disease Models, Animal; Drug Design; Femal | 2004 |
Effects of autacoid inhibitors and of an antagonist on malaria infection in mice.
Topics: Animals; Antimalarials; Autacoids; Chloroquine; Cyproheptadine; Drug Combinations; Fenclonine; Hista | 2004 |
The PfCRT (K76T) point mutation favours clone multiplicity and disease severity in Plasmodium falciparum infection.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Malaria, Falciparum; Ma | 2004 |
Pfcrt K76T mutation and its associations in imported Plasmodium falciparum malaria cases.
Topics: Adult; Amino Acid Substitution; Animals; Antimalarials; Black People; Chloroquine; Codon; Drug Resis | 2004 |
Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection.
Topics: Acetaminophen; Acute Disease; Amoxicillin; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; | 2004 |
Rifampicin antagonizes the effect of choloroquine on chloroquine-resistant Plasmodium berghei in mice.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Malaria; Mice; Para | 2004 |
Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Child; Chloroquine; Drug Resista | 2004 |
Chemosensitizing action of cepharanthine against drug-resistant human malaria, Plasmodium falciparum.
Topics: Alkaloids; Animals; Benzylisoquinolines; Chloroquine; Disease Models, Animal; Dose-Response Relation | 2005 |
Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistan | 2005 |
Plasmodium berghei NK65: studies on the effect of treatment duration and inoculum size on recrudescence.
Topics: Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Erythrocytes; Female; Lethal | 2005 |
The roles of the pfcrt 76T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities.
Topics: Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Child; Child, Preschool; Chloroqui | 2005 |
Predictors of the failure of treatment with chloroquine in children with acute, uncomplicated, Plasmodium falciparum malaria, in an area with high and increasing incidences of chloroquine resistance.
Topics: Acute Disease; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Endemic Disease | 2005 |
Carriage of chloroquine-resistant parasites and delay of effective treatment increase the risk of severe malaria in Gambian children.
Topics: Alleles; Anemia; Animals; ATP-Binding Cassette Transporters; Case-Control Studies; Child; Child, Pre | 2005 |
Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86.
Topics: Animals; Antimalarials; ATP-Binding Cassette Transporters; Child; Child, Preschool; Chloroquine; Dru | 2005 |
Self-medication with chloroquine in a rural district of Tanzania: a therapeutic challenge for any future malaria treatment policy change in the country.
Topics: Antimalarials; Child, Preschool; Chloroquine; Female; Health Education; Humans; Infant; Infant, Newb | 2005 |
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Age Factors; Animals; Antimalarials; Body Temperature; CD4-Positive T-Lymphocytes | 2006 |
Fractions of an antimalarial neem-leaf extract have activities superior to chloroquine, and are gametocytocidal.
Topics: Animals; Antimalarials; Azadirachta; Cells, Cultured; Chloroquine; Dose-Response Relationship, Drug; | 2006 |
Plasmodium vivax: in vitro susceptibility of blood stages to synthetic trioxolane compounds and the diamidine DB75.
Topics: Animals; Antimalarials; Aotidae; Artemether; Artemisinins; Artesunate; Benzamidines; Chloroquine; Dr | 2006 |
Plasmodium berghei: development of an irreversible experimental malaria model in Wistar rats.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Erythrocytes; Malaria; Parasitemia; Pla | 2006 |
Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Child; Child, Preschool; Chloroq | 2006 |
The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Child; Chloroquine; Cohort Studies; Drug Combina | 2006 |
Drug-induced death of the asexual blood stages of Plasmodium falciparum occurs without typical signs of apoptosis.
Topics: Animals; Antimalarials; Apoptosis; Atovaquone; Cells, Cultured; Chloroquine; DNA Fragmentation; DNA, | 2006 |
[Successful management of malaria tropica with 50% parasitaemia].
Topics: Animals; Antimalarials; Chloroquine; Female; Germany; Humans; Kenya; Liver Function Tests; Malaria, | 2006 |
Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antimalarials; Child, Preschool; Chloroquine; Cyto | 2006 |
Vangueria infausta root bark: in vivo and in vitro antiplasmodial activity.
Topics: Animals; Antimalarials; Cells, Cultured; Chloroquine; Malaria; Malaria, Falciparum; Mice; Mice, Inbr | 2006 |
Antimalarial activity of methanolic extracts from plants used in Kenyan ethnomedicine and their interactions with chloroquine (CQ) against a CQ-tolerant rodent parasite, in mice.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Synergism; Kenya; Malaria; Medicine, Trad | 2007 |
In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum.
Topics: Aminoquinolines; Animals; Antimalarials; Blood; Chloroquine; Drug Evaluation, Preclinical; Drug Resi | 2006 |
[A plasmodium alciparum malaria case originated from Mozambique: clues for the diagnosis and therapy].
Topics: Animals; Antimalarials; Canada; Chloroquine; Doxycycline; Drug Resistance; Erythrocytes; Humans; Mal | 2006 |
Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice.
Topics: Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ma | 2006 |
Plasmodium yoelii: influence of antimalarial treatment on acquisition of immunity in BALB/c and DBA/2 mice.
Topics: Animals; Antibodies, Protozoan; Antimalarials; Artemisinins; Artesunate; Chloroquine; Female; Immuno | 2007 |
Clinical efficacy of antiparasite treatments against intestinal helminths and haematic protozoa in Gallotia caesaris (lizards).
Topics: Animals; Antiparasitic Agents; Atovaquone; Chloroquine; Drug Combinations; Feces; Fenbendazole; Helm | 2007 |
Assessing malaria burden during pregnancy in Mali.
Topics: Adult; Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; Drug Combinations; Female; Huma | 2007 |
Large-scale surveillance of Plasmodium falciparum crt(K76T) in northern Ghana.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Chloroquine; Drug | 2007 |
Effect of chloroquine on gene expression of Plasmodium yoelii nigeriensis during its sporogonic development in the mosquito vector.
Topics: Amino Acid Sequence; Animals; Antimalarials; Chloroquine; Culicidae; Female; Gene Expression; Gene E | 2007 |
Adaptation of a multi-drug resistant strain of Plasmodium falciparum from Peru to Aotus lemurinus griseimembra, A. nancymaae, and A. vociferans monkeys.
Topics: Animals; Antimalarials; Aotidae; Chloroquine; Cytochromes b; Dihydropteroate Synthase; Disease Model | 2007 |
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; G | 2008 |
Clinical diagnosis of malaria and the risk of chloroquine self-medication in rural health centres in Burkina Faso.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Burkina Faso; Child; Child, Preschool; Ch | 2008 |
Antiplasmodial activity of sesquiterpene lactone from Carpesium rosulatum in mice.
Topics: Animals; Animals, Outbred Strains; Antimalarials; Asteraceae; Chloroquine; Malaria; Male; Mice; Mice | 2008 |
Iron incorporation and post-malaria anaemia.
Topics: Anemia; Antimalarials; Child, Preschool; Chloroquine; Dietary Supplements; Erythrocytes; Gambia; Hem | 2008 |
Malaria--an experience at CMH Khuzdar (Balochistan).
Topics: Antimalarials; Chloroquine; Disease Outbreaks; Doxycycline; Female; Humans; Malaria, Falciparum; Mal | 2008 |
Status of hepatic glutathione-S-transferase(s) during Plasmodium berghei infection and chloroquine treatment in Mastomys natalensis.
Topics: Animals; Chloroquine; Cytosol; Glutathione Transferase; Liver; Malaria; Microsomes, Liver; Mitochond | 1995 |
Susceptibility of Guyanan Saimiri monkeys to a chloroquine-sensitive and a chloroquine-resistant strain of Plasmodium vivax from Papua New Guinea.
Topics: Animals; Anopheles; Aotus trivirgatus; Chloroquine; Disease Models, Animal; Drug Resistance; Insect | 1995 |
Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo.
Topics: Animals; Chloroquine; Drug Resistance; Glutathione; Glutathione Peroxidase; Glutathione Reductase; G | 1995 |
Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Oubritenga province, Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Resist | 1994 |
Hyper parasitaemia due to plasmodium falciparum malaria.
Topics: Animals; Chloroquine; Host-Parasite Interactions; Humans; Infusions, Intravenous; Injections, Intram | 1994 |
Plasmodium falciparum and Plasmodium berghei: effect of magnesium on the development of parasitemia.
Topics: Analysis of Variance; Animals; Calcium; Chloroquine; Culture Media; Dose-Response Relationship, Drug | 1995 |
Plasmodium falciparum and Plasmodium vivax: lactate dehydrogenase activity and its application for in vitro drug susceptibility assay.
Topics: Animals; Antimalarials; Chloroquine; Colorimetry; Erythrocytes; Humans; L-Lactate Dehydrogenase; Mal | 1995 |
Studies of a chloroquine-resistant strain of Plasmodium vivax from Papua New Guinea in Aotus and Anopheles farauti s.l.
Topics: Animals; Anopheles; Aotus trivirgatus; Chloroquine; Disease Models, Animal; Drug Resistance; Insect | 1994 |
Subclinical avian malaria infections in African black-footed penguins (Spheniscus demersus) and induction of parasite recrudescence.
Topics: Animals; Animals, Zoo; Baltimore; Birds; Chloroquine; Dexamethasone; Ducks; Immunosuppression Therap | 1994 |
Serum complement levels in asymptomatic Plasmodium falciparum parasitaemic children.
Topics: Child; Child, Preschool; Chloroquine; Complement System Proteins; Humans; Infant; Malaria, Falciparu | 1994 |
Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Female; Fetal Death; Fever; Humans; Malaria, Falcipar | 1996 |
Malaria in São Tomé and Principe: prevalence and drug-susceptibility.
Topics: Africa, Western; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Parasitemia; Prevalen | 1996 |
Prevalence of malaria parasitaemia in transfused donor blood in Benin City, Nigeria.
Topics: Animals; Blood-Borne Pathogens; Chi-Square Distribution; Chloroquine; Humans; Infant, Newborn; Malar | 1996 |
Resistance to chloroquine therapy in pregnant women with malaria parasitemia.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance; Female; Humans; Kenya; Malaria, Falcipa | 1996 |
In vitro drug sensitivity and clinical aspects of Plasmodium falciparum malaria in African children.
Topics: Animals; Child; Child, Preschool; Chloroquine; Congo; Humans; Infant; Malaria, Falciparum; Mefloquin | 1995 |
Survey of in vivo sensitivity to chloroquine by Plasmodium falciparum and P. vivax in Lombok, Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1997 |
The chemotherapy of rodent malaria. LIV. Combinations of 'Fenozan B07' (Fenozan-50F), a difluorinated 3,3'-spirocyclopentane 1,2,4-trioxane, with other drugs against drug-sensitive and drug-resistant parasites.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Drug Antagonism; Drug Resistance; Drug Synergi | 1997 |
The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy.
Topics: Animals; Antimalarials; Chloroquine; Circadian Rhythm; Disease Models, Animal; Injections, Intraperi | 1994 |
Plasmodium yoelii nigeriensis: biological mechanisms of resistance to chloroquine.
Topics: Animals; Antimalarials; Centrifugation, Density Gradient; Chloroquine; Drug Resistance; Injections, | 1994 |
Chloroquine self-treatment and clinical outcome of cerebral malaria in children.
Topics: Adolescent; Animals; Cameroon; Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Follow | 1997 |
WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys.
Topics: Aminoquinolines; Animals; Antimalarials; Aotus trivirgatus; Chloroquine; Drug Resistance; Drug Thera | 1997 |
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist | 1997 |
In-vivo resistance of Plasmodium falciparum to chloroquine and amodiaquine in south Cameroon and age-related efficacy of the drugs.
Topics: Adolescent; Age Factors; Amodiaquine; Animals; Antimalarials; Cameroon; Child; Child, Preschool; Chl | 1997 |
Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990-1993.
Topics: Acute Disease; Amodiaquine; Animals; Antimalarials; Case-Control Studies; Child; Child, Preschool; C | 1996 |
Primaquine-tolerant vivax malaria in Thailand.
Topics: Adult; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Stu | 1997 |
Modelling the chloroquine chemotherapy of falciparum malaria: the value of spacing a split dose.
Topics: Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1998 |
A systematic approach to the development of a rational malaria treatment policy in Zambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug Resist | 1998 |
[Malaria in an urban environment: the case of the city of Rufisque in Senegal].
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Inciden | 1997 |
Malaria and anaemia at different altitudes in the Muheza district of Tanzania: childhood morbidity in relation to level of exposure to infection.
Topics: Altitude; Anemia; Animals; Anopheles; Antimalarials; Child, Preschool; Chloroquine; Humans; Infant; | 1998 |
Plasmodium chabaudi chabaudi: effect of low parasitemias on immunity in CB6F1 mice.
Topics: Animals; Antibodies, Protozoan; Antimalarials; Chloroquine; Female; Malaria; Male; Mice; Parasitemia | 1999 |
In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Age Distribution; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; D | 1999 |
Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug | 1999 |
Adaptation of the AMRU-1 strain of Plasmodium vivax to Aotus and Saimiri monkeys and to four species of anopheline mosquitoes.
Topics: Adaptation, Biological; Animals; Anopheles; Aotus trivirgatus; Chloroquine; Disease Models, Animal; | 1999 |
Plasmodium berghei: a new rat model for assessment of blood schizonticidal activity.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; Eryth | 1999 |
The effect of chloroquine on the production of interferon-gamma, interleukin (IL)-4, IL-6, and IL-10 in Plasmodium chabaudi chabaudi in infected C57BL6 mice.
Topics: Animals; Antimalarials; Chloroquine; Female; Interferon-gamma; Interleukin-10; Interleukin-4; Interl | 1999 |
Pseudo-reticulocytosis as a result of malaria parasites.
Topics: Afghanistan; Animals; Autoanalysis; Chloroquine; DNA; DNA, Protozoan; Electronic Data Processing; Er | 1999 |
Anti-malarial drug use among preschool children in an area of seasonal malaria transmission in Kenya.
Topics: Adult; Animals; Antibodies, Monoclonal; Antimalarials; Child, Preschool; Chloroquine; Cluster Analys | 1999 |
Inoculum effect leads to overestimation of in vitro resistance for artemisinin derivatives and standard antimalarials: a Gambian field study.
Topics: Animals; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Gambia; Hematocrit; Humans; Mala | 1999 |
Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Doxycycline; Erythromycin; | 2000 |
Development of irreversible lesions in the brain, heart and kidney following acute and chronic murine malaria infection.
Topics: Acute Disease; Animals; Antimalarials; Brain; Chloroquine; Chronic Disease; Kidney; Malaria; Mice; M | 1999 |
[Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)].
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1999 |
Response to chloroquine of Plasmodium vivax among South Korean soldiers.
Topics: Adult; Animals; Antimalarials; Chloroquine; Humans; Korea; Malaria, Vivax; Male; Parasitemia; Plasmo | 1999 |
Population dynamics of Plasmodium falciparum in an unstable malaria area of eastern Sudan.
Topics: Alleles; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Cohort Studies; DNA Primers; DNA, | 2000 |
Chloroquine-resistant isolates of Plasmodium falciparum with alternative CG2 omega repeat length polymorphisms.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; DNA Primers; DNA, Protozoan; Drug Res | 2000 |
Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Animals; Anopheles; Antimalarials; Child | 2000 |
Effect of chloroquine prophylaxis on birthweight and malaria parasite load among pregnant women delivering in a regional hospital in Cameroon.
Topics: Adult; Animals; Birth Weight; Cameroon; Chloroquine; Educational Status; Female; Humans; Infant, Low | 2000 |
In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine among schoolchildren in rural Uganda: a comparison between 1995 and 1998.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Parasite | 2000 |
The effects of subcurative doses of chloroquine on Plasmodium vinckei petteri gametocytes and on their infectivity to mosquitoes.
Topics: Animals; Anopheles; Anthelmintics; Chloroquine; Drug Resistance; Malaria; Male; Mice; Parasitemia; P | 2000 |
Comparative clinical characteristics and response to oral antimalarial therapy of children with and without Plasmodium falciparum hyperparasitaemia in an endemic area.
Topics: Adolescent; Age Factors; Analysis of Variance; Antimalarials; Child; Child, Preschool; Chloroquine; | 2000 |
The chemotherapy of rodent malaria. LIX. Drug combinations to impede the selection of drug resistance, Part 3: Observations on cyproheptadine, an antihistaminic agent, with chloroquine.
Topics: Animals; Antimalarials; Chloroquine; Cyproheptadine; Dose-Response Relationship, Drug; Drug Combinat | 2000 |
Adaptation of a chloroquine-resistant strain of Plasmodium vivax from Indonesia to New World monkeys.
Topics: Adaptation, Physiological; Adult; Amodiaquine; Animals; Antimalarials; Aotidae; Child; Chloroquine; | 2000 |
Resistance of Plasmodium falciparum malaria to chloroquine is widespread in eastern Afghanistan.
Topics: Adolescent; Adult; Afghanistan; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; | 2001 |
Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Cost-Benefit Analysis; Disease | 2001 |
Evidence for a reduced effect of chloroquine against Plasmodium falciparum in alpha-thalassaemic children.
Topics: alpha-Thalassemia; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Stu | 2001 |
Use of the DELI-microtest to determine the drug sensitivity of Plasmodium falciparum in Burkina Faso.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Malaria, Falciparum; Mefloquine; Parasitemia; | 2001 |
Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Cell Adhesion; Chloroquine; Chon | 2001 |
[Evaluation of efficacy and tolerance of amodiaquine versus chloroquine in the treatment of uncomplicated malaria outbreak in children of Gabon].
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Femal | 2001 |
A comparison of the stage-specific efficacy of chloroquine, artemether and dioncophylline B against the rodent malaria parasite Plasmodium chabaudi chabaudi in vivo.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Chloroquine; Female; Isoquinolines; Life Cycle Sta | 2001 |
Effect of drugs inhibiting spermidine biosynthesis and metabolism on the in vitro development of Plasmodium falciparum.
Topics: Agmatine; Alkyl and Aryl Transferases; Animals; Antimalarials; Chloroquine; Cyclohexylamines; Diamin | 2001 |
Asexual erythrocytic forms of Plasmodium falciparum in asymptomatic American and Korean soldiers serving in Vietnam.
Topics: Animals; Antimalarials; Australia; Chloroquine; Erythrocytes; Humans; Korea; Malaria, Falciparum; Mi | 1967 |
Weekly chloroquine prophylaxis and the effect on maternal haemoglobin status at delivery.
Topics: Adult; Anemia; Animals; Antimalarials; Chloroquine; Female; Hemoglobins; Humans; Labor, Obstetric; M | 2002 |